

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/75131 A2

(51) International Patent Classification⁷: **C12N 15/82**,
15/63, A01H 1/00, 5/10

(21) International Application Number: PCT/US01/10236

(22) International Filing Date: 30 March 2001 (30.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/193,533 31 March 2000 (31.03.2000) US

(71) Applicant: **UNIVERSITY TECHNOLOGY CORPORATION** [US/US]; Suite 250, 3101 Iris Avenue, Boulder, CO 80301 (US).

(72) Inventors: **BERRY-LOWE, Sandra, Lee**; 6326 Mesedge Drive, Colorado Springs, CO 80919 (US). **NEWELL, Martha, Karen**; 520 North Franklin, Colorado Springs, CO 80903 (US).

(74) Agent: **LOCKHART, Helen, C.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR REGULATING METABOLISM IN PLANTS



(57) Abstract: The invention relates to methods and products for manipulating plant metabolism and resistance to infection.

WO 01/75131 A2

COMPOSITIONS AND METHODS FOR REGULATING METABOLISM IN PLANTS

FIELD OF THE INVENTION

5 The present invention relates to compositions and methods for regulating metabolism in plants by controlling photosynthetic fuel metabolism. The present invention also relates to compositions and methods for protecting plants from free radical damage. In particular, regulating plant fuel metabolism and protecting plants from free radical damage are achieved by compositions and methods for expressing and regulating
10 plant cell wall uncoupling proteins.

BACKGROUND OF THE INVENTION

 Modern agriculture faces the ever-increasing challenge of meeting the nutritional and industrial demands for high quality food stuffs and plant derived products. For
15 example, approximately one-half of the world's farm land is dedicated to the production of cereal crops. When the direct (e.g., cooked rice and bread) and indirect consumption (e.g., as animal feed for the production of milk, eggs, and meat) of cereal crops are combined, cereals account for about two-thirds of all human caloric intake. Since 1984, the rate of the world's population growth has out paced world cereal production. Thus,
20 there is a need for improved methods of crop production.

 Analysts point to the need for increased reliance on artificial crop fertilizers, herbicides, and pesticides in order to meet the world's demand for cereal and other crops. (See, e.g., Proc. Natl. Acad. Sci. USA 96:5929 (1999).) Attempts to increase crop production have mainly focused on one of two proposed approaches. First, there have
25 been attempts to produce more effective fertilizer and nutrient compounds for application (i.e., foliar spraying) to growing crop plants (See, e.g., U.S. Patent No. 5,797,976). In an alternative approach, various compounds, typically organic acids and natural and synthetic plant hormones, have been used to increase crop production and fruit ripening. It is well known that organic acids are useful in stimulating the growth of plants. It has
30 been theorized that much of the action of organic fertilizers, such as manure, is due to the presence of organic acids. For example, U.S. Patent No. 5,654,255 describes compositions comprising a mixture of N,N-dimethyl piperidinium salt, hexitol, and optionally, a cytokinesis promoter. Similarly, U.S. Patent No. 5,604,177, describes a

process for increasing plant growth and productivity comprising treating the roots, stems and/or foliage with gamma-aminobutyric acid and succinic acid as metabolizable carbon sources.

Each of these basic approaches requires repeated applications for eliciting the desired effect in crop plants. Thus, the material and application costs of these approaches is high. These approaches inherently result in the application of extraneous and often excessive levels of organic and inorganic nutrients and compounds to farm land, which leads to increased probability of nutrient leaching and eutrophication of adjacent riparian environments. Additionally, application of additional nutrient loads of crop plants does not elevate crop and biomass production where the nutrients are already in sufficient abundance and balance in the soil.

What is needed are cost effective methods and compositions for increasing crop production and controlling plant metabolism and durability (e.g., to environmental stresses) that do not require time consuming and expensive maintenance and repeated applications.

SUMMARY OF THE INVENTION

The invention in some aspects relates to a plant expressing a cell wall UCP encoded by a heterologous UCP gene. In one embodiment the heterologous UCP gene comprises a gene encoding UCP2. In other embodiments the heterologous UCP gene is a gene encoding UCP1, UCP3, UCP4, UCP5, or UCP6. In yet other embodiments the heterologous UCP gene comprises a gene encoding PUMP, StUCP, or AtPUMP.

A method for regulating fuel metabolism in a plant, is provided according to other aspects of the invention. The method involves regulating UCP expression in an alternative membrane, such as a plant cell wall/ plasma membrane or chloroplast to regulate fuel metabolism of the plant. In some embodiments the method involves increasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast. The expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast may be increased by introducing into the plant cell an expression vector including a gene encoding a heterologous UCP. Alternatively, the expression of activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by stably transforming the plant cell with an expression vector including a gene encoding a

heterologous UCP. In some embodiments the heterologous UCP gene is a gene encoding UCP1, UCP2, UCP3, UCP4, UCP5, UCP6 PUMP, StUCP, or AtPUMP.

The expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast may also be increased by contacting the plant with a UCP activator. In one
5 embodiment the UCP activator is a compound selected from the group consisting of sugars including but not limited to glucose, sucrose, maltose, and dextrose, structural analogs of sugars including but not limited to glucose, glucose, sucrose, maltose, and dextrose, inhibitors of nucleotides and nucleotide analogs, omega 3 fatty acids, omega 6 fatty acids, and norflurazon.

10 In some embodiments the expression of UCP in the cell wall/plasma membrane is increased by contacting the plant with a cell wall targeted UCP molecule, which optionally is a UCP molecule linked to a targeting molecule such as glucose transporters, sucrose transporters, maltose transporters, and fatty acid transporters.

In other embodiments the expression of UCP in the chloroplast is increased by
15 contacting the plant with a chloroplast targeted UCP molecule, which optionally is a UCP molecule linked to a targeting molecule selected from the group consisting of a chloroplast transit protein and a peptide of N terminus small subunit of ribulose 5-phosphate carboxylase.

In yet other embodiments the expression of UCP in the cell wall/plasma
20 membrane, is increased by contacting the plant with a plasma membrane targeted UCP molecule, which optionally is a UCP molecule linked to a targeting molecule which is plant specific membrane targeting sequence lacking a VSS or KDEL sequence.

The expression of UCP in the cell wall/plasma membrane is increased by
contacting the plant with a plasma desmata targeted UCP molecule in some
25 embodiments. The plasma desmata targeted UCP molecule may be a UCP molecule linked to a plasma desmata targeting molecule selected from the group consisting of porin-like targeting sequences.

In other embodiments the expression of UCP in the cell wall/plasma membrane is
increased by contacting the plant with a pore targeted UCP molecule, which may be a
30 UCP molecule linked to a targeting molecule selected from the group consisting of a porin peptide, a VSS tail and a KDEL tail.

The method, according to other embodiments involves decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast. The expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast may be decreased by contacting the plant with a UCP inhibitor, which optionally is a compound including but not limited to UCP binding peptides such as anti-UCP antibodies, UCP anti-sense nucleic acids, UCP dominant-negative nucleic acids, nucleotides, nucleotide analogs, tocopherols, including but not limited to tocotrienols, and non-omega-3, -6 fatty acids.

An expression system is provided according to other aspects of the invention. The system includes a promoter sequence, a first structural gene encoding a heterologous UCP and a second structural gene encoding a plant cell wall targeting peptide or a chloroplast targeting peptide; the first and second structural genes arranged to form a fusion protein and operably linked to and under the control of the promoter sequence.

In some embodiments the promoter sequence is a plant specific promoter. In other embodiments the UCP encoded by the first structural gene is a mammalian UCP or a plant UCP. The invention also includes plants stably transformed with the expression system as well as seeds of the plant. In other aspects a progeny, clone, cell line or cell of the plant is included in the invention.

A transgenic plant transformed with a nucleic acid construct including a nucleic acid sequence encoding a UCP operably linked to a promoter sequence is also provided. The nucleic acid construct also encodes a plant cell wall targeting peptide or a chloroplast targeting peptide. The invention also includes seeds of the transgenic plant as well as a progeny, clone, cell line or cell of the transgenic plant.

The invention also includes a method for producing a nutritionally enhanced plant. The method involves decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast to produce a nutritionally enhanced plant. A method for preventing an infection in a plant by decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast in an amount to prevent an increase in oxygen free radicals and to prevent infection in the plant is also provided. A plant produced by these methods is also provided.

In some embodiments the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is decreased by contacting the plant with a UCP inhibitor. The UCP inhibitor may be a chloroplast or cell wall UCP antisense sequence.

In other aspects the invention relates to a method for improving the light and cold sensitivity of a plant. The method involves increasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast to improve the light and cold sensitivity of the plant. In some embodiments the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by introducing into the plant cell an expression vector including a gene encoding a heterologous UCP. In other embodiments the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by stably transforming the plant cell with an expression vector including a gene encoding a heterologous UCP. The heterologous UCP gene may be a gene encoding UCP1, UCP2, UCP3, UCP4, PUMP, StUCP, or AtPUMP.

In other embodiments the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP activator. In yet other embodiments the expression of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP molecule.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1, Panel A, shows that wild type (cell-walled [CC124-]) strains of *Chlamydomonas reinhardtii* express cell surface molecules recognized by antibodies to UCP2.

Figure 1, Panel B, shows that cell wall-less (cw15+) strains of *Chlamydomonas reinhardtii* do not express cell wall surface molecules recognized by antibodies to UCP2.

Figure 2, Panel A, shows that light sensitive cell-walled (lts) strains of *Chlamydomonas reinhardtii* express high levels of UCP.

Figure 2, Panel B, shows that dark sensitive (CC2654; dark-dier) strains of *Chlamydomonas reinhardtii* do not express cell-wall UCP over control samples.

5 Figure 3 shows that norflurazon upregulates cell wall expression of UCP in wild type strains of *C. reinhardtii*.

Figure 4 is a slot blot of total RNA from *C. reinhardtii* probed for UCP expression.

BRIEF DESCRIPTION OF THE SEQUENCES

10 SEQ ID NO:1 is the nucleotide sequence of the human uncoupling (UCP-1) cDNA with GenBank Acc. no.U28480.

SEQ ID NO:2 is the predicted amino acid sequence of the translation product of human uncoupling cDNA (UCP-1).

15 SEQ ID NO:3 is the nucleotide sequence of the human uncoupling (UCP-2) cDNA with GenBank Acc. no.U82819.

SEQ ID NO:4 is the predicted amino acid sequence of the translation product of human uncoupling cDNA (UCP-2).

SEQ ID NO:5 is the nucleotide sequence of the human uncoupling (UCP-3S) cDNA with GenBank Acc. no.U82818.

20 SEQ ID NO:6 is the predicted amino acid sequence of the translation product of human uncoupling cDNA (UCP-3S).

SEQ ID NO:7 is the nucleotide sequence of the solanum tubersum UCP cDNA with GenBank Acc. no. AJ002586.

25 SEQ ID NO:8 is the nucleotide sequence of the arabidopsis thaliana UCP cDNA with GenBank Acc. no. AJ223983.

SEQ ID NO:9 is the nucleotide sequence of the arabidopsis thaliana UCP cDNA with GenBank Acc. no. AB021706.

SEQ ID NO:10 is the nucleotide sequence of the human UCP4 cDNA with GenBank Acc. no. NM_004277.

30 SEQ ID NO:11 is the nucleotide sequence of the wheat UCP cDNA with GenBank Acc. no. AB042428.

SEQ ID NO:12 is the nucleotide sequence of the human UCP5 cDNA with GenBank Acc. no. NM_022810.

SEQ ID NO:13 is a primer.

SEQ ID NO:14 is a primer.

5 SEQ ID NO:15 is a primer.

SEQ ID NO:16 is a primer.

DETAILED DESCRIPTION

The invention relates in some aspects to the finding that UCP is present in plant cellular membranes other than the mitochondrial membrane. For instance, UCP is
10 expressed on the cell wall, plasma membrane and chloroplasts of light and cold sensitive cells but not of light and cold resistant cells. This discovery has important implications for the regulation of plant metabolism.

The present invention relates in some aspects to compositions and methods for regulating fuel metabolism in plants by controlling photosynthesis through regulation of
15 plant fuel metabolism. The present invention also relates to compositions and methods for protecting plants from the free radical damage and thus in the control of infectious disease. In particular, regulation of plant fuel metabolism and protecting plants from free radical damage is achieved by compositions and methods for expressing and regulation of plant cell wall uncoupling proteins.

20 Free energy consumed by biological systems originates as solar energy. Photosynthetic organisms have evolved the processes of photosynthesis to take advantage of the solar radiation reaching the earth. Essentially, photosynthesis is a light-induced redox process in which carbon dioxide is reduced to a metabolizable storage compound by an external reductant (i.e., light is used to create reducing potential).
25 Photosynthetic organisms are primarily classified by the nature of the reductant used during photosynthetic processes. Oxygenic photosynthetic organisms, for instance, are distinguished from prokaryotic photosynthetic organisms primarily by their ability to use water as a reductant. Plants, algae, cyanobacteria, and prochlorophytes are all oxygenic photosynthetic organisms. Green plants photosynthesis takes place in chloroplasts. The
30 systems that convert solar energy in green plants to useful metabolic energy are integrated into the thylakoid membrane system of green plant chloroplasts. In particular, the thylakoid membranes contain the energy-transducing machinery: the light-

harvesting-proteins, reaction centers, electron transport chains, and ATP synthase. Photosynthesis in green plants begins by the absorption of light by a chlorophyll porphyrin (i.e., with a coordinated magnesium ion). The resulting electronic excitation passes along a series of chlorophyll molecules until the excitation is trapped in a reaction center. In the reaction center the energy of light (i.e., electron excitation) is converted into a separation of charge (i.e., reducing potential). Green plants use two light reactions: photosystem I and photosystem II. Photosystem I generates reducing potential in the form of NADPH. Photosystem II transfers the electrons of water to a quinone and concomitantly evolves diatomic oxygen. The flow of electrons in, and between, both photosystem generates a proton gradient across the thylakoid membrane that drives the synthesis of ATP. The ATP and NADPH that results from photophosphorylation processes in green plants are used to reduce carbon dioxide and convert it into 3-phosphoglycerate. The electron-motive force generated in green plant chloroplast photosystems drives electron transfer in a opposite direction from that in mitochondria. In photosynthesis, electrons are taken from water to produce diatomic oxygen, and concomitantly used to reduce carbon dioxide to synthesize carbohydrates. Chloroplasts, therefore, generate diatomic oxygen and carbohydrate, while mitochondria consume oxygen and carbohydrate.

A variety of uncoupling proteins (UCPs) are known to exist in vertebrate and photosynthetic organisms. These proteins are named for the ability to dissipate the above described proton gradient generated by the respective electron transport chains in mammalian mitochondria and green plan chloroplasts. Thus, these proteins are said to uncouple the flow of protons across a membrane through ATP synthetase and prevent the concomitant production of ATP. Dissipation of the proton gradient in this manner produces heat in a process called thermogenesis.

UCP-like proteins occur in each of the four eukaryotic kingdoms: animals, plants, fungi, and protists (See e.g., Jarmuszkiewicz et al., FEBS Lett., 467:145 [2000].) UCPs are encoded by small multi-gene families in both mammals and plants. In mammals, UCP1 is exclusively expressed in brown adipocyte tissue, while UCP2 is expressed in most tissues of humans and rodents (See e.g., Boss et al., Eur. J. of Endocrinol. 139, 1-9 [1998]); UCP3 is expressed in both skeletal muscle and in human brown adipocyte tissue (See e.g., Vidal-Puig et al., Biochem. Biophys. Res. Com 235:79

[1997]); and UCP4 is expressed in brain tissues. In mammals, UCP causes a change from glucose to fatty acid oxidation in mitochondria, and consequent thermogenesis in brown adipocyte tissue.

Plant UCP was first identified in potato tuber and has been isolated in
5 *Arabidopsis*. These potato UCP are located in the mitochondria and have been implicated in chill resistance in plants (See e.g., Nantes et al., FEBS Lett., 457:103 [1999]).

It was discovered according to the invention that UCP is expressed on other cellular membranes including the plant cell wall, plasma membrane, and the
10 chloroplasts. It was further discovered that the expression and activity of UCP in each of these distinct locations has an important impact on the regulation of cellular metabolism and free radical accumulation. These findings of the invention have important implications in the treatment of disease and the control of cellular metabolism, because it was not previously recognized that UCP was expressed in membranes such as the cell
15 wall and that such expression of UCP was involved in regulating various cellular functions.

Some of the experiments described in the Examples section demonstrated for the first time, the presence of UCP in the cell wall of plants. The following example of the characterization of a cell wall UCP are described for *Chlamydomonas reinhardtii* (*C.*
20 *reinhardtii*). *C. reinhardtii* is a unicellular green alga that has been widely utilized as a model for many systems, including studies of photosynthesis and motility. (See generally Harris, "The *Chlamydomonas* Sourcebook: A Comprehensive Guide to Biology and Laboratory Use," Academic Press, Inc., [1989]). Photosynthesis, when light is available, and acetate when light is not, are involved in energy production and
25 consumption in *C. reinhardtii*. Although the mechanism of photosynthesis has been widely studied, the mechanism of acetate transport has not been completely elucidated. ATP synthesis in photosynthetic organisms is produced by ATP synthase as a result of proton motive force and light energy. The experiments described below show the presence of uncoupling protein in the cell wall of *C. reinhardtii* in wild type and light-
30 sensitive, but not in cell wall-less or in dark-dier strains. Increased levels of uncoupling protein have been detected in wild type, light sensitive, a photosynthetic mutant algae grown in darkness, and norflurazon treated algae. Furthermore, increased levels in the

wild type strain made light-sensitive by treatment with the herbicide norflurazon have been observed. These findings show that the presence or absence of UCPs present in membranes outside of the mitochondria regulates fuel metabolism in plants.

Based on all these discoveries the invention includes in some aspects methods for
5 increasing or decreasing the membrane potential in a plant cell. The ability to
manipulate the membrane potential, e.g., of the plant cell wall provides the ability to
control the fate of the cell. When the cell wall/plasma membrane potential is increased
by increasing or decreasing expression of UCP in the cell wall/plasma membrane, the
cell is able to alter it's ability to process energy and to grow more efficiently than it
10 would otherwise, e.g. when UCP is not increased. The cell is also able to differentiate
more efficiently when UCP is increased in mitochondria. This is useful under conditions
when light is scarce and the temperatures are cold. This shift allows the cell to use
alternative non-photosynthetic fuel sources when light is scarce. The invention involves
the use of this discovery to alter a plant's metabolism. If it is desirable to increase plant
15 metabolism then UCP activity in these alternative membranes can be increased. It is
desirable to increase UCP expression, for instance, when it is desirable to increase crop
yields (even when solar energy is scarce or in cold temperatures) or to protect plants
against cold-induced injury (in cold environments or during times of frost).

If the cell wall/plasma membrane potential of a cell is decreased, however, by
20 inhibiting cell wall/plasma membrane UCP activity, the plants shift to the use of
alternative energy sources. This may be useful in plants that are grown in warm sunny
environments such as palm trees. Decreasing the activity of UCP in these alternative
membranes causes the plant to accumulate fat. The plants can be harvested and the fat
isolated and processed for consumption. Thus the yield of fat is increased. It is also
25 desirable to decrease UCP activity when alternative energy sources such as acetate are
scarce but adequate solar energy is available. Decreasing the activity of UCP in these
alternative membranes also causes an increase in free radicals. Increases in free radicals
have been demonstrated to be useful in increasing a plants resistance to infection (see
e.g., US Patent 6,166,291). The invention encompasses mechanisms for controlling
30 these complex interactions to regulate the processes of plant metabolism and resistance
to infection.

The methods of the invention have broad utility in regulating plant cell metabolism. Because plant cells utilize the membrane potential and alternative membrane UCP in regulating their own metabolism, any type of plant cell can be manipulated according to the methods of the invention.

5 In one aspect the invention is a method for regulating fuel metabolism in a plant. The method is accomplished by regulating UCP expression in a plant cell wall/ plasma membrane or chloroplast to regulate fuel metabolism of the plant.

As used herein, the term "plant" is used in its broadest sense. The term plant includes, but is not limited to, any species of woody, ornamental or decorative, crop or cereal, fruit or vegetable plant, and algae (e.g., *Chlamydomonas reinhardtii*). As used
10 herein, the term "cereal crop" is used in its broadest sense. The term includes, but is not limited to, any species of grass, or grain plant (e.g., barley, corn, oats, rice, wild rice, rye, wheat, millet, sorghum, triticale, etc.), non-grass plants (e.g., buckwheat flax, legumes [soybeans] etc.), or other common plant derived carbohydrate source, etc. As used
15 herein, the term "crop" or "crop plant" is used in its broadest sense. The term includes, but is not limited to, any species of plant or algae edible by humans or used as a feed for animals or used, or consumed by humans, or any plant or algae used in industry or commerce. As used herein, the term "dark-dier" refers to a class of mutant organisms strains that are obligate phototrophs, including but not limited to, mutant strains of
20 *Chlamydomonas reinhardtii*.

The activity of UCP in alternative membranes is manipulated according to the methods of the invention. The term "alternative membranes" refers to membranes other than mitochondrial membranes including the membranes of other plant cell compartments and organelles and the cell wall/plasma membrane. As used herein, the
25 term plant cell "compartments or organelles" is used in its broadest sense. The term includes but is not limited to, the endoplasmic reticulum, Golgi apparatus, trans Golgi network, plastids, sarcoplasmic reticulum, gloxysomes, chloroplast, and nuclear membranes, and the like. In some preferred embodiments the alternative membrane in which the UCP is manipulated is a cell wall/ plasma membrane or a chloroplast. A "cell
30 wall/ plasma membrane" as used herein refers to the cell wall or plasma membrane of the plant cell or structures located therein such as the plasma desmata or pores.

The present invention, while not intended to be limited by the selection of a particular uncoupling protein sequences, provides a variety of UCP gene or mRNA sequences, including, but not limited to, 1) plant UCPs: Genbank accession AJ002586 (*Solanum tuberosum* "potato," SEQ ID NO:7), AJ223983 (*Arabidopsis thaliana*, SEQ ID NO:8), AB021706 (*Arabidopsis thaliana*, SEQ ID NO:9), AB024733 (*Symplocarpus renifolius* "skunk cabbage"); 2) human UCPs: U28480 (UCP), AF096289 (UCP2), AF019409 (UCP2), U7637 (UCP2), AF011449 (UCP3), AF001787 (UCP3), U08476367 (UCP3), AF1104532 (UCP4); 3) mouse UCPs: AAB17666 (UCP), U63418 (UCP), U63419 (UCP), AF096288 (UCP2), AB012159 (UCP2), U69135 (UCP2), AF032902 (UCP3), AF053352 (UCP3), AF030164 (UCP3), AB010742 (UCP3); 4) rat UCPs: NM012682 (UCP), X03894 (UCP), X12925 (UCP), M11814 (UCP), AF039033 (UCP2), AB010743 (UCP2), AB005143 (UCP2), AB006613 (UCP2), AF030163 (UCP3), AB008216 (UCP3), AF035943 (UCP3), AB006614 (UCP3), U92069 (UCP3); 5) pig UCPs: AF111998 (UCP2), 111999 (UCP2), AF036757 (UCP2), A128837 (UCP3), AF095744 (UCP3); 6) cow UCPs: AF092048 (UCP3); 7) dog UCPs: AB020887 (UCP2), AB022020 (UCP3); and 8) rabbit UCP X14696.

The UCP activity may be modified with the use of UCP activators or UCP inhibitors. "UCP activity" refers to an induction of expression of new or exogenous UCP, modulation of the activity of existing UCP, or the translocation of existing sources of UCP to different membranes.

UCP activators are any compounds which increase the activity of UCP in an alternative membrane. UCP activators include but are not limited to UCP polypeptides and nucleic acids encoding the polypeptides which are delivered to the plant cell, glucose, sucrose, maltose, and dextrose, structural analogs of sugars including but not limited to glucose, glucose, sucrose, maltose, and dextrose, inhibitors of nucleotides and nucleotide analogs, omega 3 fatty acids, omega 6 fatty acids, and norflurazon. Each of these compounds is well known in the art. Omega-3 fatty acids include but are not limited to oleic acid, palmitic acid and myristic acid.

Optionally the UCP activators may be modified to include a cell wall/ plasma membrane targeting sequence or to become membrane impermeable. This is particularly desirable when the activators are being delivered to the plant cell wall. Additional targeting sequences optionally may be added to the activators. These include for

instance targeting sequences for targeting proteins to different membranes within the plant cell and include but are not limited to targeting sequences for chloroplast, plasma desmata, and pores. These types of targeting sequences are well known in the art and are described in textbooks and other references on plant physiology and biochemistry. See
5 e.g., Buchanan, Biochemistry and Molecular Biology of Plants, American Society of Plant Physiologists, Rockville, Maryland, 2000.

Cell wall/ plasma membrane targeting sequences include hydrophobic moieties and membrane attachment domains. Hydrophobic moieties are well known in the art. A "membrane attachment domain," as used herein, refers to a domain that spans the width
10 of a cell wall/ plasma membrane, or any part thereof, and that functions to attach a UCP activator or inhibitor to a cell membrane. Membrane attachment domains useful in the invention are those domains that function to attach a UCP inhibitor or activator to a cell wall/ plasma membrane of an plant cell. One skilled in the art understands that an appropriate membrane attachment domain is selected based on the type of cell in which
15 the membrane-bound fusion protein is to be expressed.

UCP nucleic acids can be delivered to a cell such that the UCP peptide will be expressed in the cell wall/ plasma membrane of the cell. The UCP expression vectors and other relevant expression vectors described herein can be prepared and inserted into cells using routine procedures known in the art. These procedures are set forth below in
20 more detail. "UCP nucleic acid", as used herein, refers to a nucleic acid molecule which: (1) hybridizes under stringent conditions to a nucleic acid having the sequence of SEQ ID NO:1, 3, 5, and 7-12 as well as any other UCP nucleic acids publicly available and (2) codes for a UCP polypeptide. Some UCP nucleic acids have the nucleic acid sequence of SEQ ID NO:1, 3, 5, and 7-12 (the nucleic acids encoding several exemplary
25 UCP polypeptides). The UCP nucleic acids may be intact UCP nucleic acids which include the nucleic acid sequence of Sequence ID No.: 1, 3, 5, and 7-12 as well as homologs and alleles of a nucleic acid having the sequence of SEQ ID NO: 1, 3, 5, and 7-12. Intact UCP nucleic acids further embrace nucleic acid molecules which differ from the sequence of SEQ ID NO: 1, 3, 5, and 7-12 in codon sequence due to the
30 degeneracy of the genetic code. The UCP nucleic acids of the invention may also be functionally equivalent variants, analogs and fragments of the foregoing nucleic acids. "Functionally equivalent", in reference to a UCP nucleic acid variant, analog or

fragment, refers to a nucleic acid that codes for a UCP polypeptide that is capable of functioning as an UCP. The invention further embraces complements of the foregoing nucleic acids or of unique fragments of the foregoing nucleic acids. Such complements can be used, for example, as antisense nucleic acids for inhibiting the expression of UCP
5 in a cell for accomplishing the effects of the inhibitors described below.

UCP nucleic acid molecules can be identified by conventional techniques, e.g., by identifying nucleic acid sequences which code for UCP polypeptides and which hybridize to a nucleic acid molecule having the sequence of SEQ ID NO: 1, 3, 5, and 7-12 or other publicly available UCP nucleic acid sequences under stringent conditions.
10 The term "stringent conditions", as used herein, refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refer to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% bovine serum albumin, 2.5mM NaH₂PO₄ (pH 7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH 7; SDS is sodium dodecyl sulphate;
15 and EDTA is ethylenediaminetetraacetic acid. After hybridization, the membrane to which the DNA is transferred is washed at 2x SSC at room temperature and then at 0.1x SSC/0.1x SDS at 65°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such
20 conditions and, thus, they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of the UCP nucleic acid of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for the expression of molecules, such as UCP, which can be isolated, followed by
25 purification and sequencing of the pertinent nucleic acid molecule. In screening for UCP nucleic acid sequences, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against x-ray film to detect the radioactive signal.

30 The term "Southern blot" refers to the analysis of DNA on agarose or acrylamide gels in which DNA is separated or fragmented according to size followed by transfer of the DNA from the gel to a solid support, such as nitrocellulose or a nylon membrane.

The immobilized DNA is then exposed to a labeled probe to detect DNA species complementary to the probe used. The DNA may be cleaved with restriction enzymes prior to electrophoresis. Following electrophoresis, the DNA may be partially depurinated and denatured prior to or during transfer to the solid support. Southern blots are a standard tool of molecular biologists (J. Sambrook et al. [1989] *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, NY, pp 9.31-9.58).

The term "Northern Blot" as used herein refers to the analysis of RNA by electrophoresis of RNA on agarose gels to fractionate the RNA according to size followed by transfer of the RNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized RNA is then probed with a labeled probe to detect RNA species complementary to the probe used. Northern blots are a standard tool of molecular biologists (J. Sambrook, J. et al. [1989] *supra*, pp. 7.39-7.52).

In general, homologs and alleles typically will share at least 40% nucleotide identity with SEQ ID NO: 1, 3, 5, and 7-12; in some instances, will share at least 50% nucleotide identity; and in still other instances, will share at least 60% nucleotide identity. The preferred homologs have at least 70% sequence homology to SEQ ID NO: 1, 3, 5, and 7-12. More preferably the preferred homologs have at least 80% and, most preferably, at least 90% sequence homology to SEQ ID NO: 1, 3, 5, and 7-12.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the naturally occurring nucleic acid that codes for the UCP polypeptide. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide codons may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to, CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the naturally occurring nucleic acids in codon sequence due to the degeneracy of the genetic code.

The UCP nucleic acid, in one embodiment, is operably linked to a gene expression sequence which directs the expression of the UCP nucleic acid within a plant cell. The "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the UCP nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a eukaryotic e.g. plant or viral promoter, such as a constitutive or inducible promoter. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription (Maniatis, T. *et al.*, *Science* 236:1237 [1987]). Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in plant, yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. A wide variety of promoters have been isolated from plants, which are functional not only in the cellular source of the promoter, but also in numerous other plant species. There are also other promoters (e.g., viral and Ti-plasmid) which can be used. For example, these promoters include promoters from the Ti-plasmid, such as the octopine synthase promoter, the nopaline synthase promoter, the mannopine synthase promoter, promoters from other open reading frames in the T-DNA, such as ORF7, etc. Promoters isolated from plant viruses include the 35S promoter from cauliflower mosaic virus (CaMV). Promoters that have been isolated and reported for use in plants include ribulose-1,3-biphosphate carboxylase small subunit promoter, phaseolin promoter, etc.

Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter
5 region which includes a promoter sequence for transcriptional control of the operably joined UCP nucleic acid. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

Preferably, the UCP nucleic acid of the invention is linked to a gene expression sequence which permits expression of the UCP nucleic acid in an alternative membrane
10 such as the cell wall/ plasma membrane or chloroplast of a cell. A sequence which permits expression of the UCP nucleic acid in a plant cell is one which is selectively active in the particular plant cell and thereby causes the expression of the UCP nucleic acid in these cells. Those of ordinary skill in the art will be able to easily identify promoters that are capable of expressing a UCP nucleic acid in a cell based on the type
15 of plant cell.

The UCP nucleic acid sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the UCP coding sequence under the influence or control of the gene expression sequence. If it is desired that the UCP sequence be
20 translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the UCP sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the UCP sequence, or (3) interfere with
25 the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a UCP nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that UCP nucleic acid sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

30 There are many ways to induce expression of UCP in a plant cell. For instance, it is possible to insert an intact UCP, or functional fragment thereof, into a cell wall/ plasma membrane using delivery vehicles such as liposomes. UCP is a naturally

occurring cell wall/ plasma membrane protein having several transmembrane spanning regions including many hydrophobic residues. Proteins of this type can spontaneously insert into a biological membrane in an aqueous environment. See, e.g., US Patent No. 5,739,273 (which is hereby incorporated by reference) describing properties of bacteriorhodopsin C helix, a transmembrane spanning protein. The UCP can be inserted in to a biological membrane consistent with the methods described in US Patent No. 5,739,273 for inserting bacteriorhodopsin C into a membrane, including in lipid vesicles and by modification of various residues to increase the hydrophobicity of the molecule, without altering the function. Additionally UCP can be conjugated to a molecule which will insert in the membrane, causing the UCP to also insert in the membrane.

As set forth in US Patent No. 5,739,273 cell membranes are composed mainly of phospholipids and proteins, both containing hydrophobic and hydrophilic groups. The lipids orient themselves into an orderly bilayer configuration within the membrane core with the hydrophobic chains facing toward the center of the membrane while the hydrophilic portions are oriented toward the outer and inner membrane surfaces. The proteins are dispersed throughout the lipid layer, in some instances protruding through the surface of the membrane or extending from one side of the membrane to the other with some of the hydrophobic residues being buried in the interior of the lipid bilayer.

US Patent No. 5,739,273 teaches that a synthetic polypeptide maintaining the characteristics of a native polypeptide by including a hydrophobic alpha-helical transmembrane region containing one or more acidic or basic amino acids can be generated. Preferably, the amino acids are aspartic acid, glutamic acid, lysine, arginine or histidine. This is based on the teachings of *Popot and Engelman, Biochem. 29:4031-4037 (1990)*, that recently proposed a two-stage model of helix formation for transmembrane proteins in which the alpha-helices first insert into the lipid bilayer and then assemble into a tertiary structure that includes interactions with other intramembrane alpha-helices of the protein or with alpha-helices of other polypeptides in the membrane.

The UCP insertion into the membrane can be enhanced using lipid vesicles. Lipid vesicles such as micelles can be formed by the addition of phospholipids to achieve a specific ratio of protein to phospholipid. The orientation of the chimeric protein components of the micelles can be controlled also, so that the micelles have an

outer surface which is predominantly composed of the phospholipid moieties or predominantly composed of the protein moieties. The size of the micelles may also be controlled by varying the detergent employed, the nature of the added phospholipid, or the phospholipid/protein ratio.

5 UCP proteins include the intact native UCP in an isolated form as well as functionally active fragments and variants thereof.

A UCP activator induces the uncoupling function of a UCP molecule that is already expressed in the an alternative membrane such as the cell wall/ plasma membrane or chloroplast or causes a functional UCP to be expressed or inserted into the
10 alternative membrane.

Thus, the present invention provides methods and compositions for the expression of UCP in plants. The present invention contemplates that any method of transfection that is suitable for transfection of plants, plant tissues, and plant cells may be used with the present invention. Such methods include, but are not limited to,
15 *Agrobacterium*-mediated transformation (*e.g.*, Komari *et al.*, Curr. Opin. Plant Biol., 1:161 [1998]), particle bombardment mediated transformation (*e.g.*, Finer *et al.*, Curr. Top. Microbiol. Immunol., 240:59 [1999]), protoplast electroporation (*e.g.*, Bates, Methods Mol. Biol., 111:359 [1999]), viral infection (*e.g.*, Porta and Lomonosoff, Mo. Biotechnol. 5:209 [1996]), microinjection, and liposome injection. Standard molecular
20 biology techniques are common in the art (*See e.g.*, Sambrook, J. *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, New York [1989]). For example, in one embodiment of the present invention tobacco or arabidopsis is transformed with a gene encoding UCP using *Agrobacterium*.

Using any of the above gene transfer techniques, an expression vector harboring
25 the UCP gene of interest is transformed into the desired plant sample to achieve temporary or prolonged expression of the UCP. Any suitable expression system may be used, so long as it is capable of undergoing transformation and expressing of the gene of interest in the host. In one embodiment of the present invention, a pET vector (Novagen, Madison, Wisconsin), or a pBI vector (Clontech, Palo Alto, California) is used as the
30 expression vector. In some embodiments an expression vector further encoding a green fluorescent protein (GFP) is used to allow simple selection of transfected cells and to monitor expression levels. Examples of such vectors include Clontech's "Living Colors

Vectors" pEYFP and pEYFP-C1. The EYFP gene is codon optimized for high expression in plant cells.

A variety of promoters and regulatory elements may be used in the expression vectors of the present invention. For example, in some preferred embodiments an inducible promoter is used to allow control of UCP expression through the presentation of external stimuli (*e.g.*, environmentally inducible promoters). Thus, the timing and amount of UCP expression may be controlled. Examples of expression systems, promoters, inducible promoters, environmentally inducible promoters, and enhancers are described in WO 00/12714, WO 00/11175, WO 00/12713, WO 00/03012, WO 00/03017, WO 00/01832, WO 99/50428, WO 99/46976 and U.S. Pat. Nos. 6,028,250, 5,959,176, 5,907,086, 5,898,096, 5,824,857, 5,744,334, 5,689,044, and 5,612,472 each of which is herein incorporated by reference in its entirety.

UCP expression may be controlled in a number of ways. For example, expression may be stimulated by expressing a UCP gene in the plant, plant tissue, or plant cell. Expression may be from a UCP gene from a different species or may be from the expression of an endogenous gene. Regulation of the endogenous gene may be achieved, for example, through the introduction of a heterologous promoter, by increasing the copy number of the gene, and through the stimulation of native gene expression by regulating the levels or presence of particular transcription factors. UCP expression may be inhibited, for example, through the introduction of antisense molecules or other RNA targeting molecules (*e.g.*, ribozymes), gene-knockout (*i.e.*, disrupting the UCP gene), down-regulation of gene expression by manipulating transcription factor activity, introduction of protein inhibitors, and other established methods. One illustrative example of induced and inhibited expression is provided below.

In one embodiment of the present invention, cDNA encoding mouse UCP2 (genbank accession #U69135, SEQ ID NO:1) is cloned into a Bluescript (Stratagene, La Jolla, California) as a 1588 bp XhoI-EcoRI fragment. The start codon begins at nucleotide position 360. The stop codon begins at nucleotide position 1290. This clone contains both 5' and 3' flanking sequences. Two sets of PCR primers were synthesized and may be used to isolate the gene fragment.

The primer set corresponds to the sense sequence of the mouse UCP2 (that is, the entire sequence, from nucleotide 360 to nucleotide 1290). Each of these primers also contains a restriction enzyme site corresponding to the cloning site.

The sense 5' primer: 5' GTACCGGGCCCCATGGTTGGTTTCAAG 3'

5 (SEQ ID NO:13)

The sense 3' primer: 5' GGCCATCTCGAGGAAAGGTGCCTCCCG 3'

(SEQ ID NO:14)

For generating an antisense fragment, the largest open reading frame in the antisense orientation was determined. The antisense fragment is approximately 550
10 nucleotides long (between nucleotides 1005 and 305 when looking at the sequence in antisense) and encodes an open reading frame. Each of the primers also contains a restriction enzyme site corresponding to the cloning site.

The sense 5' primer: 5' GTACCGGGCCCCATGGGCTCTTTTGAGCTG 3'

(SEQ ID NO:15)

15 The sense 3' primer: 5' CTTGGCCATCTCGAGCATGCAGGCATC 3'

(SEQ ID NO:16)

The sense and antisense fragments are isolated from the UCP2 gene in the Bluescript vector using the polymerase chain reaction. The isolated fragments are cloned into a GFP fusion protein vector optimized for *Chlamydomonas*. One example of such a
20 vector is pFCrGFP (Entelechon GmbH, Regensburg, Germany).

After cloning the sense and antisense constructs into this vector, *Chlamydomonas* is transformed using the glass bead-vortex method (See e.g., Kindle, "Chap 4, Nuclear Transformation: Technology and Applications," The Molecular Biology of Chloroplasts and Mitochondria in *Chlamydomonas*, Klawer Academic Publishers [1998]; Kindle,
25 Proc. Natl. Acad. Sci. USA 87:1228 [1990]). A cell-wall-less strain, nit 1-305 is used and transformed with the plasmid pMN24 containing a gene that allows transformants to grow on nitrate-containing medium. Rather than clone UCP2 into pMN24, co-transformation of the two plasmids (pMN24 and pFCrGFP) is conducted and transformants are selected on nitrate. In addition, because UCP2 is fused to GFP,
30 colonies containing UCP2 can be screened more directly by their fluorescence using flow cytometry.

In one embodiment of the present invention, a first transformation is gain-of-function. For example, the sense-GFP construct is transformed into the cell wall-less strain nit 1-305. This strain has two advantages. It lacks a cell wall and so can be easily transformed and it lacks UCP2 when analyzed by flow cytometry, as is predicted from the flow cytometry results discussed above (*i.e.*, that no cell wall-less strains will have UCP2 when grown under standard light conditions).

In another embodiment of the present invention, a second transformation involves loss-of-function. For example, the anti-sense-GFP construct is used. In some embodiments, the cell wall is removed by autolysin to facilitate transfection prior to vortexing with glass beads. The selection process is as described in Kindle, Chapter 4, Nuclear Transformation: Technology and Applications, *Supra*.

In still another embodiment of the present invention, the selection process can be achieved via drug sensitivity as described in Kindle, Chapter 4, Nuclear Transformation: Technology and Applications, *Supra*.

Successful transformation and expression levels may be detected any number of ways. In addition to the GFP-screening described above, Southern and Northern hybridization assays may be conducted to identify successful transformants and detected UCP expression levels. The UCP fragments described above may be used as probes. For Northern blot analysis, RNAs isolated from different strains of *Chlamydomonas*, and *Chlamydomonas* grown under different conditions are isolated and tested.

In still further embodiments, ribozymes may be used to bind to a target RNA through complementary base-pairing, and once bound to the correct site, act enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. Examples of ribozyme motifs with enzymatic activity include hammerheads and hairpins (*See, e.g.*, U.S. Pat. Nos. 5,891,684; 5,877,022; 5,869,253; 5,811,300; 5,795,778; 5,728,818; and 5,714,383, all of which are incorporated herein by reference).

Identification and characterization of UCP localization in the cells may be conducted by confocal microscopy or any other suitable method. In some embodiments, organelles are isolated and analyzed for the presence of UCP through their ability to bind UCP-specific antibodies.

UCP inhibitors are any compounds which decrease the activity of UCP in an alternative membrane. UCP inhibitors include but are not limited to UCP binding peptides such as anti-UCP antibodies, UCP anti-sense nucleic acids, UCP dominant negative nucleic acids, nucleotides, nucleotide analogs, tocopherols, such as tocotrienols, and non omega 3 or 6 fatty acids. Other types of inhibitors include ribozymes which interfere with the transcription, processing, or translation of UCP mRNA. In other embodiments the UCP inhibitor is tunicamycin. Tunicamycin promotes intracellular trafficking of the UCP between intracellular locations. Each of these inhibitors is well known in the art and has been described extensively in the literature.

Nucleotides and nucleotide (purine and pyrimidine) analogs include but are not limited to guanosine diphosphate (GDP). Purine analogs include but are not limited to guanosine diphosphate, 8-oxo-Adenosine, 8-oxo-Guanosine, 8-fluoro-Adenosine, 8-fluoro-Guanosine, 8-methoxy-Adenosine, 8-methoxy-Guanosine, 8-aza-Adenosine and 8-aza-Guanosine, azacitidine, Fludarabine phosphate, 6-MP, 6-TG, azathioprine, allopurinol, acyclovir, gancyclovir, deoxycoformycin, and arabinosyladenine (ara-A), guanosine diphosphate fucose, guanosine diphosphate-2-fluorofucose, guanosine diphosphate-.beta.L-2-aminofucose, guanosine diphosphate-D-arabinose and 2-aminoadenosine. Some examples of pyrimidine analogues are uracil, thymine, cytosine, 5-fluorouracil, 5-chlorouracil, 5-bromouracil, dihydrouracil, 5-methylcytosine, 5-propynylthymine, 5-propynyluracil and 5-propynylcytosine, 5-fluorocytosine, Floxuridine, uridine, thymine, 3'-azido-3'-deoxythymidine, 2-fluorodeoxycytidine, 3-fluoro-3'-deoxythymidine; 3'-dideoxycytidin-2'-ene; and 3'-deoxy-3'-deoxythymidin-2'-ene, cytosine arabinoside. Other such compounds are known to those of skill in the art.

Thus nucleotides and nucleotide analogs can be modified to produce cell wall/ plasma membrane targeted UCP inhibitors by attaching a cell wall/ plasma membrane targeting sequence to the nucleotide or nucleotide analog. This can be accomplished by linking the nucleotide analog to a cell surface targeting molecule. Several methods for linking molecules are described below and others are known in the art. The nucleotide or nucleotide analogs may also be modified such that it is membrane impermeable to prevent uptake of the nucleotide analog by the cell. By using compounds which are not taken up by a cell but simply act on the cell surface UCP many of the toxic side effects

associated with some of these drugs are avoided. The compounds will not have an effect on cells that do not have UCP expressed in the cell wall/ plasma membrane, because they cannot access the intracellular UCP. Additionally, the compounds will not be metabolized within cells to produce toxic compounds.

5 UCP inhibitors also include UCP binding peptides or molecules. The binding peptides or molecules can be delivered directly to the cell to act on the cell wall/ plasma membrane UCP. The UCP binding peptide or molecule may also be attached to a targeting molecule which targets the peptide or molecule to the cell of interest, as discussed in more detail below.

10 The UCP binding peptides and molecules of the invention can be identified using routine assays, such as the binding and activation assays described in the Examples and elsewhere throughout this patent application.

The UCP binding molecule is an isolated molecule. An isolated molecule is a molecule that is substantially pure and is free of other substances with which it is
15 ordinarily found in nature or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the molecular species are sufficiently pure and are sufficiently free from other biological constituents of host cells so as to be useful in, for example, producing pharmaceutical preparations or sequencing if the molecular species is a nucleic acid, peptide, or polysaccharide. Because an isolated molecular species of
20 the invention may be admixed with a pharmaceutically-acceptable carrier in a pharmaceutical preparation, the molecular species may comprise only a small percentage by weight of the preparation. The molecular species is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems.

25 The UCP binding molecules may be isolated from natural sources or synthesized or produced by recombinant means. Methods for preparing or identifying molecules which bind to a particular target are well-known in the art. Molecular imprinting, for instance, may be used for the de novo construction of macro molecular structures, such as peptides, which bind to a particular molecule. See for example, Kenneth J. Shea,
30 *Molecular Imprinting of Synthetic Network Polymers: The De novo Synthesis of Molecular Binding In Catalytic Sites*, Trip, to May 1994; Klaus, Mosbach, *Molecular Imprinting*, Trends in *Biochem. Sci.*, 19(9), January 1994; and Wulff, G., In *Polymeric*

Reagents and Catalysts (Ford, W.T., ed.) *ACS Symposium Series* No. 308, P.186-230, *Am. Chem. Soc.* 1986. Binding peptides, such as antibodies, may easily be prepared by generating antibodies to UCP (or obtained from commercial sources) or by screening libraries to identify peptides or other compounds which bind to the UCP.

5 Many UCP antibodies are commercially available. These include but are not limited to those antibodies commercially available from Santa Cruz Biotechnology, Inc., e.g., UCP1 (m-17, sc-6529), UCP1 (C-17, sc-6528), UCP2 (A19, sc-6527), UCP2 (N19, sc-6526), UCP2 (c-20, sc-6525), and UCP3 (C-20, sc-7756); antibodies commercially available from Research Diagnostics Inc e.g., Goat anti-UCP1 HUMAN/Mouse/Rat
10 (cat#RDI-UCP1Cabg); Goat anti-UCP1 HUMAN/Mouse/Rat (cat#RDI-MUCP1Cabg); Goat anti-UCP2 HUMAN/Mouse/Rat (cat#RDI-UCP2Nabg); Goat anti-UCP2 HUMAN/Mouse/Rat (cat#RDI-UCP2Cabg); Goat anti-UCP2 HUMAN/Mouse/Rat (cat#RDI-UCP2C1abg); Rabbit anti-Murine UCP1 (cat#RDI-MUCP12abrX); Rabbit anti-Murine UCP1 (cat#RDI-MUCP19abrX); Rabbit anti-Murine UCP2 (cat#RDI-
15 MUCP2abrX) ; Rabbit anti-Murine UCP2 (cat#RDI-MUCP2CabrX); Rabbit anti-human UCP2 (cat#RDI-UCP2MabrX); UCP3L (see Boss, O et al (1997) FEBS Lett 408,38-42; Vidal-Plug A et al (1997) BBRC 235, 79-82); Rabbit anti-HUMAN UCP3 (cat#RDI-UCP3abrX); Rabbit anti-HUMAN UCP3 (cat#RDI-UCP3CbrX); Rabbit anti-HUMAN UCP3 (cat#RDI-UCP3MabrX); Rabbit anti-Rat UCP3 (cat#RDI-RTUCP3MabrX), etc.

20 Mimics of known binding molecules may also be prepared by known methods, such as (i) polymerization of functional monomers around a known binding molecule or the binding region of an antibody which also binds to the target (the template) that exhibits the desired activity; (ii) removal of the template molecule; and then (iii) polymerization of a second class of monomers in the void left by the template, to provide
25 a new molecule which exhibits one or more desired properties which are similar to that of the template. The method is useful for preparing peptides, and other binding molecules which have the same function as binding peptides, such as polysaccharides, nucleotides, nucleoproteins, lipoproteins, carbohydrates, glycoproteins, steroids, lipids and other biologically-active material can also be prepared. Thus a template, such as a
30 UCP binding antibody can be used to identify UCP inhibitors. It is now routine to produce large numbers of inhibitors based on one or a few peptide sequences or sequence motifs. (See, e.g., Bromme, et al., *Biochem. J.* 315:85-89 (1996); Palmer, et

al., *J. Med. Chem.* 38:3193-3196 (1995)). For example, if UCP is known to interact with protein X at position Y, an inhibitor of UCP may be chosen or designed as a polypeptide or modified polypeptide having the same sequence as protein X, or structural similarity to the sequence of protein X, in the region adjacent to position Y. In fact, the region
5 adjacent to the cleavage site Y spanning residues removed by 10 residues or, more preferably 5 residues, N-terminal and C-terminal of position Y, may be defined as a "preferred protein X site" for the choice or design of UCP inhibitors. Thus, a plurality of UCP inhibitors chosen or designed to span the preferred protein X binding site around position Y, may be produced, tested for inhibitory activity, and sequentially modified to
10 optimize or alter activity, stability, and/or specificity.

The method is useful for designing a wide variety of biological mimics that are more stable than the natural counterpart, because they are typically prepared by the free radical polymerization of functional monomers, resulting in a compound with a non-biodegradable backbone. Thus, the created molecules would have the same binding
15 properties as the UCP antibody but be more stable *in vivo*, thus preventing UCP from interacting with components normally available in its native environment. Other methods for designing such molecules include, for example, drug design based on structure activity relationships which require the synthesis and evaluation of a number of compounds and molecular modeling.

20 Binding molecules may also be identified by conventional screening methods, such as phage display procedures (e.g. methods described in Hart et al., *J. Biol. Chem.* 269:12468 (1994)). Hart et al. report a filamentous phage display library for identifying novel peptide ligands. In general, phage display libraries using, e.g., M13 or fd phage, are prepared using conventional procedures such as those described in the foregoing
25 reference. The libraries generally display inserts containing from 4 to 80 amino acid residues. The inserts optionally represent a completely degenerate or biased array of peptides. Ligands having the appropriate binding properties are obtained by selecting those phage which express on their surface a ligand that binds to the target molecule. These phage are then subjected to several cycles of reselection to identify the peptide
30 ligand expressing phage that have the most useful binding characteristics. Typically, phage that exhibit the best binding characteristics (e.g., highest affinity) are further characterized by nucleic acid analysis to identify the particular amino acid sequences of

the peptide expressed on the phage surface in the optimum length of the express peptide to achieve optimum binding.

Alternatively, UCP binding molecules can be identified from combinatorial libraries. Many types of combinatorial libraries have been described. For instance, U.S. Patent Nos. 5,712,171 (which describes methods for constructing arrays of synthetic molecular constructs by forming a plurality of molecular constructs having the scaffold backbone of the chemical molecule and modifying at least one location on the molecule in a logically-ordered array); 5,962,412 (which describes methods for making polymers having specific physiochemical properties); and 5,962,736 (which describes specific arrayed compounds).

To determine whether a molecule binds to the appropriate target any known binding assay may be employed. For example, in the case of a peptide that binds to the cell wall/ plasma membrane UCP the molecule may be immobilized on a surface and then contacted with a labeled UCP (or vice versa). The amount of UCP which interacts with the molecule or the amount which does not bind to the molecule may then be quantitated to determine whether the molecule binds to UCP. A surface having a known molecule that binds to UCP such as a commercially available monoclonal antibody immobilized thereto may serve as a positive control. Several types of commercially available antibodies are described above.

Screening of molecules of the invention, also can be carried out utilizing a competition assay. If the molecule being tested competes with the known monoclonal antibody, as shown by a decrease in binding of the known monoclonal antibody, then it is likely that the molecule and the known monoclonal antibody bind to the same, or a closely related, epitope. Still another way to determine whether a molecule has the specificity of the known monoclonal antibody is to pre-incubate the known monoclonal antibody with the target with which it is normally reactive, and then add the molecule being tested to determine if the molecule being tested is inhibited in its ability to bind the target. If the molecule being tested is inhibited then, in all likelihood, it has the same, or a functionally equivalent, epitope and specificity as the known monoclonal antibody.

By using the known UCP (and other target) monoclonal antibodies of the invention, it is also possible to produce anti-idiotypic antibodies which can be used to screen other antibodies to identify whether the antibody has the same binding specificity

- 28 -

as the known monoclonal antibody. Such anti-idiotypic antibodies can be produced using well-known hybridoma techniques (*Kohler and Milstein, Nature, 256:495, 1975*). An anti-idiotypic antibody is an antibody which recognizes unique determinants present on the known monoclonal antibodies. These determinants are located in the

5 hypervariable region of the antibody. It is this region which binds to a given epitope and, thus, is responsible for the specificity of the antibody. An anti-idiotypic antibody can be prepared by immunizing an animal with the known monoclonal antibodies. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing known monoclonal antibodies and produce an antibody to these idiotypic

10 determinants. By using the anti-idiotypic antibodies of the immunized animal, which are specific for the known monoclonal antibodies of the invention, it is possible to identify other clones with the same idio type as the known monoclonal antibody used for immunization. Idiotypic identity between monoclonal antibodies of two cell lines demonstrates that the two monoclonal antibodies are the same with respect to their

15 recognition of the same epitopic determinant. Thus, by using anti-idiotypic antibodies, it is possible to identify other hybridomas expressing monoclonal antibodies having the same epitopic specificity.

It is also possible to use the anti-idiotypic technology to produce monoclonal antibodies which mimic an epitope. For example, an anti-idiotypic monoclonal antibody

20 made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the image of the epitope bound by the first monoclonal antibody.

In one embodiment the binding peptides useful according to the invention are antibodies or functionally active antibody fragments. Antibodies are well known to those of ordinary skill in the science of immunology. Many of the binding peptides

25 described herein are available from commercial sources as intact functional antibodies, as described above. As used herein, the term "antibody" means not only intact antibody molecules but also fragments of antibody molecules retaining specific binding ability. Such fragments are also well known in the art. In particular, as used herein, the term "antibody" means not only intact immunoglobulin molecules but also the well-known

30 active fragments $F(ab')_2$, and Fab. $F(ab')_2$, and Fab fragments which lack the Fc fragment of intact antibody (*Wahl et al., J. Nucl. Med. 24:316-325 (1983)*).

As is well-known in the art, the complementarity determining regions (CDRs) of an antibody are the portions of the antibody which are largely responsible for antibody specificity. The CDR's directly interact with the epitope of the antigen (see, in general, *Clark, 1986; Roitt, 1991*). In both the heavy chain and the light chain variable regions of
5 IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The framework regions (FRs) maintain the tertiary structure of the paratope, which is the portion of the antibody which is involved in the interaction with the antigen. The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3
10 contribute to antibody specificity. Because these CDR regions and in particular the CDR3 region confer antigen specificity on the antibody these regions may be incorporated into other antibodies or peptides to confer the identical specificity onto that antibody or peptide.

According to one embodiment, the peptide of the invention is an intact soluble
15 monoclonal antibody in an isolated form or in a pharmaceutical preparation. An intact soluble monoclonal antibody, as is well known in the art, is an assembly of polypeptide chains linked by disulfide bridges. Two principle polypeptide chains, referred to as the light chain and heavy chain, make up all major structural classes (isotypes) of antibody. Both heavy chains and light chains are further divided into subregions referred to as
20 variable regions and constant regions. As used herein the term "monoclonal antibody" refers to a homogenous population of immunoglobulins which specifically bind to an epitope (i.e. antigenic determinant), e.g., of cell wall/ plasma membrane UCP, chloroplast UCP etc.

The binding peptides may also be functionally active antibody fragments.
25 Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (*see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford*). The pFc' and Fc regions of the antibody, for example,
30 are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the

- 30 -

antigen binding sites of an intact antibody. An isolated $F(ab')_2$ fragment is referred to as a bivalent monoclonal fragment because of its two antigen binding sites. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd (heavy chain variable region). The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

The terms Fab, Fc, pFc', $F(ab')_2$ and Fv are used consistently with their standard immunological meanings [Klein, *Immunology* (John Wiley, New York, NY, 1982); Clark, W.R. (1986) *The Experimental Foundations of Modern Immunology* (Wiley & Sons, Inc., New York); Roitt, I. (1991) *Essential Immunology*, 7th Ed., (Blackwell Scientific Publications, Oxford)].

In addition to the binding peptides and molecules, the invention also encompasses the use of antisense oligonucleotides that selectively bind to a UCP nucleic acid molecule, and dominant negative UCP to reduce the expression of UCP. Antisense oligonucleotides are useful, for example, for inhibiting UCP in a cell in which it is ordinarily expressed in alternative membranes such as the cell wall/ plasma membrane and chloroplasts.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an RNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of the mRNA. The antisense molecules are designed so as to hybridize with the target gene or target gene product and thereby, interfere with transcription or translation of the target plant cell gene. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. The antisense must be a unique fragment. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its

- 31 -

precise sequence is not found in molecules outside of the UCP gene. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NO:1, 3, 5, and 7-12, will require longer segments to be unique while others will require only short segments, typically between 12 and 32 base pairs (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases long).

It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the known sequence of a gene that is targeted for inhibition by antisense hybridization, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 7 and, more preferably, at least 15 consecutive bases which are complementary to the target. Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or RNA (e.g., mRNA) transcripts, in preferred embodiments the antisense oligonucleotides are complementary to 5' sites, such as translation initiation, transcription initiation or promoter sites, that are upstream of the gene that is targeted for inhibition by the antisense oligonucleotides. In addition, 3'-untranslated regions may be targeted. Furthermore, 5' or 3' enhancers may be targeted. Targeting to mRNA splice sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In at least some embodiments, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.*, (1994) 14(5):439-457) and at which proteins are not expected to bind. The selective binding of the antisense oligonucleotide to a plant cell nucleic acid effectively decreases or eliminates the transcription or translation of the plant target cell nucleic acid molecule, thus reducing UCP expression in the plant.

The invention also includes the use of a "dominant negative cell wall/ plasma membrane UCP" polypeptide. A dominant negative polypeptide is an inactive variant of

- 32 -

a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide as used herein in a cell is a reduction in membrane expressed UCP. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, one of ordinary skill in the art can modify the sequence of the cell wall/ plasma membrane UCP by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity, or simply for presence in the cell wall/ plasma membrane. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

Optionally, a plant cell targeting sequence can be used to target the UCP inhibitor or activator to a specific type of plant cell. It is desirable in many instances to specifically target the activator or inhibitor to a specific plant cell type to increase the efficiency and specificity of administration of the UCP inhibitor or activator and to avoid delivering the compounds to another plant cell in close physical proximity, for which the treatment may not be beneficial.

Methods of targeting drugs and other compounds to target cells are well known in the art. One method of targeting involves antibody or receptor targeting. Receptor or

antibody targeting involves linking the UCP inhibitor or activator to a ligand or an antibody which has an affinity for a receptor or cell surface molecule expressed on the desired target cell surface. Using this approach, the UCP inhibitor or activator is intended to adhere to the target cell following formation of a ligand-receptor or antibody-cell surface antigen complex on the cell surface. The type of receptor or antibody used to target the cell will depend on the specific cell type being targeted.

A plant cell targeting sequence may be attached by a peptide or other type of bond such as a sulfhydryl or disulfide bond. Targeting molecules are described, for instance in US Patent No. 5,849,718 as well as many other references.

In general the plant cell targeting sequence is coupled to the UCP inhibitor or activator. The molecules may be directly coupled to one another, such as by conjugation or may be indirectly coupled to one another where, for example, plant cell targeting sequence is on the surface of a liposome and the UCP inhibitor or activator is contained within the liposome. If the molecules are linked to one another, then the plant cell targeting sequence is covalently or noncovalently bound to the UCP inhibitor or activator in a manner that preserves the targeting specificity of the plant cell targeting sequence. As used herein, "linked" or "linkage" means two entities are bound to one another by any physiochemical means. It is important that the linkage be of such a nature that it does not impair substantially the effectiveness of the UCP inhibitor or activator or the binding specificity of the plant cell targeting sequence. Keeping these parameters in mind, any linkage known to those of ordinary skill in the art may be employed, covalent or noncovalent. Such means and methods of linkage are well known to those of ordinary skill in the art.

Linkage according to the invention need not be direct linkage. The components of the compositions of the invention may be provided with functionalized groups to facilitate their linkage and/or linker groups may be interposed between the components of these compositions to facilitate their linkage. In addition, the components of the present invention may be synthesized in a single process, whereby the components could be regarded as one in the same entity. For example, a plant cell targeting sequence specific for a plant cell could be synthesized together with the UCP inhibitor or activator. These and other modifications are intended to be embraced by the present invention.

Specific examples of covalent bonds include those wherein bifunctional cross-linker molecules are used. The cross-linker molecules may be homobifunctional or heterobifunctional, depending upon the nature of the molecules to be conjugated. Homobifunctional cross-linkers have two identical reactive groups. Heterobifunctional cross-linkers have two different reactive groups that allow sequential conjugation reaction. Various types of commercially available cross-linkers are reactive with one or more of the following groups: primary amines, secondary amines, sulfhydryles, carboxyls, carbonyls and carbohydrates.

Non-covalent methods of conjugation also may be used to join the targeting moiety and the UCP inhibitor or activator. Non-covalent conjugation may be accomplished by direct or indirect means including hydrophobic interaction, ionic interaction, intercalation, binding to major or minor grooves of a nucleic acid and other affinity interactions.

Covalent linkages may be noncleavable in physiological environments or cleavable in physiological environments, such as linkers containing disulfide bonds. Such molecules may resist degradation and/or may be subject to different intracellular transport mechanisms. One of ordinary skill in the art will be able to ascertain without undue experimentation the preferred bond for linking the targeting moiety and the UCP inhibitor or activator, based on the chemical properties of the molecules being linked and the preferred characteristics of the bond.

For indirect linkage, the plant cell targeting sequence may be part of a particle, such as a liposome, which targets the liposome to the plant cell or organelle. The liposome, in turn, may contain the UCP inhibitor or activator. The manufacture of liposomes containing a protein or nucleic acid such as a UCP inhibitor or activator is fully described in the literature. Many are based upon cholesteric molecules as starting ingredients and/or phospholipids. They may be synthetically derived or isolated from natural membrane components. Virtually any hydrophobic substance can be used, including cholesteric molecules, phospholipids and fatty acids preferably of medium chain length (12C-20C). Preferred are naturally occurring fatty acids of between 14 and 18 carbons in length. These molecules can be attached to the UCP inhibitor or activator of the invention, with the lipophilic anchor inserting into the membrane of a liposome

and the UCP inhibitor or activator tethered on the surface of the liposome for targeting the liposome to the cell.

In some embodiments the UCP activators and inhibitors are targeted to the intracellular organelles or to the cell wall or plasma membrane, including the plasma
5 desmata or pores. These types of targeting molecules are described above and can be linked to the activators and inhibitors as described herein.

The term "heterologous," as used herein in reference to a membrane attachment domain operatively fused to a UCP inhibitor or activator, means a membrane attachment domain derived from a source other than the gene encoding the UCP inhibitor or
10 activator. A heterologous membrane attachment domain can be synthetic or can be encoded by a gene distinct from the gene encoding the UCP inhibitor or activator to which it is fused.

The term "operatively fused," as used herein in reference to a UCP inhibitor or activator and a heterologous membrane attachment domain, means that the UCP
15 inhibitor or activator and membrane attachment domain are fused in the correct reading frame such that, under appropriate conditions, a full-length fusion protein is expressed. One skilled in the art would recognize that such a fusion protein can comprise, for example, an amino-terminal UCP inhibitor or activator operatively fused to a carboxyl-terminal heterologous membrane attachment domain or can comprise an amino-terminal
20 heterologous membrane attachment domain operatively fused to a carboxyl-terminal UCP inhibitor or activator

The term "membrane-bound," as used herein in reference to a fusion protein means stably attached to a cellular membrane. The term "fusion protein," as used herein, means a hybrid protein including a synthetic or heterologous amino acid sequence.

25 As used herein, the term "dissipation of cellular proton motor force" refers to the relative amount of protons in the cell. It can be assessed by measuring cell wall/ plasma, chloroplast, or mitochondrial membrane potential depending on the UCP being studied. As used herein "cell wall/ plasma membrane potential" is the pressure on the inside of the cell wall/ plasma membrane measured relative to the extracellular fluid which is
30 created by the generation and dissipation of charge within the cell. The "chloroplast membrane potential" is the pressure on the inside of the chloroplast membrane measured relative to the cytoplasm which is created by the generation and dissipation of charge

- 36 -

within the chloroplast. The cell wall/ plasma or chloroplast membrane potential is maintained by the energy generating system of the cell wall/ plasma or chloroplast membrane respectively. In most tissues electron transport is coupled to oxidative phosphorylation resulting in the production of ATP from glucose. UCPs can cause the reversible uncoupling of electron transport and oxidative phosphorylation, which leads to a decrease in the mitochondrial membrane potential, or as discovered herein the cell wall/ plasma or chloroplast membrane potential.

The absolute levels of the cell wall/ plasma membrane potential vary depending on the cell or tissue type. As used herein an "increase in cell wall/ plasma or chloroplast membrane potential" is an increase relative to the normal status of the cell being examined and results from the prevention of dissipation of proton motor force with respect to cell wall/ plasma or chloroplast respectively. "Prevention" as used herein refers to a decrease or reduction in the amount of dissipation that would ordinarily occur in the absence of the stimulus applied according to the methods of the invention to cause coupling. If electron transport and oxidative phosphorylation are normally uncoupled within the cell wall/ plasma or chloroplast membrane of the cell then the baseline potential will be relatively low and when the ATP generating systems are coupled an increase in cell wall/ plasma or chloroplast membrane potential from that baseline level is observed. Likewise, a "decrease in cell wall/ plasma or chloroplast membrane potential" is a decrease relative to the normal status of the cell being examined and results from the dissipation of proton motor force. If electron transport and oxidative phosphorylation are normally coupled within the cell then the baseline potential will be relatively high and when the ATP generating systems are uncoupled a decrease in cell wall/ plasma membrane potential from that baseline level is observed. Cell wall/ plasma or chloroplast membrane ATP synthase is likely the source of ATP for the cell wall/ plasma or chloroplast membrane UCP.

Changes in cell wall/ plasma or chloroplast membrane potential can be assessed by any method known in the art for making such measurements. For example the cell wall/ plasma or chloroplast membrane potential may be assessed using the well known comet assay, where whole cells are electrophoresed on an agarose gel and examined for the presence of a tail. Alternatively it may be measured using electrodes placed on opposite sides of the membrane. Cell wall/ plasma or chloroplast membrane potential

may also be measured cytometrically by incubating cells for approximately 20 minutes at room temperature with a cell wall/ plasma or chloroplast membrane specific fluorescent probe. The aggregation state and consequently the fluorescence emission of fluorescent probe changes as the cell wall/ plasma or chloroplast membrane potential is altered.

- 5 Flow cytometry permits the examination of more than one, for instance eight, fluorescent markers concurrently.

The invention also relates to the discovery that modulation of UCP activity also influences reactive oxygen generation and accumulation. This finding has important implications for the regulation of many physiological processes including infectious
10 disease. Thus the invention relates to the treatment and prevention of disease in plants.

Each of the compositions of the invention may optionally be associated with a delivery system or vector. In its broadest sense, a "vector" is any vehicle capable of facilitating: (1) delivery of a composition to a target cell or (2) uptake of a composition by a target cell, if uptake is important. In general, the vectors useful in the invention are
15 divided into two classes: colloidal dispersion systems and biological vectors.

As used herein, a "colloidal dispersion system" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering to and releasing the active agent to the plant cell. Colloidal dispersion systems include macromolecular complexes, beads, and lipid-based systems including
20 oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vessels. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2 - 4.0 μ can encapsulate large macromolecules within the aqueous interior and these macromolecules can be delivered to cells in a biologically active form (Fraley, et al.,
25 *Trends Biochem. Sci.*, 6:77 (1981)).

Lipid formulations for transfection are commercially available from QIAGEN, for example as EFFECTENE™ (a non-liposomal lipid with a special DNA condensing enhancer) and SUPER-FECT™ (a novel acting dendrimeric technology) as well as Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of
30 cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many

publications. Liposomes were described in a review article by Gregoriadis, G., *Trends in Biotechnology* 3:235-241 (1985), which is hereby incorporated by reference.

It is envisioned that the UCP activator or UCP inhibitor may be delivered to the subject in a biological vector which is a nucleic acid molecule which encodes for the UCP activator or UCP inhibitor such that the UCP activator or UCP inhibitor is expressed. The nucleic acid encoding the UCP activator or UCP inhibitor is operatively linked to a gene expression sequence, such as that described above.

The UCP activator or UCP inhibitor nucleic acid of the invention may be delivered to the cell alone or in association with a vector. In its broadest sense, a "vector" is any vehicle capable of facilitating the transfer of the UCP activator or UCP inhibitor nucleic acid to the appropriate cells so that the UCP activator or UCP inhibitor can be expressed on the cell wall/ plasma membrane or within the cell respectively.

Preferably, the vector transports the nucleic acid to the cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. The vector optionally includes the above-described gene expression sequence to enhance expression of the UCP activator or UCP inhibitor nucleic acid. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the UCP activator or UCP inhibitor nucleic acid sequences.

Viral vectors are a preferred type of vector and include, but are not limited to nucleic acid sequences from the following viruses: retrovirus, such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rouse sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known to the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. An example of virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication -deficient

and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions.

5 Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al., "Molecular Cloning: A Laboratory Manual," Second Edition, Cold Spring Harbor Laboratory Press, 1989. These plasmids having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid. Some
10 commonly used plasmids include pBR322, pUC18, pUC19, pRC/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

Other exemplary compositions that can be used to facilitate uptake by a target
15 cell of the compositions of the invention include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a composition of the invention into a preselected location within the target cell chromosome).

As used herein the term "transgenic" when used in reference to a plant or fruit
20 (i.e., a "transgenic plant" or "transgenic fruit") refers to a plant or fruit that contains at least one heterologous gene in one or more of its cells.

As used herein, the term "sample" is used in its broadest sense. In one sense it can refer to a plant cell or tissue. In another sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples.
25 Biological samples may be obtained from plants or animals and encompass fluids, solids, tissues, and gases. Environmental samples include environmental material such as surface matter, soil, water, and industrial samples. These examples are not to be construed as limiting the sample types applicable to the present invention.

The words "transformants" or "transformed cells" include the primary
30 transformed cell and cultures derived from that cell without regard to the number of transfers. All progeny may not be precisely identical in DNA content, due to deliberate

or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included in the definition of transformants.

As used herein, the term "selectable marker" refers to the use of a gene that encodes an enzymatic or other detectable activity (e.g., luminescence, fluorescence, or radioactivity) that confers the ability to grow in medium lacking what would otherwise be an essential nutrient. A selectable marker may also confer resistance to an antibiotic or drug upon the cell in which the selectable marker is expressed. Selectable markers may be "dominant"; a dominant selectable marker encodes an enzymatic or other activity (e.g., luminescence, fluorescence, or radioactivity) that can be detected in any cell line.

The term "transfection" as used herein refers to the introduction of foreign DNA into cells. Transfection may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, glass beads, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, viral infection, biolistics (i.e., particle bombardment) and the like.

The following examples are provided to illustrate specific instances of the practice of the present invention and are not to be construed as limiting the present invention to these examples. As will be apparent to one of ordinary skill in the art, the present invention will find application in a variety of compositions and methods.

Examples

Example 1:

Wild type (CC124, mt-) and cell wall-less (CC, mt+) *C. reinhardtii* were tested for the presence of UCP by flow cytometry. Non-permeabilized cells were stained with anti-UCP2 antibody (Santa Cruz Technologies). Cells were prepared for staining with goat anti-UCP2 antibody (Santa Cruz Pharmaceuticals) followed by fluorescein conjugated anti-rabbit or goat outer step antibodies, respectively. Data were acquired on a Coulter Elite Epics flow cytometer (Coulter, Hialeah, Florida) and analyzed with CellQuest software, (Becton Dickinson, San Jose, California). Cells were stained for intracellular peroxide using 6-carboxy-2'-7'-dichlorodihydrofluorescein diacetate (DCF-DA, Molecular Probes, Eugene, Oregon). Briefly, cells were incubated with DCF-DA for 20 minutes, washed twice in PBS containing 5% fetal calf serum and analyzed flow

cytometrically. Mitochondrial membrane potential was assessed using Mitotracker Red (CM-H2XROS, Molecular Probes, Eugene, Oregon). The cells were resuspended in cold, or room temperature, PBS containing 13% fetal calf serum, 0.5 micromolar Mitotracker Red dye was then added to the suspension. The cells were incubated at 37°C for 20 minutes, pelleted, and resuspended in prewarmed medium for analysis. The Coulter Excel flow cytometer was used with a single excitation wavelength (488 nm) and band filters for PE (575 nm), FITC (525 nm) and Red613 (613 nm) to analyze the stained cells. Each sample population was classified for cell size (forward scatter) and complexity (side scatter), gated on a population of interest and evaluated using 40,000 cells.

Figure 1, Panel A, illustrates that in wild type (cell-walled [CC124-]), but not in cell wall-less strains (cw15+) of *C. reinhardtii*, as shown in Figure 1, Panel B, express cell surface molecules recognized by antibodies to UCP2. This result confirms that UCP can be localized to the cell wall, in addition to mitochondria and chloroplast.

It was also hypothesized that if cell wall expression of UCP2 facilitates uptake of acetate as an alternative carbon source during non-photosynthetic periods, then mutant strains of *C. reinhardtii* that die in the dark should not express cell wall UCP2. Such mutants were tested for the presence of cell wall UCP. Figure 2, Panel A, shows that light-sensitive, cell-walled strains of *C. reinhardtii* (lts) express high levels of UCP. However, as seen in Figure 2, Panel B, dark sensitive strains (CC2654; dark-dier) of *C. reinhardtii* express no cell-wall UCP over control samples. These results demonstrate a role of the cell wall UCP in non-photosynthetic metabolism.

It was discovered that wild type strains of algae can be made light-sensitive in the presence of the herbicide norflurazon. Thus, it was reasoned, in view of the discoveries described above, that norflurazon upregulates cell wall expression of UCP. Algae made light-sensitive by treatment with norflurazon were tested for the presence of cell wall UCP. Figure 3 demonstrates that norflurazon does indeed upregulate cell wall expression of UCP in wild type strains of *C. reinhardtii*. The above experiments, when taken together, demonstrate that UCP functions in *C. reinhardtii* when an alternative energy source to photosynthesis is required.

RNA from *C. reinhardtii* was also examined. Total RNA was isolated from wild type, wild type treated with norflurazon, cell wall less CW15+, and light sensitive cells.

- 42 -

Four concentrations of RNA were attached to the blot, 20ug, 10 ug, 5 ug, and 2,5 ug. A ³²P labeled probe from mouse clone in Bluescript was utilized. The results are shown in Figure 4.

Regulation of UCPs may also be utilized to protect plants, tissues, or cells against free radical damage. Experiments conducted during the development of the present invention have demonstrated that UCP in *C. reinhardtii* cell walls protects against free radical damage. Specifically, *C. reinhardtii* was tested for changes in reactive oxygen levels flow cytometrically using DCF-DA (Molecular Probes, Eugene, Oregon). It was shown that levels of peroxide are different between strains of *C. reinhardtii*. It was reasoned that UCP functions to prevent increased levels of oxygen free radicals, thus, mitochondrial membrane potential was measured using Cm-CS ros (Molecular Probes, Eugene, Oregon). The accuracy of this method for free radical quantification has been validated. The results demonstrate that UCP in *C. reinhardtii* protects against free radical damage.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

We claim:

CLAIMS

1. A plant expressing a cell wall UCP encoded by a heterologous UCP gene.
- 5 2. The plant of claim 1, wherein the heterologous UCP gene comprises a gene encoding UCP2.
3. The plant of claim 1, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding UCP1, UCP3, UCP4, UCP5, and UCP6.
- 10 4. The plant of claim 1, wherein the heterologous UCP gene comprises a gene encoding PUMP.
5. The plant of claim 1, wherein the heterologous UCP gene comprises a gene
15 encoding StUCP.
6. The plant of claim 1, wherein the heterologous UCP gene comprises a gene encoding AtPUMP.
7. A method for regulating fuel metabolism in a plant, comprising,
20 regulating UCP expression in a plant cell wall/ plasma membrane or chloroplast to regulate fuel metabolism of the plant.
8. The method of claim 7, wherein the method involves increasing the expression
25 or activity of UCP in the plant cell wall/ plasma membrane or chloroplast.
9. The method of claim 8, wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by introducing into the plant cell an expression vector including a gene encoding a heterologous UCP.
- 30 10. The method of claim 8, wherein the expression of activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by stably transforming the plant cell with an expression vector including a gene encoding a heterologous UCP.

11. The method of claim 9 or 10, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding UCP1, UCP2, UCP3, UCP4, UCP5, and UCP6.

5

12. The method of claim 9 or 10, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding PUMP, StUCP, and AtPUMP.

13. The method of claim 8, wherein the expression or activity of UCP in the
10 plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP activator.

14. The method of claim 13, wherein the cell wall UCP activator is a compound selected from the group consisting of sugars including but not limited to glucose,
15 sucrose, maltose, and dextrose, structural analogs of sugars including but not limited to glucose, sucrose, maltose, and dextrose, inhibitors of nucleotides and nucleotide analogs, omega 3 fatty acids, omega 6 fatty acids, and norflurazon.

15. The method of claim 8, wherein the expression of UCP in the cell
20 wall/plasma membrane is increased by contacting the plant with a cell wall targeted UCP molecule.

16. The method of claim 15, wherein the cell wall targeted UCP molecule is a UCP molecule linked to a targeting molecule selected from the group consisting of
25 glucose transporters, sucrose transporters, maltose transporters, and fatty acid transporters.

17. The method of claim 8, wherein the expression of UCP in the chloroplast is increased by contacting the plant with a chloroplast targeted UCP molecule.

30

18. The method of claim 17, wherein the chloroplast targeted UCP molecule is a UCP molecule linked to a targeting molecule selected from the group consisting of a

- 45 -

chloroplast transit protein and a peptide of N terminus small subunit of ribulose 5-phosphate carboxylase.

19. The method of claim 8, wherein the expression of UCP in the cell
5 wall/plasma membrane, is increased by contacting the plant with a plasma membrane targeted UCP molecule.

20. The method of claim 19, wherein plasma membrane targeted UCP molecule
is a UCP molecule linked to a targeting molecule which is plant specific membrane
10 targeting sequence lacking a VSS or KDEL sequence.

21. The method of claim 8, wherein the expression of UCP in the cell
wall/plasma membrane is increased by contacting the plant with a plasma desmata
targeted UCP molecule.
15

22. The method of claim 21, wherein the plasma desmata targeted UCP molecule
is a UCP molecule linked to a plasma desmata targeting molecule which is a porin-like
targeting sequences.

23. The method of claim 8, wherein the expression of UCP in the cell
20 wall/plasma membrane is increased by contacting the plant with a pore targeted UCP molecule.

24. The method of claim 23, wherein the pore targeted UCP molecule is a UCP
25 molecule linked to a targeting molecule selected from the group consisting of a porin peptide, a VSS tail and a KDEL tail.

25. The method of claim 7, wherein the method involves decreasing the
expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast.
30

- 46 -

26. The method of claim 25 wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is decreased by contacting the plant with a UCP inhibitor.

5 27. The method of claim 26, wherein the cell wall UCP inhibitor is a compound selected from the group consisting of UCP binding peptides such as anti-UCP antibodies, UCP anti-sense nucleic acids, UCP dominant-negative nucleic acids, nucleotides, nucleotide analogs tocopherols, and non-omega-3, -6 fatty acids.

10 28. An expression system, comprising:
a promoter sequence,
a first structural gene encoding a heterologous UCP and a second structural gene encoding a plant cell wall targeting peptide or a chloroplast targeting peptide, the first and second structural genes arranged to form a fusion protein and operably linked to and
15 under the control of the promoter sequence.

29. The expression system of claim 28, wherein the promoter sequence is a plant specific promoter.

20 30. The expression system of claim 28, wherein the UCP encoded by the first structural gene is a mammalian UCP.

31. The expression system of claim 28, wherein the UCP encoded by the first structural gene is a plant UCP.

25 32. A plant stably transformed with the expression system of claim 28.

33. A seed of the plant of claim 32.

30 34. A progeny, clone, cell line or cell of the plant of claim 32.

- 47 -

35 A transgenic plant transformed with a nucleic acid construct comprising a nucleic acid sequence encoding a UCP operably linked to a promoter sequence, wherein the nucleic acid contract also encodes a plant cell wall targeting peptide or a chloroplast targeting peptide.

5

36. A seed of the transgenic plant of claim 35.

37. A progeny, clone, cell line or cell of the transgenic plant of claim 35.

10

38. A method for producing a nutritionally enhanced plant, comprising: decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast to produce a nutritionally enhanced plant.

15

39. The method of claim 38, wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is decreased by contacting the plant with a UCP inhibitor.

20

40. The method of claim 38 wherein the UCP inhibitor is a chloroplast or cell wall UCP antisense sequence.

41. A plant produced by the method of claim 38.

42. A method for improving the light and cold sensitivity of a plant, comprising: increasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast to improve the light and cold sensitivity of the plant.

25

43. The method of claim 42, wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by introducing into the plant cell an expression vector including a gene encoding a heterologous UCP.

30

44. The method of claim 43, wherein the expression of activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by stably transforming the plant cell with an expression vector including a gene encoding a heterologous UCP.

5 45. The method of claim 43, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding UCP1, UCP2, UCP3, and UCP4.

46. The method of claim 43, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding PUMP, StUCP, and AtPUMP.

10


47. The method of claim 42, wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP activator.

15 48. The method of claim 42, wherein the expression of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP molecule.

49. A method for preventing an infection in a plant, comprising:
20 decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast in an amount to prevent an increase in oxygen free radicals and to prevent infection in the plant.


1/6

FIG. 1




2/6

FIG. 2



3/6



| |
|---------|
| FIG. 3A |
| FIG. 3B |
| FIG. 3C |

FIG. 3A

4/6




FIG. 3B

5/6






FIG. 3C


6/6




LIGHT
SENSITIVE
CELLS



CELL WALL LESS
CW15+



WILD TYPE
TREATED WITH
NORFLURAZON



WILD TYPE
CC124-

FIG. 4

SEQUENCE LISTING

<110> University Technology Corporation

<120> Compositions and methods for regulating metabolism in plants

<130> C1102/7002WO

<140> Not assigned

<141> 2001-03-30

<150> US 60/193,533

<151> 2000-03-31

<160> 16

<170> PatentIn version 3.0

<210> 1

<211> 924

<212> DNA

<213> Homo sapiens

<400> 1

| | |
|---|-----|
| atgggggggcc tgacagcctc ggacgtacac ccgaccctgg ggggccagct cttctcagct | 60 |
| ggaatagcgg cgtgcttggc ggacgtgatc accttcccgc tggacacggc caaagtccgg | 120 |
| ctccaggtcc aaggtgaatg cccgacgtcc agtggtatta ggtataaagg tgtcctggga | 180 |
| acaatcaccg ctgtggtaaa aacagaaggg cggatgaaac tctacagcgg gctgcctgcg | 240 |
| gggcttcagc ggcaaatacag ctccgcctct ctcaggatcg gcctctacga cacgggtccag | 300 |
| gagttcctca ccgcagggaa agaaacagca cctagtttag gaagcaagat ttagctggt | 360 |
| ctaacgactg gaggagtggc agtattcatt gggcaacca cagaggctcg gaaagtcaga | 420 |
| cttcaagcac agagccatct ccacggaatc aaacctcgct acacggggac ttataatgcg | 480 |
| tacagaataa tagcaacaac cgaaggcttg acgggtcttt ggaaagggac tactcccaat | 540 |
| ctgatgagaa gtgtcatcat caattgtaca gagctagtaa catatgatct aatgaaggag | 600 |


```

gcctttgtga aaaacaacat attagcagat gacgtcccct gccacttggt gtcggctctt      660
atcgctggat tttgcgcaac agctatgtcc tccccggtgg atgtagtaaa aaccagattt      720
attaattctc caccaggaca gtacaaaagt gtgcccaact gtgcaatgaa agtgttcact      780
aacgaaggac caacggcttt cttcaagggg ttggtacctt ctttcttgcg acttggatcc      840
tggaacgtca ttatgtttgt gtgctttgaa caactgaaac gagaactgtc aaagtcaagg      900
cagactatgg actgtgccac ataa                                           924

```

<210> 2

<211> 307

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Gly Gly Leu Thr Ala Ser Asp Val His Pro Thr Leu Gly Val Gln
1           5           10           15
Leu Phe Ser Ala Gly Ile Ala Ala Cys Leu Ala Asp Val Ile Thr Phe
20          25          30
Pro Leu Asp Thr Ala Lys Val Arg Leu Gln Val Gln Gly Glu Cys Pro
35          40          45
Thr Ser Ser Val Ile Arg Tyr Lys Gly Val Leu Gly Thr Ile Thr Ala
50          55          60
Val Val Lys Thr Glu Gly Arg Met Lys Leu Tyr Ser Gly Leu Pro Ala
65          70          75          80
Gly Leu Gln Arg Gln Ile Ser Ser Ala Ser Leu Arg Ile Gly Leu Tyr
85          90          95
Asp Thr Val Gln Glu Phe Leu Thr Ala Gly Lys Glu Thr Ala Pro Ser
100         105         110
Leu Gly Ser Lys Ile Leu Ala Gly Leu Thr Thr Gly Gly Val Ala Val
115         120         125
Phe Ile Gly Gln Pro Thr Glu Val Val Lys Val Arg Leu Gln Ala Gln
130         135         140
Ser His Leu His Gly Ile Lys Pro Arg Tyr Thr Gly Thr Tyr Asn Ala
145         150         155         160
Tyr Arg Ile Ile Ala Thr Thr Glu Gly Leu Thr Gly Leu Trp Lys Gly
165         170         175

```

Thr Thr Pro Asn Leu Met Arg Ser Val Ile Ile Asn Cys Thr Glu Leu
 180 185 190

Val Thr Tyr Asp Leu Met Lys Glu Ala Phe Val Lys Asn Asn Ile Leu
 195 200 205

Ala Asp Asp Val Pro Cys His Leu Val Ser Ala Leu Ile Ala Gly Phe
 210 215 220

Cys Ala Thr Ala Met Ser Ser Pro Val Asp Val Val Lys Thr Arg Phe
 225 230 235 240

Ile Asn Ser Pro Pro Gly Gln Tyr Lys Ser Val Pro Asn Cys Ala Met
 245 250 255

Lys Val Phe Thr Asn Glu Gly Pro Thr Ala Phe Phe Lys Gly Leu Val
 260 265 270

Pro Ser Phe Leu Arg Leu Gly Ser Trp Asn Val Ile Met Phe Val Cys
 275 280 285

Phe Glu Gln Leu Lys Arg Glu Leu Ser Lys Ser Arg Gln Thr Met Asp
 290 295 300

Cys Ala Thr
 305

<210> 3

<211> 1105

<212> DNA

<213> Homo sapiens

<400> 3

| | |
|--|-----|
| gttcctctat ctcgtcttgt tgctgattaa aggtgccct gtctccagtt tttctccatc | 60 |
| tcctgggacg tagcaggaaa tcagcatcat ggttgggttc aaggccacag atgtgcccc | 120 |
| tactgccact gtgaagtttc ttggggctgg cacagctgcc tgcacgcag atctcatcac | 180 |
| ctttcctctg gatactgcta aagtccggtt acagatccaa ggagaaagtc aggggccagt | 240 |
| gcgcgctaca gccagcgccc agtaccgcgg tgtgatgggc accattctga ccatgggtgcg | 300 |
| tactgagggc cccgaagcc tctacaatgg gctggttgcc ggctgcagc gccaaatgag | 360 |
| ctttgcctct gtccgcacgc gcctgtatga ttctgtcaaa cagttctaca ccaagggctc | 420 |
| tgagcatgcc agcattggga gccgcctcct agcaggcagc accacaggtg ccctggctgt | 480 |
| ggctgtggcc cagcccacgg atgtggtaaa ggtccgattc caagctcagg cccgggctgg | 540 |
| aggtggctcg agataccaaa gcaccgtcaa tgcctacaag accattgccc gagaggaagg | 600 |

```

gttccggggc ctctggaaag ggacctctcc caatgttgct cgtaatgcca ttgtcaactg      660
tgctgagctg gtgacctatg acctcatcaa ggatgccctc ctgaaagcca acctcatgac      720
agatgacctc ccttgccact tcacttctgc ctttggggca ggcttctgca ccaactgtcat      780
cgctccccc gttagacgtgg tcaagacgag atacatgaac tctgccctgg gccagtacag      840
tagcgctggc cactgtgccc ttaccatgct ccagaaggag gggcccgag ccttctacaa      900
agggttcatg ccttcctttc tccgcttggg ttcttggaac gtggtgatgt tcgtcaccta      960
tgagcagctg aaacgagccc tcatggctgc ctgcacttcc cgagaggctc ccttctgagc     1020
ctctcctgct gctgacctga tcacctctgg ctttgtctct agccggggcca tgctttcctt     1080
ttcttcttc tttctcttcc ctccg                                           1105

```

<210> 4

<211> 314

<212> PRT

<213> Homo sapiens

<400> 4

```

Gln Glu Ile Ser Ile Met Val Gly Phe Lys Ala Thr Asp Val Pro Pro
1           5           10           15
Thr Ala Thr Val Lys Phe Leu Gly Ala Gly Thr Ala Ala Cys Ile Ala
20          25          30
Asp Leu Ile Thr Phe Pro Leu Asp Thr Ala Lys Val Arg Leu Gln Ile
35          40          45
Gln Gly Glu Ser Gln Gly Pro Val Arg Ala Thr Ala Ser Ala Gln Tyr
50          55          60
Arg Gly Val Met Gly Thr Ile Leu Thr Met Val Arg Thr Glu Gly Pro
65          70          75          80
Arg Ser Leu Tyr Asn Gly Leu Val Ala Gly Leu Gln Arg Gln Met Ser
85          90          95
Phe Ala Ser Val Arg Ile Gly Leu Tyr Asp Ser Val Lys Gln Phe Tyr
100         105         110
Thr Lys Gly Ser Glu His Ala Ser Ile Gly Ser Arg Leu Leu Ala Gly
115         120         125
Ser Thr Thr Gly Ala Leu Ala Val Ala Val Ala Gln Pro Thr Asp Val
130         135         140

```

Val Lys Val Arg Phe Gln Ala Gln Ala Arg Ala Gly Gly Gly Arg Arg
145 150 155 160

Tyr Gln Ser Thr Val Asn Ala Tyr Lys Thr Ile Ala Arg Glu Glu Gly
165 170 175

Phe Arg Gly Leu Trp Lys Gly Thr Ser Pro Asn Val Ala Arg Asn Ala
180 185 190

Ile Val Asn Cys Ala Glu Leu Val Thr Tyr Asp Leu Ile Lys Asp Ala
195 200 205

Leu Leu Lys Ala Asn Leu Met Thr Asp Asp Leu Pro Cys His Phe Thr
210 215 220

Ser Ala Phe Gly Ala Gly Phe Cys Thr Thr Val Ile Ala Ser Pro Val
225 230 235 240

Asp Val Val Lys Thr Arg Tyr Met Asn Ser Ala Leu Gly Gln Tyr Ser
245 250 255

Ser Ala Gly His Cys Ala Leu Thr Met Leu Gln Lys Glu Gly Pro Arg
260 265 270

Ala Phe Tyr Lys Gly Phe Met Pro Ser Phe Leu Arg Leu Gly Ser Trp
275 280 285

Asn Val Val Met Phe Val Thr Tyr Glu Gln Leu Lys Arg Ala Leu Met
290 295 300

Ala Ala Cys Thr Ser Arg Glu Ala Pro Phe
305 310

<210> 5

<211> 1132

<212> DNA

<213> Homo sapiens

<400> 5

tcttggggatg gagccctagg gagcccctgt gctgcccctg ccgtggcagg actcacagcc 60
ccaccgctgc actgaagccc agggctgtgg agcagcctct ctccctggac ctccctctcg 120
ccctaaaggg actgggcaga gccttccagg actatgggtg gactgaagcc ttcagacgtg 180
cctcccacca tggctgtgaa gttcctgggg gcaggcacag cagcctgttt tgctgacctc 240
gttacctttc cactggacac agccaaggtc cgcctgcaga tccaggggga gaaccaggcg 300
gtccagacgg cccggctcgt gcagtaccgt ggcgtgctgg gcaccatcct gaccatgggtg 360
cggactgagg gtcctgcag cccctacaat gggctgggtg ccggcctgca gcgccagatg 420

```

agcttcgcct ccatccgcat cggcctctat gactccgtca agcaggtgta ccccccaaa 480
ggcgcggaaca actccagcct cactaccggg attttggccg gctgcaccac aggagccatg 540
gcggtgacct gtgcccagcc cacagatgtg gtgaagggtcc gatttcaggc cagcatacac 600
ctcggggccat ccaggagcga cagaaaatac agcgggacta tggacgccta cagaaccatc 660
gccagggagg aaggagtcag gggcctgtgg aaaggaactt tgcccaacat catgaggaat 720
gctatcgta actgtgctga ggtggtgacc tacgacatcc tcaaggagaa gctgctggac 780
taccacctgc tcaactgacaa cttcccctgc cactttgtct ctgcctttgg agccggcttc 840
tgtgccacag tgggtggcctc cccggtggac gtggtgaaga cccggtatat gaactcacct 900
ccaggccagt acttcagccc cctcgactgt atgataaaga tgggtggcca ggagggcccc 960
acagccttct acaaggggtg agcctcctcc tgctccagc actccctccc agagaacagg 1020
ggcttctttc ttttcgaatg tggctaccgt gggtaaacct gggatgtagc ggtgaagagt 1080
acagatgtaa atgccacaaa gaagaagttt aaaaaacat gcaaaaaaaaa aa 1132

```

<210> 6

<211> 284

<212> PRT

<213> Homo sapiens

<400> 6

```

Arg Asp Trp Ala Glu Pro Ser Arg Thr Met Val Gly Leu Lys Pro Ser
1          5          10          15

Asp Val Pro Pro Thr Met Ala Val Lys Phe Leu Gly Ala Gly Thr Ala
20          25          30

Ala Cys Phe Ala Asp Leu Val Thr Phe Pro Leu Asp Thr Ala Lys Val
35          40          45

Arg Leu Gln Ile Gln Gly Glu Asn Gln Ala Val Gln Thr Ala Arg Leu
50          55          60

Val Gln Tyr Arg Gly Val Leu Gly Thr Ile Leu Thr Met Val Arg Thr
65          70          75          80

Glu Gly Pro Cys Ser Pro Tyr Asn Gly Leu Val Ala Gly Leu Gln Arg
85          90          95

Gln Met Ser Phe Ala Ser Ile Arg Ile Gly Leu Tyr Asp Ser Val Lys
100         105         110

```

Gln Val Tyr Thr Pro Lys Gly Ala Asp Asn Ser Ser Leu Thr Thr Arg
 115 120 125
 Ile Leu Ala Gly Cys Thr Thr Gly Ala Met Ala Val Thr Cys Ala Gln
 130 135 140
 Pro Thr Asp Val Val Lys Val Arg Phe Gln Ala Ser Ile His Leu Gly
 145 150 155 160
 Pro Ser Arg Ser Asp Arg Lys Tyr Ser Gly Thr Met Asp Ala Tyr Arg
 165 170 175
 Thr Ile Ala Arg Glu Glu Gly Val Arg Gly Leu Trp Lys Gly Thr Leu
 180 185 190
 Pro Asn Ile Met Arg Asn Ala Ile Val Asn Cys Ala Glu Val Val Thr
 195 200 205
 Tyr Asp Ile Leu Lys Glu Lys Leu Leu Asp Tyr His Leu Leu Thr Asp
 210 215 220
 Asn Phe Pro Cys His Phe Val Ser Ala Phe Gly Ala Gly Phe Cys Ala
 225 230 235 240
 Thr Val Val Ala Ser Pro Val Asp Val Val Lys Thr Arg Tyr Met Asn
 245 250 255
 Ser Pro Pro Gly Gln Tyr Phe Ser Pro Leu Asp Cys Met Ile Lys Met
 260 265 270
 Val Ala Gln Glu Gly Pro Thr Ala Phe Tyr Lys Gly
 275 280

<210> 7

<211> 6428

<212> DNA

<213> Solanum tuberosum

<400> 7

gaattcatca catataaata gtgtggtctt ccttgtgttg ggtagaagta gaaacaacaa 60
 gaaatataaa agagaaagag tggaagaaaa gatgagaaat attatattgt gtatattgag 120
 taagtgtagt gaacgagaga gttgagacag agaaaatatt ttaagtcttt aactatatct 180
 actatacaaaa ggagaatatt catatgttga aggaaagtgt tcttgtgtgg agttttggac 240
 tcttcaacta attcagagtt gtacaacgtt attggactat tgtatcctgg agaggacaag 300
 tcaagagtga tactgctgga tcggtgtaga ttatgccgta gttgacttga atcttcttaa 360
 agagagtggag atattcgtgc ctcagtctaa aaatttggtt attcattttt gtcattttat 420

tttcaactat aatattttgt atttgtggta tattacactg cttatcatg ataatcatcg 480
tgattttctaa ctagatcatg acgtctcaat taaatgtttt cttccaacta aacacatccc 540
atattttatat tattcgacat tggttaattt gattatttat ccactttta gcctatgcac 600
aggggcgtag ctatgttaaa gtcagggtgt taaattgaat atccttcgtc aaaaactaat 660
atcatattta tgtaaaatta tatacgaagt gattaaataa catattttgg acattcttaa 720
cagaacaagg tgttgttgcc caatcgtttc attattttctg tcacaattaa caaatctacc 780
atgtgaaata ggtgtacttc accatggccc ttgaatgtat gacaagccgt atattcgata 840
ggaaagagta acgtttacgc atccttaata aaatgttaga tgatgaatga ggatctaatac 900
agcatatgtg caaagctcca accaatcatg attatctaata aaagtgtgct ttattcatta 960
ttctaaaatt caacaattaa taaaataatt aggtcaaaag cacatgggtg agtggatgag 1020
tttgatcaac ttgtaaatat attattgcct ttattcatct ctagcttcat tattattatt 1080
ttattaggtt ctatttaatt tctcgtattt gatatttgca ttaaaattca attaatTTTg 1140
attcacatga tataaaaccc caatcacact actcgaattt aaaaccttta attaagggga 1200
gtaacaattg aataacaaaa aaaaatctgt tgggagtgcc accccgaat agaccctgta 1260
gagcgcgatt caaatttaat cgaaactcta atgtgggctc cgagaaacaa aaaaaaaaaa 1320
caattgaata gcaaaggaaa acagagtagt gctgactgag caagcaaaag cccaattgaa 1380
atattagtag taaatgacag caatggccgt tgcgtaggac aagcacagca gcagcccggt 1440
tttcgctttt cccaagatct ctctgcaaaa tccttagcct tctttactat ataatagccc 1500
ctaaaacccc attttttact ataccattt cttactcttg ctctgtgac atcctttctt 1560
ctaggagtag ccatctccta gaaccctttt agtttctctt tgtgtttttt tgggtcaattt 1620
agtcatggga ggaggagatc acggcgga atcggatata tcattcgccg gaatattcgc 1680
aagtagtgcc tttgctgctt gtttcgctga ggtaattctt ccatcaatct aatccctttt 1740
ttgcaatcct gtcttgaaac ttgctttgtt gattcagtct tacatctggt gctaagattt 1800
ttgatgattc gaataggata aatgggggtg tttccttttc cttttttttt ttgtttctgg 1860
attgtcagga attgttgatc ccattgagc tgtaaagtgt ttatgagctt ataatccttt 1920
actggattgc tttgctggtc aatttaagtt ttgtttaatc tcctaatgct gtatgtttgt 1980
attaaggtgc aatctgtttt ggcagataaa tgagtctctt ggttgagtgt ttgagtcag 2040
cgagagggtg agtaagaata ctattgatcc tccttttggg gggcgggggg atctgtttcg 2100

gcagataagt gaggccttggg tggagggtttg agtcacactg gagggtaagt aggaacacta 2160
ttgatecctcc ttttagggggg tggggaatct gtttcagcaa ataagtgagg cttgggttggg 2220
ggtgtgactc aacttgaggg gtatgtagga acagtattga tcctcctttt agggaggtgg 2280
ggaatctgtt tcggcagata attgaggctt gggtgagggt tcgagtcaca ctggagggtgta 2340
agtaggaaca ttattgatcc tcctagaaga aagtgagggt tgatttggtc tgtatttagt 2400
ttaagagatt aatcacctta ctacagcatc tgtaggaag ggaaaagagg atateggatg 2460
acctttaaac aaggtgatga tggtagaaaa taaatttgta ctcattgtttc cttaaaaaata 2520
attacttgta gaaatttggg ggacttgatt gtgtgaatac ttttatgaaa aaccatgact 2580
tgcttaattt tggaggaatc agttttctat cttttgcttt ttatgaagct aggccttgat 2640
gatgtatgta gttttcaaag aacagtgtat tgcgtatggg tgtatgaaat gaggtttggt 2700
aagttttgat tgcgtctttt ggggtcatccg acatgtatgg tgtctacatg tagtagatcg 2760
ttttgaagtg tgcattgccg gctattattc gtgttattga ttcttcgct gctgttaat 2820
cttggttgct gcatacaaaa ttctgttctc caggcgtgta ctttaccatt ggatactgct 2880
aaagtttagac ttcagcttca aaagaaggca gttgaagggg atgggctagc ttacctaata 2940
tataggggat tattaggtac tgttggcacc attgcaaagg aagaaggaat agcttcacta 3000
tggaagggtg tcgtacctgg gttacatcgt caatgtatat atggagggtc tcggattggg 3060
atgtatgaac ctgtaagtta acatttctag cttaaacagc tacaagttta ttttggcctt 3120
ttacgggactg tttgctgggt gaccagggtta aaaacttata tggtaggcaa gatcatgttg 3180
gggatgtgcc attgtcaaag aaaatacttg ctgcacttac aactgggtgag tgccttttag 3240
atgttttgcg tttattgtca ctttgcctga gagtaaatgg acagcgaagc ttttatatcc 3300
atttagaaaa catctggaca taggctatag aagttcagt ttaagattat caataacata 3360
cttctgtttt tccttgattt attcttttat actgtctggg ctttcaatat attttaaagt 3420
aatttggtga ttctttatca aataggtgcg ttgggcatta caattgcaa tcctacagat 3480
ctagttaaag tacgtcttca agctgaagga aaattgccag cagggtgtgcc gaggcgttat 3540
tctggagctc taaatgcta ctcaacaata gtgaaacagg ttatatgtct tgtctagctc 3600
agttgtttac taaatcatga taactaacga cagcgggggc tgtgaaattg tgtacaccta 3660
ctttgaatca tgacttgga attagttacc ccttgaattg aaattcaata ttacctaata 3720
aattatatat gtgttgctat tcaaactccc acaatgtcta cctatcaagc ggacatacaa 3780
cctgcaaaaa tatgtgcctt tagtatgtaa catttaacaa ctattatgtc cctagaattg 3840

gatacatgac atttcttaaa gattctttcg ttgaactatt ctttgataac tgattctttg 3900
ttcgactttc tcattctcca tctaacttag tgtattcggt tatcattctc agagaaaaag 3960
ggtagtactt ttcttctctg tgtgggttcc attctcctgg aaatgttagg aaattatgaa 4020
aagttctatt tcatttaaat taatcaaata cccaggctcg tcagcttact ggagcatttg 4080
caatataatg taaatagaac aggtttcaca tgtgaaaatt tgaggaaact cattgttgag 4140
tcatagtttt cccaacaaaa taagactcct atttgaactt gcatgttaac ctctttgcat 4200
tttgtttcta ccatatcttg attttaggaa ggagttcgag ctctgtggac tggctttgga 4260
cccaatattg ggcggaatgc catcatcaat gcagctgaat tagcaagtta tgatcaagtg 4320
aaggaggtag agaaaccata aatttcttat tcccacctca ttttcgggac catctaattg 4380
ggtgttttct tgaatttgga tgtttacatt gtcattcttt tcaactgttg ttctttaaaa 4440
atttctgtgc aggctgttct taggattcct gggttcacag acaatgttgt tactcatttg 4500
attgcggggc ttggagctgg tttttttgca gtttgcatag ggtctcctgt tgatgtggta 4560
tcttctatgt ttcttattat ttgaaattgc tttcctttta gtcctttctg acggcagccc 4620
atgattcagt aatatttggt agtatttttag atcttcttgc ccaaatagag gatcttcttg 4680
gctatatagg gggaaaagtt atgcatagtc ttacttttca tgaaaaagat tatcaaagtc 4740
aatatctagc ctgttaaaca cagccttca tcttgtgaat ttgaagtcct ctgctcatga 4800
attttcttta ttattgtgca gtgcgtgcct aataataaaa ctctagtttg gctggggtaa 4860
atggaggagg gattaaagga ttaaaagtaa cattgggagt gtaaggggat gtcttgtaat 4920
taaaaaagga tcaataaaaa ataaaataaa gagagataat ctgtcctaaa ttgggcggaa 4980
gcatgtctat ttacaaata ttaaaaccat acaaagaata ataaacaaat atagataatt 5040
cacttaacaa gttacttttt cttttctcaa ccgcttcctt ccccttctg gaatcaaaca 5100
tagtagagct gggatcaaca gtactgatat cttgttactt ggttgtgtat gatggcaata 5160
ccgatttttt tcaaatttgc gtacttaaga agttcaccaa acacccaaat gcttcttata 5220
ttttgggttag gtgattttta ttcaacacta atcttttaga tcaccatttt taatctgtct 5280
tctaatttca tccctttaaa gttgcattat caatagactt tgtaaaaatt tattagatta 5340
attttgttga ttattcttgt atagccatga agcactgaca tggtaaaactg tggatgcagg 5400
taaagtcgag aatgatggga gattccgcat acaaaaatac tcttgattgt tttgtcaaaa 5460
cattgaagaa tgatgtgagt tcatgatctg tcctttctat tggttattga agaatccagc 5520

cgttttgcag acataaattt tcctcttagt ctttttgttt aaataactta tcgtggcttc 5580
ttattagatg cagaactcta cctaaaacaa cataacctct catttctctc aagatagttt 5640
aatttttttt actaaaatca gatccctatt attacaaatt ttccctactg ctattagttt 5700
tttggttggtg tagttttcag ttcccttgcca acagcaactt taatgtgtaa tgactgcaaa 5760
aatgacactt ctccatggc ctttatgttt gcagggacct ttggctttct acaaaggctt 5820
tatcccaaatt tttggacgct tgggatcttg gaatgtcatt atgtttctaa cattggagca 5880
ggtaaagagt ggaaccatat tcccagcgac acaaattctt ttccatttca caattattta 5940
taaaacttta tgccagatta ctattccaga ctagcacatg ttttgcttca atgagaggct 6000
ttctcaattt ccagttgctt cctgtttcaa ctgttgactt ggcaacactt tgttccatta 6060
ggctttgaca aattcctgat gaatagctga ctggcttacc ctttgtttct tattttttgg 6120
caggcgaaga agttcgtaa aagttagaa tcacctgat gtcaaagagg aatgaatcat 6180
caagcagagg attactaatt tacattaaac atggattggt tcagcaatca ttagaagatg 6240
gaatcaacaa agatattttt caatattccc cttttttttc gtttttttat caataattcc 6300
cattggggaa cccatagaaa ctatgagaaa ccaagcttag aagtgttag ttttctcctt 6360
taaaggggac ccttactctt actattctta gactgcaaaa tgtttttcct tccttttgggt 6420
tgccatgg 6428

<210> 8

<211> 1225

<212> DNA

<213> *Arabidopsis thaliana*

<400> 8

gacgatcttt tctataactg aaacactact cgaggccaag ttgctttagc cgtaatcgtc 60
gtcgtccctc ttcccgaat tatctcttct ctgttcttcg atttcgaaac cctaacctcc 120
tctctttaat tcgctgtttc tggatcgaag atgggtggcg ctggtaaate cgacctttcc 180
ttgccccaaa ctttcgcctg cagtgccttc gctgcttgcg tcggcgagggt atgcacaatt 240
ccattggaca ctgctaaagt taggcttcag ctccaaaagt ctgctcttgc tggatgatgtt 300
actctgccta aatatcgagg attgttggga actgttggtta ccatagcaag ggaagaaggg 360
ttacgttcac tatggaaagg tgttgtagct ggattgcate gtcaatgcct atttggagggt 420

cttaggattg gaatgtatga gccggtgaaa aacttgtatg ttggaaaaga ctttgtaggt 480
 gatgttccat tgagcaagaa aattcttgct ggtttgacaa cagggtgcact gggatatcatg 540
 gtagcaaate ccactgatct tgtgaaagtt aggcttcagg cggaaggaaa attagctgca 600
 ggtgcgccaa gacggtactc tggagcgctg aatgcgtatt caacaattgt gagacaggaa 660
 ggagtcogag ctctttggac tgttcttgga cctaacgtag caagaaacgc tattatcaat 720
 gctgctgaat tagcgagtta cgatcaagtg aaagagacta tcttgaagat tccagggttc 780
 actgacaacg ttgtcacaca tattctatct ggactggggg caggattctt tgctgtttgc 840
 atcggttctc ctggtgacgt ggtaagtca agaagatgag gagattctgg tgcttacaag 900
 ggcaccattg attgcttcgt caaaactctg aagagcgacg gtcctatggc attttacaag 960
 ggtttcatcc ccaactttgg acgccttggc tcatggaacg taatcatgtt tttgaccctc 1020
 gaacaggcaa agaagtatgt cggggaactc gatgcgtcca aaagaaactg agacacaaag 1080
 ttttaagcag agggaatgag agcaacattg ttttcttctt cattttcggt gattgagaga 1140
 ggccagaact tggtcgaata ttgttttcgg aatagagatt cagttttcga gtaaaactgt 1200
 gaaataaaat ttctgtggat tgctc 1225

<210> 9

<211> 1088

<212> DNA

<213> *Arabidopsis thaliana*

<400> 9

tcctatagca taacaatggc ggatttcaaa ccaaggatcg agatttcgtt ccttgaaacc 60
 ttcatttgca gcgctttcgc tgcttgtttt gctgagttat gtactatacc gttggacaca 120
 gccaaagtta gacttcagct tcaaagaaag attcccactg gagatgggtga gaatttgccc 180
 aagtatagag gatcaattgg tactctagct accatagcta gagaagaagg tatttcaggt 240
 ctttggaag gtgttattgc aggacttcat cgccaatgta tctatggtgg ctttaaggatt 300
 gggttatatg agcctgtgaa gacacttttg gttggaagtg actttattgg cgatattcct 360
 ttatatcaaa agattcttgc agctttgtta actggagcta tagctattat tgtagcta 420
 ccaactgac ttgttaaagt tcggcttcaa tcagaaggaa agttaccggc tggggttcct 480
 aggcgttatg caggagctgt agacgcttat ttcaccattg tgaagctgga aggagttagt 540

gcgctatgga ctggacttgg tcccaatatt gcccggaatg ctattgtaaa tgctgcagag 600
ttagctagtt atgatcaaat aaaggagaca attatgaaaa ttccgttctt cagagacagt 660
gttttaactc atctactagc tggtttagct gcaggcttct tcgctgtctg catcggttct 720
ccaattgatg tggtgaaatc tagaatgatg ggagactcta cttaccgaaa cacagtcgat 780
tgcttcatca aaacgatgaa gaccgagggg attatggcat tctacaaagg atttctcccg 840
aattttacac ggctaggaac ctggaatgcc attatgttcc tcacattaga acaagtgaaa 900
aaagtgtttc taagagaagt cttgtacgat tgattctcag atccctagtc gaaaaccata 960
ccttattaca taatcccttc tataaaactt tgaattgtta gaattaaaac atatatactt 1020
tctatgttat gtgagctttg ttatttagat tagtatagaa acattttatc caaaaaaaaa 1080
ttctttgc 1088

<210> 10

<211> 972

<212> DNA

<213> Homo sapiens

<400> 10

atgtccgtcc cggaggagga ggagaggtt ttgccgtga cccagagatg gccccgagcg 60
agcaaattcc tactgtccgg ctgcgcggct accgtggccg agctagcaac ctttccctg 120
gatctcacia aaactcgact ccaaatgcaa ggagaagcag ctcttgctcg gttgggagac 180
ggtgcaagag aatctgcccc ctatagggga atggtgcgca cagccctagg gatcattgaa 240
gaggaaggct ttctaaagct ttggcaagga gtgacacccg ccatttacag acacgtagtg 300
tattctggag gtcgaatggt cacatatgaa catctccgag aggttgtgtt tggcaaaagt 360
gaagatgagc attatccctt ttggaaatca gtcattggag ggatgatggc tgggtgttatt 420
ggccagtttt tagccaatcc aactgaccta gtgaagggtc agatgcaa at ggaaggaaaa 480
aggaaactgg aaggaaaacc attgcgattt cgtggtgtac atcatgcatt tgcaaaaatc 540
ttagctgaag gaggaatacg agggctttgg gcaggctggg tacccaatat acaaagagca 600
gcactggtga atatgggaga tttaaccact tatgatacag tgaaacacta cttggtattg 660
aatacaccac ttgaggacaa tatcatgact cacggtttat caagtttatg ttctggactg 720
gtagcttcta ttctgggaac accagccgat gtcatcaaaa gcagaataat gaatcaacca 780

14

cgagataaac aaggaagggg acttttgtat aaatcatcga ctgactgctt gattcaggct 840
gttcaagggtg aaggattcat gagtctatat aaaggctttt taccatcttg gctgagaatg 900
acccttgggt caatggtggt ctggcttact tatgaaaaaa tcagagagat gagtggagtc 960
agtcattttt aa 972

<210> 11

<211> 974

<212> DNA

<213> Triticum aestivum

<400> 11

cttctaccct tctttccctc tgctcgccat cgaccgaacc acagccgccg ccgcttcccc 60
ggggataaaa tggcgacggc ctcttctctc gccgccgtct tcatcagcag cgccatcgcc 120
tctgcttcg ctgaggtgtg caccattcct ctggacacag ccaaggtgcg tcttcagctg 180
caaaagaaaa cagctgctgg gcctgcaggt acagtaggaa tgctgggcac aatgatgtcg 240
attgcaaggg aggaaggcgt caccgcactt tggaagggca tcatccttg ctttcatcgc 300
cagtgcctct atggcgccct ccgtgtcggc ttgtatgagc ctgtcaaagc cttatttgtg 360
tttgtaggtg atgccacttt aatgaacaag attcttgccg ctcttacaac tgggtgtcata 420
gcgattgctg tcgcaaatec aactgatctt gtcaaagtga gattgcaagc agatggaaaa 480
tctactgccg tcaagaggca ctattctgga gcccttaatg cgtatgccac catagtcaga 540
caggaaggta tcggagcttt gtggactggc cttggctcta atatggcacg aaatgctttg 600
attaatgccg ccgagttggc cagctacgac caatttaaag agatgtttct aggtcttctc 660
gggtttacag ataatgttta tactcatctt ttagctggac tcggtgccgg tatttttgct 720
gtttgcattg gatctccagt ggatgtggtg aaatcaagaa tgatgggcga ttcaacatac 780
agaagtacat ttgattgttt cgccaagaca ttaaaaaatg atggacttgc tgctttctac 840
aaggggttta ttgcaaactt ttgtcgagtt gggtcattga atgtgataat gttcttaact 900
ttggaacagg ttagaagctt ctttcagtaa ggattatata tgaaatctgc gctgcaagg 960
ttcatggaac aagc 974

<210> 12

<211> 1592

<212> DNA

<213> Homo sapiens

<400> 12

| | |
|--|------|
| gcttaacggt cctctgggtct ctctctcccc tcagctgagt cccttccttg tctttcactc | 60 |
| ttctggcatc ggtgggtttta cttcttcgat tgaaccctgc ttctctgacc ccctggggag | 120 |
| gccgccttct tcaggcgctt cccttctctc cagcagctcg ctctgacagc tgaggaactg | 180 |
| gcaagatcct gctaccaga ggggtgaatgg gtatctttcc cggaataatc ctaatttttc | 240 |
| taagggtgaa gtttgcaacg gcggccgtga ttcaccagaa aagtaccact gtaagtcatg | 300 |
| agatgtctgg tctgaattgg aaaccctttg tatatggcgg ccttgccctct atcgtggctg | 360 |
| agtttgggac tttccctgtg gaccttacca aaacacgact tcagggttcaa ggccaaagca | 420 |
| ttgatgcccg tttcaaagag ataaaatata gagggatggt ccatgcgctg tttcgcactc | 480 |
| gtaaagagga aggtgtattg gctctctatt caggaattgc tctgcggtg ctaagacaag | 540 |
| catcatatgg caccattaaa attgggattt accaaagctt gaagcgctta ttcgtagaac | 600 |
| gtttagaaga tgaaactctt ttaattaata tgatctgtgg ggtagtgtca ggagtgatat | 660 |
| cttcactat agccaatccc accgatgttc taaagattcg aatgcaggct caaggaagct | 720 |
| tgttccaagg gagcatgatt ggaagcttta tcgatatata ccaacaagaa ggcaccaggg | 780 |
| gtctgtggag ggggtgtggtt ccaactgctc agcgtgctgc catcgttgta ggagtagagc | 840 |
| taccagtcta tgatattact aagaagcatt taatattgtc aggaatgatg ggcgatacaa | 900 |
| ttttaactca cttcgtttcc agctttacat gtggtttggc tggggctctg gcctccaacc | 960 |
| cggttgatgt ggttcgaact cgcgatga accagagggc aatcgtggga catgtggatc | 1020 |
| tctataaggg cactgttgat ggtattttaa agatgtggaa acatgagggc ttttttgac | 1080 |
| tctataaagg attttgcca aactggcttc ggcttggaac ctggaacatc atttttttta | 1140 |
| ttacatacga gcagctaaag aggttcaaa tctaagaact gaattatatg tgagcccagc | 1200 |
| cctgccagcc tttctactcc tttgcccttt tcccgtgttc taatgtattt tgacaatgtt | 1260 |
| gtaagtgttt accaagccgt tgggtctcta agggcctcct gatggaagaa cagtggggtg | 1320 |
| gttcaaagtt atttctatgt ttgtgttacc atgttaactt ttccccgaga gaaagtgtta | 1380 |
| acattgagac tctggcccca gattggtatc ttctatgaag atggatactg atgggtgaca | 1440 |
| ttgaaaacgg cctgctttcc aaatgtggtt aaatgtaatt ggtagcccc agacttgggc | 1500 |

tagagcagaa ggcataggcc aggggtggta ttgctatatg tgttacagac ctcgggttctc 1560
attaaagtat ttattggcag aatcacaaaa aa 1592

<210> 13

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> Artificial Sequence

<222> (1)..(27)

<223> Synthetic oligonucleotide

<400> 13

gtaccggggcc ccatggttgg tttcaag

27

<210> 14

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> Artificial Sequence

<222> (1)..(27)

<223> Synthetic oligonucleotide

<400> 14

ggccatctcg aggaaaggtg cctcccg

27

<210> 15

<211> 30

17

<212> DNA

<213> Artificial Sequence

<220>

<221> Artificial Sequence

<222> (1)..(30)

<223> Synthetic oligonucleotide

<400> 15

gtaccgggccc ccatgggctc ttttgagctg

30

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> Artificial Sequence

<222> (1)..(27)

<400> 16

cttggccatc tcgagcatgc aggcac

27

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/75131 A3

(51) International Patent Classification⁷: **C12N 15/82**,
15/63, A01H 1/00, 5/10

(74) Agent: **LOCKHART, Helen, C.**; Wolf, Greenfield &
Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210
(US).

(21) International Application Number: **PCT/US01/10236**

(22) International Filing Date: **30 March 2001 (30.03.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/193,533 **31 March 2000 (31.03.2000)** **US**

(71) Applicant: **UNIVERSITY TECHNOLOGY CORPO-
RATION [US/US]**; Suite 250, 3101 Iris Avenue, Boulder,
CO 80301 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(72) Inventors: **BERRY-LOWE, Sandra, Lee**; 6326 Mesedge
Drive, Colorado Springs, CO 80919 (US). **NEWELL,
Martha, Karen**; 520 North Franklin, Colorado Springs,
CO 80903 (US).

(88) Date of publication of the international search report:
14 March 2002

[Continued on next page]

(54) Title: **EXPRESSION OF UNCOUPLING PROTEIN (UCP) IN PLANTS**



(57) Abstract: The invention relates to methods and products for manipulating plant metabolism and resistance to infection by expression of a cell wall uncoupling protein (UCP).

WO 01/75131 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

This Page Blank (uspto)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/10236

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/82 C12N15/63 A01H1/00 A01H5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, MEDLINE, SCISEARCH, CHEM ABS Data, BIOTECHNOLOGY ABS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| X | WO 90 08831 A (ICI PLC) | 1,3, |
| Y | 9 August 1990 (1990-08-09) | 7-11,15 |
| | claims 1,2,9-11; examples 4,5 | 2-6, |
| | | 11-14, |
| | | 17,18, |
| | | 23-37, |
| | | 42-48 |
| | --- | |
| | -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

24 October 2001

Date of mailing of the international search report

09/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG..., A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/10236

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|--|
| Y | <p>RICQUIER DANIEL ET AL: "The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP." BIOCHEMICAL JOURNAL, vol. 345, no. 2, 15 January 2000 (2000-01-15), pages 161-179, XP002180562 ISSN: 0264-6021 page 173, right-hand column, last paragraph -page 174, left-hand column, paragraph 1 page 167, right-hand column, paragraph 2 - paragraph 3</p> | <p>2,3,5, 11,12, 25-27, 42-48</p> |
| Y | <p>LALOI M ET AL: "A plant cold-induced uncoupling protein." NATURE, vol. 389, no. 6647, 11 September 1997 (1997-09-11), page 135-136 XP002180563 the whole document</p> | <p>5,12</p> |
| Y | <p>MAIA IVAN G ET AL: "AtPUMP: An Arabidopsis gene encoding a plant uncoupling mitochondrial protein." FEBS LETTERS, vol. 429, no. 3, 16 June 1998 (1998-06-16), pages 403-406, XP002180564 ISSN: 0014-5793 the whole document</p> | <p>4,6,12</p> |
| Y | <p>SAVIANI ELZIRA E ET AL: "Fatty acid-mediated uncoupling of potato tuber mitochondria." BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, vol. 44, no. 4, April 1998 (1998-04), pages 833-839, XP001034371 ISSN: 1039-9712 the whole document</p> | <p>13,14</p> |
| Y | <p>FR 2 767 058 A (CENTRE NAT RECH SCIENT) 12 February 1999 (1999-02-12) page 6, line 21-28 page 3, line 11 -page 5, line 15</p> | <p>13</p> |
| Y | <p>WO 88 02402 A (CALGENE INC) 7 April 1988 (1988-04-07) see examples and claims</p> | <p>17,18, 28-37</p> |
| Y | <p>US 5 360 726 A (RAIKHEL NATASHA V) 1 November 1994 (1994-11-01) examples 1,2</p> | <p>23,24</p> |
| | -/-- | |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/10236

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| T | <p>WINKLER EDITH ET AL: "UCP3 expressed in yeast is primarily localized in extramitochondrial particles." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 282, no. 1, 23 March 2001 (2001-03-23), pages 334-340, XP002180565 ISSN: 0006-291X</p> <p>-----</p> | |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1, 7-10, 13-44 and 47-49 (partially)

Present claims 1-49 relate to an extremely large number of possible of polypeptides, namely, every possible extra-mitochondrial (cell wall, plasma membrane, chloroplast, pore and plasmodesmata) uncoupling protein (UCP). Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the UCPs claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the mammalian UCP1, UCP2, UCP3, UCP4, UCP5 and UCP6 and to the plant StUCP, AtUCP and AtPUMP (see page 6, line 10 to page 7, line 2 and page 12 of the description).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/10236

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9008831 | A | 09-08-1990 | AU 621201 B2 | 05-03-1992 |
| | | | AU 5022690 A | 24-08-1990 |
| | | | CA 2008697 A1 | 26-07-1990 |
| | | | EP 0455690 A1 | 13-11-1991 |
| | | | WO 9008831 A1 | 09-08-1990 |
| | | | ZA 9000606 A | 31-10-1990 |
| FR 2767058 | A | 12-02-1999 | FR 2767058 A1 | 12-02-1999 |
| | | | AU 8543098 A | 01-03-1999 |
| | | | EP 1018338 A1 | 12-07-2000 |
| | | | WO 9907358 A1 | 18-02-1999 |
| | | | ES 2147519 A1 | 01-09-2000 |
| WO 8802402 | A | 07-04-1988 | AU 620317 B2 | 20-02-1992 |
| | | | AU 8079787 A | 21-04-1988 |
| | | | EP 0285646 A1 | 12-10-1988 |
| | | | JP 1501038 T | 13-04-1989 |
| | | | WO 8802402 A1 | 07-04-1988 |
| US 5360726 | A | 01-11-1994 | US 5525713 A | 11-06-1996 |
| | | | US 6127532 A | 03-10-2000 |
| | | | US 5276269 A | 04-01-1994 |

This Page Blank (uspto)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/075131 A3

(51) International Patent Classification?: **C12N 15/82**,
15/63, A01H 1/00, 5/10

(21) International Application Number: PCT/US01/10236

(22) International Filing Date: 30 March 2001 (30.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/193,533 31 March 2000 (31.03.2000) US

(71) Applicant: **UNIVERSITY TECHNOLOGY CORPORATION** [US/US]; Suite 250, 3101 Iris Avenue, Boulder, CO 80301 (US).

(72) Inventors: **BERRY-LOWE, Sandra, Lee**; 6326 Mesedge Drive, Colorado Springs, CO 80919 (US). **NEWELL, Martha, Karen**; 520 North Franklin, Colorado Springs, CO 80903 (US).

(74) Agent: **LOCKHART, Helen, C.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: EXPRESSION OF UNCOUPLING PROTEIN (UCP) IN PLANTS



(57) Abstract: The invention relates to methods and products for manipulating plant metabolism and resistance to infection by expression of a cell wall uncoupling protein (UCP).

WO 01/075131 A3



(88) Date of publication of the international search report:
14 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(48) Date of publication of this corrected version:
27 December 2002

(15) Information about Correction:
see PCT Gazette No. 52/2002 of 27 December 2002, Section II

COMPOSITIONS AND METHODS FOR REGULATING METABOLISM IN PLANTS

FIELD OF THE INVENTION

5 The present invention relates to compositions and methods for regulating metabolism in plants by controlling photosynthetic fuel metabolism. The present invention also relates to compositions and methods for protecting plants from free radical damage. In particular, regulating plant fuel metabolism and protecting plants from free radical damage are achieved by compositions and methods for expressing and regulating
10 plant cell wall uncoupling proteins.

BACKGROUND OF THE INVENTION

Modern agriculture faces the ever-increasing challenge of meeting the nutritional and industrial demands for high quality food stuffs and plant derived products. For
15 example, approximately one-half of the world's farm land is dedicated to the production of cereal crops. When the direct (e.g., cooked rice and bread) and indirect consumption (e.g., as animal feed for the production of milk, eggs, and meat) of cereal crops are combined, cereals account for about two-thirds of all human caloric intake. Since 1984, the rate of the world's population growth has out paced world cereal production. Thus,
20 there is a need for improved methods of crop production.

Analysts point to the need for increased reliance on artificial crop fertilizers, herbicides, and pesticides in order to meet the world's demand for cereal and other crops. (See, e.g., Proc. Natl. Acad. Sci. USA 96:5929 (1999).) Attempts to increase crop production have mainly focused on one of two proposed approaches. First, there have
25 been attempts to produce more effective fertilizer and nutrient compounds for application (i.e., foliar spraying) to growing crop plants (See, e.g., U.S. Patent No. 5,797,976). In an alternative approach, various compounds, typically organic acids and natural and synthetic plant hormones, have been used to increase crop production and fruit ripening. It is well known that organic acids are useful in stimulating the growth of plants. It has
30 been theorized that much of the action of organic fertilizers, such as manure, is due to the presence of organic acids. For example, U.S. Patent No. 5,654,255 describes compositions comprising a mixture of N,N-dimethyl piperidinium salt, hexitol, and optionally, a cytokinesis promoter. Similarly, U.S. Patent No. 5,604,177, describes a

process for increasing plant growth and productivity comprising treating the roots, stems and/or foliage with gamma-aminobutyric acid and succinic acid as metabolizable carbon sources.

Each of these basic approaches requires repeated applications for eliciting the
5 desired effect in crop plants. Thus, the material and application costs of these
approaches is high. These approaches inherently result in the application of extraneous
and often excessive levels of organic and inorganic nutrients and compounds to farm
land, which leads to increased probability of nutrient leaching and eutrophication of
adjacent riparian environments. Additionally, application of additional nutrient loads of
10 crop plants does not elevate crop and biomass production where the nutrients are already
in sufficient abundance and balance in the soil.

What is needed are cost effective methods and compositions for increasing crop
production and controlling plant metabolism and durability (e.g., to environmental
stresses) that do not require time consuming and expensive maintenance and repeated
15 applications.

SUMMARY OF THE INVENTION

The invention in some aspects relates to a plant expressing a cell wall UCP
encoded by a heterologous UCP gene. In one embodiment the heterologous UCP gene
20 comprises a gene encoding UCP2. In other embodiments the heterologous UCP gene is
a gene encoding UCP1, UCP3, UCP4, UCP5, or UCP6. In yet other embodiments the
heterologous UCP gene comprises a gene encoding PUMP, StUCP, or AtPUMP.

A method for regulating fuel metabolism in a plant, is provided according to
other aspects of the invention. The method involves regulating UCP expression in an
25 alternative membrane, such as a plant cell wall/ plasma membrane or chloroplast to
regulate fuel metabolism of the plant. In some embodiments the method involves
increasing the expression or activity of UCP in the plant cell wall/ plasma membrane or
chloroplast. The expression or activity of UCP in the plant cell wall/ plasma membrane
or chloroplast may be increased by introducing into the plant cell an expression vector
30 including a gene encoding a heterologous UCP. Alternatively, the expression of activity
of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by stably
transforming the plant cell with an expression vector including a gene encoding a

- 3 -

heterologous UCP. In some embodiments the heterologous UCP gene is a gene encoding UCP1, UCP2, UCP3, UCP4, UCP5, UCP6 PUMP, StUCP, or AtPUMP.

The expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast may also be increased by contacting the plant with a UCP activator. In one
5 embodiment the UCP activator is a compound selected from the group consisting of sugars including but not limited to glucose, sucrose, maltose, and dextrose, structural analogs of sugars including but not limited to glucose, glucose, sucrose, maltose, and dextrose, inhibitors of nucleotides and nucleotide analogs, omega 3 fatty acids, omega 6 fatty acids, and norflurazon.

10 In some embodiments the expression of UCP in the cell wall/plasma membrane is increased by contacting the plant with a cell wall targeted UCP molecule, which optionally is a UCP molecule linked to a targeting molecule such as glucose transporters, sucrose transporters, maltose transporters, and fatty acid transporters.

In other embodiments the expression of UCP in the chloroplast is increased by
15 contacting the plant with a chloroplast targeted UCP molecule, which optionally is a UCP molecule linked to a targeting molecule selected from the group consisting of a chloroplast transit protein and a peptide of N terminus small subunit of ribulose 5-phosphate carboxylase.

In yet other embodiments the expression of UCP in the cell wall/plasma
20 membrane, is increased by contacting the plant with a plasma membrane targeted UCP molecule, which optionally is a UCP molecule linked to a targeting molecule which is plant specific membrane targeting sequence lacking a VSS or KDEL sequence.

The expression of UCP in the cell wall/plasma membrane is increased by
25 contacting the plant with a plasma desmata targeted UCP molecule in some embodiments. The plasma desmata targeted UCP molecule may be a UCP molecule linked to a plasma desmata targeting molecule selected from the group consisting of porin-like targeting sequences.

In other embodiments the expression of UCP in the cell wall/plasma membrane is
30 increased by contacting the plant with a pore targeted UCP molecule, which may be a UCP molecule linked to a targeting molecule selected from the group consisting of a porin peptide, a VSS tail and a KDEL tail.

The method, according to other embodiments involves decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast. The expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast may be decreased by contacting the plant with a UCP inhibitor, which optionally is a compound including but not limited to UCP binding peptides such as anti-UCP antibodies, UCP anti-sense nucleic acids, UCP dominant-negative nucleic acids, nucleotides, nucleotide analogs, tocopherols, including but not limited to tocotrienols, and non-omega-3, -6 fatty acids.

An expression system is provided according to other aspects of the invention. The system includes a promoter sequence, a first structural gene encoding a heterologous UCP and a second structural gene encoding a plant cell wall targeting peptide or a chloroplast targeting peptide, the first and second structural genes arranged to form a fusion protein and operably linked to and under the control of the promoter sequence.

In some embodiments the promoter sequence is a plant specific promoter. In other embodiments the UCP encoded by the first structural gene is a mammalian UCP or a plant UCP. The invention also includes plants stably transformed with the expression system as well as seeds of the plant. In other aspects a progeny, clone, cell line or cell of the plant is included in the invention.

A transgenic plant transformed with a nucleic acid construct including a nucleic acid sequence encoding a UCP operably linked to a promoter sequence is also provided. The nucleic acid construct also encodes a plant cell wall targeting peptide or a chloroplast targeting peptide. The invention also includes seeds of the transgenic plant as well as a progeny, clone, cell line or cell of the transgenic plant.

The invention also includes a method for producing a nutritionally enhanced plant. The method involves decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast to produce a nutritionally enhanced plant. A method for preventing an infection in a plant by decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast in an amount to prevent an increase in oxygen free radicals and to prevent infection in the plant is also provided. A plant produced by these methods is also provided.

In some embodiments the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is decreased by contacting the plant with a UCP inhibitor. The UCP inhibitor may be a chloroplast or cell wall UCP antisense sequence.

In other aspects the invention relates to a method for improving the light and cold sensitivity of a plant. The method involves increasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast to improve the light and cold sensitivity of the plant. In some embodiments the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by introducing into the plant cell an expression vector including a gene encoding a heterologous UCP. In other
10 embodiments the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by stably transforming the plant cell with an expression vector including a gene encoding a heterologous UCP. The heterologous UCP gene may be a gene encoding UCP1, UCP2, UCP3, UCP4, PUMP, StUCP, or AtPUMP.

In other embodiments the expression or activity of UCP in the plant cell wall/
15 plasma membrane or chloroplast is increased by contacting the plant with a UCP activator. In yet other embodiments the expression of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP molecule.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention
20 involving any one element or combinations of elements can be included in each aspect of the invention.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention
25 involving any one element or combinations of elements can be included in each aspect of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1, Panel A, shows that wild type (cell-walled [CC124-]) strains of *Chlamydomonas reinhardtii* express cell surface molecules recognized by antibodies to UCP2.
30 UCP2.

Figure 1, Panel B, shows that cell wall-less (cw15+) strains of *Chlamydomonas reinhardtii* do not express cell wall surface molecules recognized by antibodies to UCP2.

- 6 -

Figure 2, Panel A, shows that light sensitive cell-walled (lts) strains of *Chlamydomonas reinhardtii* express high levels of UCP.

Figure 2, Panel B, shows that dark sensitive (CC2654; dark-dier) strains of *Chlamydomonas reinhardtii* do not express cell-wall UCP over control samples.

5 Figures 3A-3C show that norflurazon upregulates cell wall expression of UCP in wild type strains of *C. reinhardtii*.

Figure 4 is a slot blot of total RNA from *C. reinhardtii* probed for UCP expression.

BRIEF DESCRIPTION OF THE SEQUENCES

10 SEQ ID NO:1 is the nucleotide sequence of the human uncoupling (UCP-1) cDNA with GenBank Acc. no.U28480.

SEQ ID NO:2 is the predicted amino acid sequence of the translation product of human uncoupling cDNA (UCP-1).

15 SEQ ID NO:3 is the nucleotide sequence of the human uncoupling (UCP-2) cDNA with GenBank Acc. no.U82819.

SEQ ID NO:4 is the predicted amino acid sequence of the translation product of human uncoupling cDNA (UCP-2).

SEQ ID NO:5 is the nucleotide sequence of the human uncoupling (UCP-3S) cDNA with GenBank Acc. no.U82818.

20 SEQ ID NO:6 is the predicted amino acid sequence of the translation product of human uncoupling cDNA (UCP-3S).

SEQ ID NO:7 is the nucleotide sequence of the solanum tubersum UCP cDNA with GenBank Acc. no. AJ002586.

25 SEQ ID NO:8 is the nucleotide sequence of the arabidopsis thaliana UCP cDNA with GenBank Acc. no. AJ223983.

SEQ ID NO:9 is the nucleotide sequence of the arabidopsis thaliana UCP cDNA with GenBank Acc. no. AB021706.

SEQ ID NO:10 is the nucleotide sequence of the human UCP4 cDNA with GenBank Acc. no. NM_004277.

30 SEQ ID NO:11 is the nucleotide sequence of the wheat UCP cDNA with GenBank Acc. no. AB042428.

SEQ ID NO:12 is the nucleotide sequence of the human UCP5 cDNA with GenBank Acc. no. NM_022810.

SEQ ID NO:13 is a primer.

SEQ ID NO:14 is a primer.

5 SEQ ID NO:15 is a primer.

SEQ ID NO:16 is a primer.

DETAILED DESCRIPTION

The invention relates in some aspects to the finding that UCP is present in plant cellular membranes other than the mitochondrial membrane. For instance, UCP is
10 expressed on the cell wall, plasma membrane and chloroplasts of light and cold sensitive cells but not of light and cold resistant cells. This discovery has important implications for the regulation of plant metabolism.

The present invention relates in some aspects to compositions and methods for regulating fuel metabolism in plants by controlling photosynthesis through regulation of
15 plant fuel metabolism. The present invention also relates to compositions and methods for protecting plants from the free radical damage and thus in the control of infectious disease. In particular, regulation of plant fuel metabolism and protecting plants from free radical damage is achieved by compositions and methods for expressing and regulation of plant cell wall uncoupling proteins.

20 Free energy consumed by biological systems originates as solar energy. Photosynthetic organisms have evolved the processes of photosynthesis to take advantage of the solar radiation reaching the earth. Essentially, photosynthesis is a light-induced redox process in which carbon dioxide is reduced to a metabolizable storage compound by an external reductant (i.e., light is used to create reducing potential).
25 Photosynthetic organisms are primarily classified by the nature of the reductant used during photosynthetic processes. Oxygenic photosynthetic organisms, for instance, are distinguished from prokaryotic photosynthetic organisms primarily by their ability to use water as a reductant. Plants, algae, cyanobacteria, and prochlorophytes are all oxygenic photosynthetic organisms. Green plants photosynthesis takes place in chloroplasts. The
30 systems that convert solar energy in green plants to useful metabolic energy are integrated into the thylakoid membrane system of green plant chloroplasts. In particular, the thylakoid membranes contain the energy-transducing machinery: the light-

harvesting-proteins, reaction centers, electron transport chains, and ATP synthase. Photosynthesis in green plants begins by the absorption of light by a chlorophyll porphyrin (i.e., with a coordinated magnesium ion). The resulting electronic excitation passes along a series of chlorophyll molecules until the excitation is trapped in a reaction center. In the reaction center the energy of light (i.e., electron excitation) is converted into a separation of charge (i.e., reducing potential). Green plants use two light reactions: photosystem I and photosystem II. Photosystem I generates reducing potential in the form of NADPH. Photosystem II transfers the electrons of water to a quinone and concomitantly evolves diatomic oxygen. The flow of electrons in, and between, both photosystem generates a proton gradient across the thylakoid membrane that drives the synthesis of ATP. The ATP and NADPH that results from photophosphorylation processes in green plants are used to reduce carbon dioxide and convert it into 3-phosphoglycerate. The electron-motive force generated in green plant chloroplast photosystems drives electron transfer in a opposite direction from that in mitochondria., In photosynthesis, electrons are taken from water to produce diatomic oxygen, and concomitantly used to reduce carbon dioxide to synthesize carbohydrates. Chloroplasts, therefore, generate diatomic oxygen and carbohydrate, while mitochondria consume oxygen and carbohydrate.

A variety of uncoupling proteins (UCPs) are known to exist in vertebrate and photosynthetic organisms. These proteins are named for the ability to dissipate the above described proton gradient generated by the respective electron transport chains in mammalian mitochondria and green plan chloroplasts. Thus, these proteins are said to uncouple the flow of protons across a membrane through ATP synthetase and prevent the concomitant production of ATP. Dissipation of the proton gradient in this manner produces heat in a process called thermogenesis.

UCP-like proteins occur in each of the four eukaryotic kingdoms: animals, plants, fungi, and protists (See e.g., Jarmuszkiewicz et al., FEBS Lett., 467:145 [2000].) UCPs are encoded by small multi-gene families in both mammals and plants. In mammals, UCP1 is exclusively expressed in brown adipocyte tissue, while UCP2 is expressed in most tissues of humans and rodents (See e.g., Boss et al., Eur. J. of Endocrinol. 139, 1-9 [1998]); UCP3 is expressed in both skeletal muscle and in human brown adipocyte tissue (See e.g., Vidal-Puig et al., Biochem. Biophys. Res. Com 235:79

[1997]); and UCP4 is expressed in brain tissues. In mammals, UCP causes a change from glucose to fatty acid oxidation in mitochondria, and consequent thermogenesis in brown adipocyte tissue.

Plant UCP was first identified in potato tuber and has been isolated in
5 *Arabidopsis*. These potato UCP are located in the mitochondria and have been implicated in chill resistance in plants (See e.g., Nantes et al., FEBS Lett., 457:103 [1999]).

It was discovered according to the invention that UCP is expressed on other cellular membranes including the plant cell wall, plasma membrane, and the
10 chloroplasts. It was further discovered that the expression and activity of UCP in each of these distinct locations has an important impact on the regulation of cellular metabolism and free radical accumulation. These findings of the invention have important implications in the treatment of disease and the control of cellular metabolism, because it was not previously recognized that UCP was expressed in membranes such as the cell
15 wall and that such expression of UCP was involved in regulating various cellular functions.

Some of the experiments described in the Examples section demonstrated for the first time, the presence of UCP in the cell wall of plants. The following example of the characterization of a cell wall UCP are described for *Chlamydomonas reinhardtii* (*C. reinhardtii*).
20 *C. reinhardtii* is a unicellular green alga that has been widely utilized as a model for many systems, including studies of photosynthesis and motility. (See generally Harris, "The *Chlamydomonas* Sourcebook: A Comprehensive Guide to Biology and Laboratory Use," Academic Press, Inc., [1989]). Photosynthesis, when light is available, and acetate when light is not, are involved in energy production and
25 consumption in *C. reinhardtii*. Although the mechanism of photosynthesis has been widely studied, the mechanism of acetate transport has not been completely elucidated. ATP synthesis in photosynthetic organisms is produced by ATP synthase as a result of proton motive force and light energy. The experiments described below show the presence of uncoupling protein in the cell wall of *C. reinhardtii* in wild type and light-
30 sensitive, but not in cell wall-less or in dark-dier strains. Increased levels of uncoupling protein have been detected in wild type, light sensitive, a photosynthetic mutant algae grown in darkness, and norflurazon treated algae. Furthermore, increased levels in the

wild type strain made light-sensitive by treatment with the herbicide norflurazon have been observed. These findings show that the presence or absence of UCPs present in membranes outside of the mitochondria regulates fuel metabolism in plants.

Based on all these discoveries the invention includes in some aspects methods for increasing or decreasing the membrane potential in a plant cell. The ability to manipulate the membrane potential, e.g., of the plant cell wall provides the ability to control the fate of the cell. When the cell wall/plasma membrane potential is increased by increasing or decreasing expression of UCP in the cell wall/plasma membrane, the cell is able to alter its ability to process energy and to grow more efficiently than it would otherwise, e.g. when UCP is not increased. The cell is also able to differentiate more efficiently when UCP is increased in mitochondria. This is useful under conditions when light is scarce and the temperatures are cold. This shift allows the cell to use alternative non-photosynthetic fuel sources when light is scarce. The invention involves the use of this discovery to alter a plant's metabolism. If it is desirable to increase plant metabolism then UCP activity in these alternative membranes can be increased. It is desirable to increase UCP expression, for instance, when it is desirable to increase crop yields (even when solar energy is scarce or in cold temperatures) or to protect plants against cold-induced injury (in cold environments or during times of frost).

If the cell wall/plasma membrane potential of a cell is decreased, however, by inhibiting cell wall/plasma membrane UCP activity, the plants shift to the use of alternative energy sources. This may be useful in plants that are grown in warm sunny environments such as palm trees. Decreasing the activity of UCP in these alternative membranes causes the plant to accumulate fat. The plants can be harvested and the fat isolated and processed for consumption. Thus the yield of fat is increased. It is also desirable to decrease UCP activity when alternative energy sources such as acetate are scarce but adequate solar energy is available. Decreasing the activity of UCP in these alternative membranes also causes an increase in free radicals. Increases in free radicals have been demonstrated to be useful in increasing a plants resistance to infection (see e.g., US Patent 6,166,291). The invention encompasses mechanisms for controlling these complex interactions to regulate the processes of plant metabolism and resistance to infection.

- 11 -

The methods of the invention have broad utility in regulating plant cell metabolism. Because plant cells utilize the membrane potential and alternative membrane UCP in regulating their own metabolism, any type of plant cell can be manipulated according to the methods of the invention.

5 In one aspect the invention is a method for regulating fuel metabolism in a plant. The method is accomplished by regulating UCP expression in a plant cell wall/ plasma membrane or chloroplast to regulate fuel metabolism of the plant.

As used herein, the term "plant" is used in its broadest sense. The term plant includes, but is not limited to, any species of woody, ornamental or decorative, crop or
10 cereal, fruit or vegetable plant, and algae (e.g., *Chlamydomonas reinhardtii*). As used herein, the term "cereal crop" is used in its broadest sense. The term includes, but is not limited to, any species of grass, or grain plant (e.g., barley, corn, oats, rice, wild rice, rye, wheat, millet, sorghum, triticale, etc.), non-grass plants (e.g., buckwheat flax, legumes [soybeans] etc.), or other common plant derived carbohydrate source, etc. As used
15 herein, the term "crop" or "crop plant" is used in its broadest sense. The term includes, but is not limited to, any species of plant or algae edible by humans or used as a feed for animals or used, or consumed by humans, or any plant or algae used in industry or commerce. As used herein, the term "dark-dier" refers to a class of mutant organisms strains that are obligate phototrophs, including but not limited to, mutant strains of
20 *Chamydomonas reinhardtii*.

The activity of UCP in alternative membranes is manipulated according to the methods of the invention. The term "alternative membranes" refers to membranes other than mitochondrial membranes including the membranes of other plant cell compartments and organelles and the cell wall/plasma membrane. As used herein, the
25 term plant cell "compartments or organelles" is used in its broadest sense. The term includes but is not limited to, the endoplasmic reticulum, Golgi apparatus, trans Golgi network, plastids, sarcoplasmic reticulum, gloxysomes, chloroplast, and nuclear membranes, and the like. In some preferred embodiments the alternative membrane in which the UCP is manipulated is a cell wall/ plasma membrane or a chloroplast. A "cell
30 wall/ plasma membrane" as used herein refers to the cell wall or plasma membrane of the plant cell or structures located therein such as the plasma desmata or pores.

The present invention, while not intended to be limited by the selection of a particular uncoupling protein sequences, provides a variety of UCP gene or mRNA sequences, including, but not limited to, 1) plant UCPs: Genbank accession AJ002586 (*Solanum tuberosum* "potato," SEQ ID NO:7), AJ223983 (*Arabidopsis thaliana*, SEQ ID NO:8), AB021706 (*Arabidopsis thaliana*, SEQ ID NO:9), AB024733 (*Symplocarpus renifolius* "skunk cabbage"); 2) human UCPs: U28480 (UCP), AF096289 (UCP2), AF019409 (UCP2), U7637 (UCP2), AF011449 (UCP3), AF001787 (UCP3), U08476367 (UCP3), AF1104532 (UCP4); 3) mouse UCPs: AAB17666 (UCP), U63418 (UCP), U63419 (UCP), AF096288 (UCP2), AB012159 (UCP2), U69135 (UCP2), AF032902 (UCP3), AF053352 (UCP3), AF030164 (UCP3), AB010742 (UCP3); 4) rat UCPs: NM012682 (UCP), X03894 (UCP), X12925 (UCP), M11814 (UCP), AF039033 (UCP2), AB010743 (UCP2), AB005143 (UCP2), AB006613 (UCP2), AF030163 (UCP3), AB008216 (UCP3), AF035943 (UCP3), AB006614 (UCP3), U92069 (UCP3); 5) pig UCPs: AF111998 (UCP2), U11999 (UCP2), AF036757 (UCP2), A128837 (UCP3), AF095744 (UCP3); 6) cow UCPs: AF092048 (UCP3); 7) dog UCPs: AB020887 (UCP2), AB022020 (UCP3); and 8) rabbit UCP X14696.

The UCP activity may be modified with the use of UCP activators or UCP inhibitors. "UCP activity" refers to an induction of expression of new or exogenous UCP, modulation of the activity of existing UCP, or the translocation of existing sources of UCP to different membranes.

UCP activators are any compounds which increase the activity of UCP in an alternative membrane. UCP activators include but are not limited to UCP polypeptides and nucleic acids encoding the polypeptides which are delivered to the plant cell, glucose, sucrose, maltose, and dextrose, structural analogs of sugars including but not limited to glucose, sucrose, maltose, and dextrose, inhibitors of nucleotides and nucleotide analogs, omega 3 fatty acids, omega 6 fatty acids, and norflurazon. Each of these compounds is well known in the art. Omega-3 fatty acids include but are not limited to oleic acid, palmitic acid and myristic acid.

Optionally the UCP activators may be modified to include a cell wall/ plasma membrane targeting sequence or to become membrane impermeable. This is particularly desirable when the activators are being delivered to the plant cell wall. Additional targeting sequences optionally may be added to the activators. These include for

instance targeting sequences for targeting proteins to different membranes within the plant cell and include but are not limited to targeting sequences for chloroplast, plasma desmata, and pores. These types of targeting sequences are well known in the art and are described in textbooks and other references on plant physiology and biochemistry. See
5 e.g., Buchanan, Biochemistry and Molecular Biology of Plants, American Society of Plant Physiologists, Rockville, Maryland, 2000.

Cell wall/ plasma membrane targeting sequences include hydrophobic moieties and membrane attachment domains. Hydrophobic moieties are well known in the art. A "membrane attachment domain," as used herein, refers to a domain that spans the width
10 of a cell wall/ plasma membrane, or any part thereof, and that functions to attach a UCP activator or inhibitor to a cell membrane. Membrane attachment domains useful in the invention are those domains that function to attach a UCP inhibitor or activator to a cell wall/ plasma membrane of an plant cell. One skilled in the art understands that an appropriate membrane attachment domain is selected based on the type of cell in which
15 the membrane-bound fusion protein is to be expressed.

UCP nucleic acids can be delivered to a cell such that the UCP peptide will be expressed in the cell wall/ plasma membrane of the cell. The UCP expression vectors and other relevant expression vectors described herein can be prepared and inserted into cells using routine procedures known in the art. These procedures are set forth below in
20 more detail. "UCP nucleic acid", as used herein, refers to a nucleic acid molecule which:
(1) hybridizes under stringent conditions to a nucleic acid having the sequence of SEQ ID NO:1, 3, 5, and 7-12 as well as any other UCP nucleic acids publicly available and
(2) codes for a UCP polypeptide. Some UCP nucleic acids have the nucleic acid sequence of SEQ ID NO:1, 3, 5, and 7-12 (the nucleic acids encoding several exemplary
25 UCP polypeptides). The UCP nucleic acids may be intact UCP nucleic acids which include the nucleic acid sequence of Sequence ID No.: 1, 3, 5, and 7-12 as well as homologs and alleles of a nucleic acid having the sequence of SEQ ID NO: 1, 3, 5, and 7-12. Intact UCP nucleic acids further embrace nucleic acid molecules which differ from the sequence of SEQ ID NO: 1, 3, 5, and 7-12 in codon sequence due to the
30 degeneracy of the genetic code. The UCP nucleic acids of the invention may also be functionally equivalent variants, analogs and fragments of the foregoing nucleic acids. "Functionally equivalent", in reference to a UCP nucleic acid variant, analog or

fragment, refers to a nucleic acid that codes for a UCP polypeptide that is capable of functioning as an UCP. The invention further embraces complements of the foregoing nucleic acids or of unique fragments of the foregoing nucleic acids. Such complements can be used, for example, as antisense nucleic acids for inhibiting the expression of UCP in a cell for accomplishing the effects of the inhibitors described below.

UCP nucleic acid molecules can be identified by conventional techniques, e.g., by identifying nucleic acid sequences which code for UCP polypeptides and which hybridize to a nucleic acid molecule having the sequence of SEQ ID NO: 1, 3, 5, and 7-12 or other publicly available UCP nucleic acid sequences under stringent conditions. The term "stringent conditions", as used herein, refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refer to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% bovine serum albumin, 2.5mM NaH₂PO₄ (pH 7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH 7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetraacetic acid. After hybridization, the membrane to which the DNA is transferred is washed at 2x SSC at room temperature and then at 0.1x SSC/0.1x SDS at 65°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions and, thus, they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of the UCP nucleic acid of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for the expression of molecules, such as UCP, which can be isolated, followed by purification and sequencing of the pertinent nucleic acid molecule. In screening for UCP nucleic acid sequences, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against x-ray film to detect the radioactive signal.

The term "Southern blot" refers to the analysis of DNA on agarose or acrylamide gels in which DNA is separated or fragmented according to size followed by transfer of the DNA from the gel to a solid support, such as nitrocellulose or a nylon membrane.

The immobilized DNA is then exposed to a labeled probe to detect DNA species complementary to the probe used. The DNA may be cleaved with restriction enzymes prior to electrophoresis. Following electrophoresis, the DNA may be partially depurinated and denatured prior to or during transfer to the solid support. Southern blots are a standard tool of molecular biologists (J. Sambrook et al. [1989] *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, NY, pp 9.31-9.58).

The term "Northern Blot" as used herein refers to the analysis of RNA by electrophoresis of RNA on agarose gels to fractionate the RNA according to size followed by transfer of the RNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized RNA is then probed with a labeled probe to detect RNA species complementary to the probe used. Northern blots are a standard tool of molecular biologists (J. Sambrook, J. et al. [1989] *supra*, pp. 7.39-7.52).

In general, homologs and alleles typically will share at least 40% nucleotide identity with SEQ ID NO: 1, 3, 5, and 7-12; in some instances, will share at least 50% nucleotide identity; and in still other instances, will share at least 60% nucleotide identity. The preferred homologs have at least 70% sequence homology to SEQ ID NO: 1, 3, 5, and 7-12. More preferably the preferred homologs have at least 80% and, most preferably, at least 90% sequence homology to SEQ ID NO: 1, 3, 5, and 7-12.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the naturally occurring nucleic acid that codes for the UCP polypeptide. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide codons may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to, CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the naturally occurring nucleic acids in codon sequence due to the degeneracy of the genetic code.

The UCP nucleic acid, in one embodiment, is operably linked to a gene expression sequence which directs the expression of the UCP nucleic acid within a plant cell. The "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the UCP nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a eukaryotic e.g. plant or viral promoter, such as a constitutive or inducible promoter. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription (Maniatis, T. *et al.*, *Science* 236:1237 [1987]). Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in plant, yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. A wide variety of promoters have been isolated from plants, which are functional not only in the cellular source of the promoter, but also in numerous other plant species. There are also other promoters (e.g., viral and Ti-plasmid) which can be used. For example, these promoters include promoters from the Ti-plasmid, such as the octopine synthase promoter, the nopaline synthase promoter, the mannopine synthase promoter, promoters from other open reading frames in the T-DNA, such as ORF7, etc. Promoters isolated from plant viruses include the 35S promoter from cauliflower mosaic virus (CaMV). Promoters that have been isolated and reported for use in plants include ribulose-1,3-biphosphate carboxylase small subunit promoter, phaseolin promoter, etc.

Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter
5 region which includes a promoter sequence for transcriptional control of the operably joined UCP nucleic acid. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

Preferably, the UCP nucleic acid of the invention is linked to a gene expression sequence which permits expression of the UCP nucleic acid in an alternative membrane
10 such as the cell wall/ plasma membrane or chloroplast of a cell. A sequence which permits expression of the UCP nucleic acid in a plant cell is one which is selectively active in the particular plant cell and thereby causes the expression of the UCP nucleic acid in these cells. Those of ordinary skill in the art will be able to easily identify promoters that are capable of expressing a UCP nucleic acid in a cell based on the type
15 of plant cell.

The UCP nucleic acid sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the UCP coding sequence under the influence or control of the gene expression sequence. If it is desired that the UCP sequence be
20 translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the UCP sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the UCP sequence, or (3) interfere with
25 the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a UCP nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that UCP nucleic acid sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

30 There are many ways to induce expression of UCP in a plant cell. For instance, it is possible to insert an intact UCP, or functional fragment thereof, into a cell wall/ plasma membrane using delivery vehicles such as liposomes. UCP is a naturally

occurring cell wall/ plasma membrane protein having several transmembrane spanning regions including many hydrophobic residues. Proteins of this type can spontaneously insert into a biological membrane in an aqueous environment. See, e.g., US Patent No. 5,739,273 (which is hereby incorporated by reference) describing properties of bacteriorhodopsin C helix, a transmembrane spanning protein. The UCP can be inserted in to a biological membrane consistent with the methods described in US Patent No. 5,739,273 for inserting bacteriorhodopsin C into a membrane, including in lipid vesicles and by modification of various residues to increase the hydrophobicity of the molecule, without altering the function. Additionally UCP can be conjugated to a molecule which will insert in the membrane, causing the UCP to also insert in the membrane.

As set forth in US Patent No. 5,739,273 cell membranes are composed mainly of phospholipids and proteins, both containing hydrophobic and hydrophilic groups. The lipids orient themselves into an orderly bilayer configuration within the membrane core with the hydrophobic chains facing toward the center of the membrane while the hydrophilic portions are oriented toward the outer and inner membrane surfaces. The proteins are dispersed throughout the lipid layer, in some instances protruding through the surface of the membrane or extending from one side of the membrane to the other with some of the hydrophobic residues being buried in the interior of the lipid bilayer.

US Patent No. 5,739,273 teaches that a synthetic polypeptide maintaining the characteristics of a native polypeptide by including a hydrophobic alpha-helical transmembrane region containing one or more acidic or basic amino acids can be generated. Preferably, the amino acids are aspartic acid, glutamic acid, lysine, arginine or histidine. This is based on the teachings of *Popot and Engelman, Biochem. 29:4031-4037 (1990)*, that recently proposed a two-stage model of helix formation for transmembrane proteins in which the alpha-helices first insert into the lipid bilayer and then assemble into a tertiary structure that includes interactions with other intramembrane alpha-helices of the protein or with alpha-helices of other polypeptides in the membrane.

The UCP insertion into the membrane can be enhanced using lipid vesicles. Lipid vesicles such as micelles can be formed by the addition of phospholipids to achieve a specific ratio of protein to phospholipid. The orientation of the chimeric protein components of the micelles can be controlled also, so that the micelles have an

outer surface which is predominantly composed of the phospholipid moieties or predominantly composed of the protein moieties. The size of the micelles may also be controlled by varying the detergent employed, the nature of the added phospholipid, or the phospholipid/protein ratio.

5 UCP proteins include the intact native UCP in an isolated form as well as functionally active fragments and variants thereof.

A UCP activator induces the uncoupling function of a UCP molecule that is already expressed in the an alternative membrane such as the cell wall/ plasma membrane or chloroplast or causes a functional UCP to be expressed or inserted into the
10 alternative membrane.

Thus, the present invention provides methods and compositions for the expression of UCP in plants. The present invention contemplates that any method of transfection that is suitable for transfection of plants, plant tissues, and plant cells may be used with the present invention. Such methods include, but are not limited to,
15 *Agrobacterium*-mediated transformation (*e.g.*, Komari *et al.*, Curr. Opin. Plant Biol., 1:161 [1998]), particle bombardment mediated transformation (*e.g.*, Finer *et al.*, Curr. Top. Microbiol. Immunol., 240:59 [1999]), protoplast electroporation (*e.g.*, Bates, Methods Mol. Biol., 111:359 [1999]), viral infection (*e.g.*, Porta and Lomonosoff, Mo. Biotechnol. 5:209 [1996]), microinjection, and liposome injection. Standard molecular
20 biology techniques are common in the art (*See e.g.*, Sambrook, J. *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, New York [1989]). For example, in one embodiment of the present invention tobacco or arabidopsis is transformed with a gene encoding UCP using *Agrobacterium*.

Using any of the above gene transfer techniques, an expression vector harboring
25 the UCP gene of interest is transformed into the desired plant sample to achieve temporary or prolonged expression of the UCP. Any suitable expression system may be used, so long as it is capable of undergoing transformation and expressing of the gene of interest in the host. In one embodiment of the present invention, a pET vector (Novagen, Madison, Wisconsin), or a pBI vector (Clontech, Palo Alto, California) is used as the
30 expression vector. In some embodiments an expression vector further encoding a green fluorescent protein (GFP) is used to allow simple selection of transfected cells and to monitor expression levels. Examples of such vectors include Clontech's "Living Colors

- 20 -

Vectors" pEYFP and pEYFP-C1. The EYFP gene is codon optimized for high expression in plant cells.

A variety of promoters and regulatory elements may be used in the expression vectors of the present invention. For example, in some preferred embodiments an inducible promoter is used to allow control of UCP expression through the presentation of external stimuli (*e.g.*, environmentally inducible promoters). Thus, the timing and amount of UCP expression may be controlled. Examples of expression systems, promoters, inducible promoters, environmentally inducible promoters, and enhancers are described in WO 00/12714, WO 00/11175, WO 00/12713, WO 00/03012, WO 00/03017, WO 00/01832, WO 99/50428, WO 99/46976 and U.S. Pat. Nos. 6,028,250, 5,959,176, 5,907,086, 5,898,096, 5,824,857, 5,744,334, 5,689,044, and 5,612,472 each of which is herein incorporated by reference in its entirety.

UCP expression may be controlled in a number of ways. For example, expression may be stimulated by expressing a UCP gene in the plant, plant tissue, or plant cell. Expression may be from a UCP gene from a different species or may be from the expression of an endogenous gene. Regulation of the endogenous gene may be achieved, for example, through the introduction of a heterologous promoter, by increasing the copy number of the gene, and through the stimulation of native gene expression by regulating the levels or presence of particular transcription factors. UCP expression may be inhibited, for example, through the introduction of antisense molecules or other RNA targeting molecules (*e.g.*, ribozymes), gene-knockout (*i.e.*, disrupting the UCP gene), down-regulation of gene expression by manipulating transcription factor activity, introduction of protein inhibitors, and other established methods. One illustrative example of induced and inhibited expression is provided below.

In one embodiment of the present invention, cDNA encoding mouse UCP2 (genbank accession #U69135, SEQ ID NO:1) is cloned into a Bluescript (Stratagene, La Jolla, California) as a 1588 bp XhoI-EcoRI fragment. The start codon begins at nucleotide position 360. The stop codon begins at nucleotide position 1290. This clone contains both 5' and 3' flanking sequences. Two sets of PCR primers were synthesized and may be used to isolate the gene fragment.

The primer set corresponds to the sense sequence of the mouse UCP2 (that is, the entire sequence, from nucleotide 360 to nucleotide 1290). Each of these primers also contains a restriction enzyme site corresponding to the cloning site.

The sense 5' primer: 5' GTACCGGGCCCCATGGTTGGTTTCAAG 3'
(SEQ ID NO:13)

The sense 3' primer: 5' GGCCATCTCGAGGAAAGGTGCCTCCCG 3'
(SEQ ID NO:14)

For generating an antisense fragment, the largest open reading frame in the antisense orientation was determined. The antisense fragment is approximately 550 nucleotides long (between nucleotides 1005 and 305 when looking at the sequence in antisense) and encodes an open reading frame. Each of the primers also contains a restriction enzyme site corresponding to the cloning site.

The sense 5' primer: 5' GTACCGGGCCCCATGGGCTCTTTTGAGCTG 3'
(SEQ ID NO:15)

The sense 3' primer: 5' CTTGGCCATCTCGAGCATGCAGGCATC 3'
(SEQ ID NO:16)

The sense and antisense fragments are isolated from the UCP2 gene in the Bluescript vector using the polymerase chain reaction. The isolated fragments are cloned into a GFP fusion protein vector optimized for *Chlamydomonas*. One example of such a vector is pFCrGFP (Entelechon GmbH, Regensburg, Germany).

After cloning the sense and antisense constructs into this vector, *Chlamydomonas* is transformed using the glass bead-vortex method (See e.g., Kindle, "Chap 4, Nuclear Transformation: Technology and Applications," The Molecular Biology of Chloroplasts and Mitochondria in *Chlamydomonas*, Klawer Academic Publishers [1998]; Kindle, Proc. Natl. Acad. Sci. USA 87:1228 [1990]). A cell-wall-less strain, nit 1-305 is used and transformed with the plasmid pMN24 containing a gene that allows transformants to grow on nitrate-containing medium. Rather than clone UCP2 into pMN24, co-transformation of the two plasmids (pMN24 and pFCrGFP) is conducted and transformants are selected on nitrate. In addition, because UCP2 is fused to GFP, colonies containing UCP2 can be screened more directly by their fluorescence using flow cytometry.

- 22 -

In one embodiment of the present invention, a first transformation is gain-of-function. For example, the sense-GFP construct is transformed into the cell wall-less strain nit 1-305. This strain has two advantages. It lacks a cell wall and so can be easily transformed and it lacks UCP2 when analyzed by flow cytometry, as is predicted from the flow cytometry results discussed above (*i.e.*, that no cell wall-less strains will have UCP2 when grown under standard light conditions).

In another embodiment of the present invention, a second transformation involves loss-of-function. For example, the anti-sense-GFP construct is used. In some embodiments, the cell wall is removed by autolysin to facilitate transfection prior to vortexing with glass beads. The selection process is as described in Kindle, Chapter 4, Nuclear Transformation: Technology and Applications, *Supra*.

In still another embodiment of the present invention, the selection process can be achieved via drug sensitivity as described in Kindle, Chapter 4, Nuclear Transformation: Technology and Applications, *Supra*.

Successful transformation and expression levels may be detected any number of ways. In addition to the GFP-screening described above, Southern and Northern hybridization assays may be conducted to identify successful transformants and detected UCP expression levels. The UCP fragments described above may be used as probes. For Northern blot analysis, RNAs isolated from different strains of *Chlamydomonas*, and *Chlamydomonas* grown under different conditions are isolated and tested.

In still further embodiments, ribozymes may be used to bind to a target RNA through complementary base-pairing, and once bound to the correct site, act enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. Examples of ribozymes motifs with enzymatic activity include hammerheads and hairpins (*See, e.g.*, U.S. Pat. Nos. 5,891,684; 5,877,022; 5,869,253; 5,811,300; 5,795,778; 5,728,818; and 5,714,383, all of which are incorporated herein by reference).

Identification and characterization of UCP localization in the cells may be conducted by confocal microscopy or any other suitable method. In some embodiments, organelles are isolated and analyzed for the presence of UCP through their ability to bind UCP-specific antibodies.

UCP inhibitors are any compounds which decrease the activity of UCP in an alternative membrane. UCP inhibitors include but are not limited to UCP binding peptides such as anti-UCP antibodies, UCP anti-sense nucleic acids, UCP dominant negative nucleic acids, nucleotides, nucleotide analogs, tocopherols, such as tocotrienols, and non omega 3 or 6 fatty acids. Other types of inhibitors include ribozymes which interfere with the transcription, processing, or translation of UCP mRNA. In other embodiments the UCP inhibitor is tunicamycin. Tunicamycin promotes intracellular trafficking of the UCP between intracellular locations. Each of these inhibitors is well known in the art and has been described extensively in the literature.

Nucleotides and nucleotide (purine and pyrimidine) analogs include but are not limited to guanosine diphosphate (GDP). Purine analogs include but are not limited to guanosine diphosphate, 8-oxo-Adenosine, 8-oxo-Guanosine, 8-fluoro-Adenosine, 8-fluoro-Guanosine, 8-methoxy-Adenosine, 8-methoxy-Guanosine, 8-aza-Adenosine and 8-aza-Guanosine, azacitidine, Fludarabine phosphate, 6-MP, 6-TG, azathioprine, allopurinol, acyclovir, gancyclovir, deoxycytosine, and arabinosyladenine (ara-A), guanosine diphosphate fucose, guanosine diphosphate-2-fluorofucose, guanosine diphosphate-.beta.L-2-aminofucose, guanosine diphosphate-D-arabinose and 2-aminoadenosine. Some examples of pyrimidine analogues are uracil, thymine, cytosine, 5-fluorouracil, 5-chlorouracil, 5-bromouracil, dihydrouracil, 5-methylcytosine, 5-propynylthymine, 5-propynyluracil and 5-propynylcytosine, 5-fluorocytosine, Floxuridine, uridine, thymine, 3'-azido-3'-deoxythymidine, 2-fluorodeoxycytidine, 3-fluoro-3'-deoxythymidine; 3'-dideoxycytidin-2'-ene; and 3'-deoxy-3'-deoxythymidin-2'-ene, cytosine arabinoside. Other such compounds are known to those of skill in the art.

Thus nucleotides and nucleotide analogs can be modified to produce cell wall/plasma membrane targeted UCP inhibitors by attaching a cell wall/plasma membrane targeting sequence to the nucleotide or nucleotide analog. This can be accomplished by linking the nucleotide analog to a cell surface targeting molecule. Several methods for linking molecules are described below and others are known in the art. The nucleotide or nucleotide analogs may also be modified such that it is membrane impermeable to prevent uptake of the nucleotide analog by the cell. By using compounds which are not taken up by a cell but simply act on the cell surface UCP many of the toxic side effects

associated with some of these drugs are avoided. The compounds will not have an effect on cells that do not have UCP expressed in the cell wall/ plasma membrane, because they cannot access the intracellular UCP. Additionally, the compounds will not be metabolized within cells to produce toxic compounds.

5 UCP inhibitors also include UCP binding peptides or molecules. The binding peptides or molecules can be delivered directly to the cell to act on the cell wall/ plasma membrane UCP. The UCP binding peptide or molecule may also be attached to a targeting molecule which targets the peptide or molecule to the cell of interest, as discussed in more detail below.

10 The UCP binding peptides and molecules of the invention can be identified using routine assays, such as the binding and activation assays described in the Examples and elsewhere throughout this patent application.

The UCP binding molecule is an isolated molecule. An isolated molecule is a molecule that is substantially pure and is free of other substances with which it is
15 ordinarily found in nature or *in vivo* systems to an extent practical and appropriate for its intended use. In particular, the molecular species are sufficiently pure and are sufficiently free from other biological constituents of host cells so as to be useful in, for example, producing pharmaceutical preparations or sequencing if the molecular species is a nucleic acid, peptide, or polysaccharide. Because an isolated molecular species of
20 the invention may be admixed with a pharmaceutically-acceptable carrier in a pharmaceutical preparation, the molecular species may comprise only a small percentage by weight of the preparation. The molecular species is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems.

25 The UCP binding molecules may be isolated from natural sources or synthesized or produced by recombinant means. Methods for preparing or identifying molecules which bind to a particular target are well-known in the art. Molecular imprinting, for instance, may be used for the de novo construction of macro molecular structures, such as peptides, which bind to a particular molecule. See for example, Kenneth J. Shea,
30 *Molecular Imprinting of Synthetic Network Polymers: The De novo Synthesis of Molecular Binding In Catalytic Sites*, Trip, to May 1994; Klaus, Mosbach, *Molecular Imprinting*, Trends in *Biochem. Sci.*, 19(9), January 1994; and Wulff, G., In *Polymeric*

Reagents and Catalysts (Ford, W.T., ed.) *ACS Symposium Series* No. 308, P.186-230, *Am. Chem. Soc.* 1986. Binding peptides, such as antibodies, may easily be prepared by generating antibodies to UCP (or obtained from commercial sources) or by screening libraries to identify peptides or other compounds which bind to the UCP.

- 5 Many UCP antibodies are commercially available. These include but are not limited to those antibodies commercially available from Santa Cruz Biotechnology, Inc., e.g., UCP1 (m-17, sc-6529), UCP1 (C-17, sc-6528), UCP2 (A19, sc-6527), UCP2 (N19, sc-6526), UCP2 (c-20, sc-6525), and UCP3 (C-20, sc-7756); antibodies commercially available from Research Diagnostics Inc e.g., Goat anti-UCP1 HUMAN/Mouse/Rat
- 10 (cat#RDI-UCP1Cabg); Goat anti-UCP1 HUMAN/Mouse/Rat (cat#RDI-MUCP1Cabg); Goat anti-UCP2 HUMAN/Mouse/Rat (cat#RDI-UCP2Nabg); Goat anti-UCP2 HUMAN/Mouse/Rat (cat#RDI-UCP2Cabg); Goat anti-UCP2 HUMAN/Mouse/Rat (cat#RDI-UCP2C1abg); Rabbit anti-Murine UCP1 (cat#RDI-MUCP12abrX); Rabbit anti-Murine UCP1 (cat#RDI-MUCP19abrX); Rabbit anti-Murine UCP2 (cat#RDI-
- 15 MUCP2abrX); Rabbit anti-Murine UCP2 (cat#RDI-MUCP2CabrX); Rabbit anti-human UCP2 (cat#RDI-UCP2MabrX); UCP3L (see Boss, O et al (1997) FEBS Lett 408,38-42; Vidal-Plug A et al (1997) BBRC 235, 79-82); Rabbit anti-HUMAN UCP3 (cat#RDI-UCP3abrX); Rabbit anti-HUMAN UCP3 (cat#RDI-UCP3CbrX); Rabbit anti-HUMAN UCP3 (cat#RDI-UCP3MabrX); Rabbit anti-Rat UCP3 (cat#RDI-RTUCP3MabrX), etc.
- 20 Mimics of known binding molecules may also be prepared by known methods, such as (i) polymerization of functional monomers around a known binding molecule or the binding region of an antibody which also binds to the target (the template) that exhibits the desired activity; (ii) removal of the template molecule; and then (iii) polymerization of a second class of monomers in the void left by the template, to provide
- 25 a new molecule which exhibits one or more desired properties which are similar to that of the template. The method is useful for preparing peptides, and other binding molecules which have the same function as binding peptides, such as polysaccharides, nucleotides, nucleoproteins, lipoproteins, carbohydrates, glycoproteins, steroids, lipids and other biologically-active material can also be prepared. Thus a template, such as a
- 30 UCP binding antibody can be used to identify UCP inhibitors. It is now routine to produce large numbers of inhibitors based on one or a few peptide sequences or sequence motifs. (See, e.g., Bromme, et al., *Biochem. J.* 315:85-89 (1996); Palmer, et

- 26 -

al., *J. Med. Chem.* 38:3193-3196 (1995)). For example, if UCP is known to interact with protein X at position Y, an inhibitor of UCP may be chosen or designed as a polypeptide or modified polypeptide having the same sequence as protein X, or structural similarity to the sequence of protein X, in the region adjacent to position Y. In fact, the region
5 adjacent to the cleavage site Y spanning residues removed by 10 residues or, more preferably 5 residues, N-terminal and C-terminal of position Y, may be defined as a "preferred protein X site" for the choice or design of UCP inhibitors. Thus, a plurality of UCP inhibitors chosen or designed to span the preferred protein X binding site around position Y, may be produced, tested for inhibitory activity, and sequentially modified to
10 optimize or alter activity, stability, and/or specificity.

The method is useful for designing a wide variety of biological mimics that are more stable than the natural counterpart, because they are typically prepared by the free radical polymerization of functional monomers, resulting in a compound with a non-biodegradable backbone. Thus, the created molecules would have the same binding
15 properties as the UCP antibody but be more stable *in vivo*, thus preventing UCP from interacting with components normally available in its native environment. Other methods for designing such molecules include, for example, drug design based on structure activity relationships which require the synthesis and evaluation of a number of compounds and molecular modeling.

20 Binding molecules may also be identified by conventional screening methods, such as phage display procedures (e.g. methods described in Hart et al., *J. Biol. Chem.* 269:12468 (1994)). Hart et al. report a filamentous phage display library for identifying novel peptide ligands. In general, phage display libraries using, e.g., M13 or fd phage, are prepared using conventional procedures such as those described in the foregoing
25 reference. The libraries generally display inserts containing from 4 to 80 amino acid residues. The inserts optionally represent a completely degenerate or biased array of peptides. Ligands having the appropriate binding properties are obtained by selecting those phage which express on their surface a ligand that binds to the target molecule. These phage are then subjected to several cycles of reselection to identify the peptide
30 ligand expressing phage that have the most useful binding characteristics. Typically, phage that exhibit the best binding characteristics (e.g., highest affinity) are further characterized by nucleic acid analysis to identify the particular amino acid sequences of

- 27 -

the peptide expressed on the phage surface in the optimum length of the express peptide to achieve optimum binding.

Alternatively, UCP binding molecules can be identified from combinatorial libraries. Many types of combinatorial libraries have been described. For instance, U.S. Patent Nos. 5,712,171 (which describes methods for constructing arrays of synthetic
5 molecular constructs by forming a plurality of molecular constructs having the scaffold backbone of the chemical molecule and modifying at least one location on the molecule in a logically-ordered array); 5,962,412 (which describes methods for making polymers having specific physiochemical properties); and 5,962,736 (which describes specific
10 arrayed compounds).

To determine whether a molecule binds to the appropriate target any known binding assay may be employed. For example, in the case of a peptide that binds to the cell wall/ plasma membrane UCP the molecule may be immobilized on a surface and then contacted with a labeled UCP (or vice versa). The amount of UCP which interacts
15 with the molecule or the amount which does not bind to the molecule may then be quantitated to determine whether the molecule binds to UCP. A surface having a known molecule that binds to UCP such as a commercially available monoclonal antibody immobilized thereto may serve as a positive control. Several types of commercially available antibodies are described above.

20 Screening of molecules of the invention, also can be carried out utilizing a competition assay. If the molecule being tested competes with the known monoclonal antibody, as shown by a decrease in binding of the known monoclonal antibody, then it is likely that the molecule and the known monoclonal antibody bind to the same, or a closely related, epitope. Still another way to determine whether a molecule has the
25 specificity of the known monoclonal antibody is to pre-incubate the known monoclonal antibody with the target with which it is normally reactive, and then add the molecule being tested to determine if the molecule being tested is inhibited in its ability to bind the target. If the molecule being tested is inhibited then, in all likelihood, it has the same, or a functionally equivalent, epitope and specificity as the known monoclonal antibody.

30 By using the known UCP (and other target) monoclonal antibodies of the invention, it is also possible to produce anti-idiotypic antibodies which can be used to screen other antibodies to identify whether the antibody has the same binding specificity

- 28 -

as the known monoclonal antibody. Such anti-idiotypic antibodies can be produced using well-known hybridoma techniques (*Kohler and Milstein, Nature, 256:495, 1975*). An anti-idiotypic antibody is an antibody which recognizes unique determinants present on the known monoclonal antibodies. These determinants are located in the

5 hypervariable region of the antibody. It is this region which binds to a given epitope and, thus, is responsible for the specificity of the antibody. An anti-idiotypic antibody can be prepared by immunizing an animal with the known monoclonal antibodies. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing known monoclonal antibodies and produce an antibody to these idiotypic

10 determinants. By using the anti-idiotypic antibodies of the immunized animal, which are specific for the known monoclonal antibodies of the invention, it is possible to identify other clones with the same idio type as the known monoclonal antibody used for immunization. Idiotypic identity between monoclonal antibodies of two cell lines demonstrates that the two monoclonal antibodies are the same with respect to their

15 recognition of the same epitopic determinant. Thus, by using anti-idiotypic antibodies, it is possible to identify other hybridomas expressing monoclonal antibodies having the same epitopic specificity.

It is also possible to use the anti-idiotypic technology to produce monoclonal antibodies which mimic an epitope. For example, an anti-idiotypic monoclonal antibody

20 made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the image of the epitope bound by the first monoclonal antibody.

In one embodiment the binding peptides useful according to the invention are antibodies or functionally active antibody fragments. Antibodies are well known to those of ordinary skill in the science of immunology. Many of the binding peptides

25 described herein are available from commercial sources as intact functional antibodies, as described above. As used herein, the term "antibody" means not only intact antibody molecules but also fragments of antibody molecules retaining specific binding ability. Such fragments are also well known in the art. In particular, as used herein, the term "antibody" means not only intact immunoglobulin molecules but also the well-known

30 active fragments $F(ab')_2$, and Fab. $F(ab')_2$, and Fab fragments which lack the Fc fragment of intact antibody (*Wahl et al., J. Nucl. Med. 24:316-325 (1983)*).

As is well-known in the art, the complementarity determining regions (CDRs) of an antibody are the portions of the antibody which are largely responsible for antibody specificity. The CDR's directly interact with the epitope of the antigen (see, in general, *Clark, 1986; Roitt, 1991*). In both the heavy chain and the light chain variable regions of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The framework regions (FRs) maintain the tertiary structure of the paratope, which is the portion of the antibody which is involved in the interaction with the antigen. The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3 contribute to antibody specificity. Because these CDR regions and in particular the CDR3 region confer antigen specificity on the antibody these regions may be incorporated into other antibodies or peptides to confer the identical specificity onto that antibody or peptide.

According to one embodiment, the peptide of the invention is an intact soluble monoclonal antibody in an isolated form or in a pharmaceutical preparation. An intact soluble monoclonal antibody, as is well known in the art, is an assembly of polypeptide chains linked by disulfide bridges. Two principle polypeptide chains, referred to as the light chain and heavy chain, make up all major structural classes (isotypes) of antibody. Both heavy chains and light chains are further divided into subregions referred to as variable regions and constant regions. As used herein the term "monoclonal antibody" refers to a homogenous population of immunoglobulins which specifically bind to an epitope (i.e. antigenic determinant), e.g., of cell wall/ plasma membrane UCP, chloroplast UCP etc.

The binding peptides may also be functionally active antibody fragments. Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, *Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford*). The pFc' and Fc regions of the antibody, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the

- 30 -

antigen binding sites of an intact antibody. An isolated $F(ab')_2$ fragment is referred to as a bivalent monoclonal fragment because of its two antigen binding sites. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd (heavy chain variable region). The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

The terms Fab, Fc, pFc' , $F(ab')_2$ and Fv are used consistently with their standard immunological meanings [Klein, *Immunology* (John Wiley, New York, NY, 1982); Clark, W.R. (1986) *The Experimental Foundations of Modern Immunology* (Wiley & Sons, Inc., New York); Roitt, I. (1991) *Essential Immunology*, 7th Ed., (Blackwell Scientific Publications, Oxford)].

In addition to the binding peptides and molecules, the invention also encompasses the use of antisense oligonucleotides that selectively bind to a UCP nucleic acid molecule, and dominant negative UCP to reduce the expression of UCP. Antisense oligonucleotides are useful, for example, for inhibiting UCP in a cell in which it is ordinarily expressed in alternative membranes such as the cell wall/ plasma membrane and chloroplasts.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an RNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of the mRNA. The antisense molecules are designed so as to hybridize with the target gene or target gene product and thereby, interfere with transcription or translation of the target plant cell gene. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. The antisense must be a unique fragment. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its

precise sequence is not found in molecules outside of the UCP gene. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NO:1, 3, 5, and 7-12, will require longer segments to be unique while others will require only short segments, typically between 12 and 32 base pairs (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases long).

It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the known sequence of a gene that is targeted for inhibition by antisense hybridization, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 7 and, more preferably, at least 15 consecutive bases which are complementary to the target. Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or RNA (e.g., mRNA) transcripts, in preferred embodiments the antisense oligonucleotides are complementary to 5' sites, such as translation initiation, transcription initiation or promoter sites, that are upstream of the gene that is targeted for inhibition by the antisense oligonucleotides. In addition, 3'-untranslated regions may be targeted. Furthermore, 5' or 3' enhancers may be targeted. Targeting to mRNA splice sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In at least some embodiments, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.*, (1994) 14(5):439-457) and at which proteins are not expected to bind. The selective binding of the antisense oligonucleotide to a plant cell nucleic acid effectively decreases or eliminates the transcription or translation of the plant target cell nucleic acid molecule, thus reducing UCP expression in the plant.

The invention also includes the use of a "dominant negative cell wall/ plasma membrane UCP" polypeptide. A dominant negative polypeptide is an inactive variant of

a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the
5 ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase
10 gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide as used herein in a cell is a reduction in membrane expressed UCP. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using
15 standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, one of ordinary skill in the art can modify the sequence of the cell wall/ plasma membrane UCP by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second
20 Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity, or simply for presence in the cell wall/ plasma membrane. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

25 Optionally, a plant cell targeting sequence can be used to target the UCP inhibitor or activator to a specific type of plant cell. It is desirable in many instances to specifically target the activator or inhibitor to a specific plant cell type to increase the efficiency and specificity of administration of the UCP inhibitor or activator and to avoid delivering the compounds to another plant cell in close physical proximity, for which the
30 treatment may not be beneficial.

Methods of targeting drugs and other compounds to target cells are well known in the art. One method of targeting involves antibody or receptor targeting. Receptor or

- 33 -

antibody targeting involves linking the UCP inhibitor or activator to a ligand or an antibody which has an affinity for a receptor or cell surface molecule expressed on the desired target cell surface. Using this approach, the UCP inhibitor or activator is intended to adhere to the target cell following formation of a ligand-receptor or antibody-cell surface antigen complex on the cell surface. The type of receptor or antibody used to target the cell will depend on the specific cell type being targeted.

A plant cell targeting sequence may be attached by a peptide or other type of bond such as a sulfhydryl or disulfide bond. Targeting molecules are described, for instance in US Patent No. 5,849,718 as well as many other references.

In general the plant cell targeting sequence is coupled to the UCP inhibitor or activator. The molecules may be directly coupled to one another, such as by conjugation or may be indirectly coupled to one another where, for example, plant cell targeting sequence is on the surface of a liposome and the UCP inhibitor or activator is contained within the liposome. If the molecules are linked to one another, then the plant cell targeting sequence is covalently or noncovalently bound to the UCP inhibitor or activator in a manner that preserves the targeting specificity of the plant cell targeting sequence. As used herein, "linked" or "linkage" means two entities are bound to one another by any physiochemical means. It is important that the linkage be of such a nature that it does not impair substantially the effectiveness of the UCP inhibitor or activator or the binding specificity of the plant cell targeting sequence. Keeping these parameters in mind, any linkage known to those of ordinary skill in the art may be employed, covalent or noncovalent. Such means and methods of linkage are well known to those of ordinary skill in the art.

Linkage according to the invention need not be direct linkage. The components of the compositions of the invention may be provided with functionalized groups to facilitate their linkage and/or linker groups may be interposed between the components of these compositions to facilitate their linkage. In addition, the components of the present invention may be synthesized in a single process, whereby the components could be regarded as one in the same entity. For example, a plant cell targeting sequence specific for a plant cell could be synthesized together with the UCP inhibitor or activator. These and other modifications are intended to be embraced by the present invention.

- 34 -

Specific examples of covalent bonds include those wherein bifunctional cross-linker molecules are used. The cross-linker molecules may be homobifunctional or heterobifunctional, depending upon the nature of the molecules to be conjugated. Homobifunctional cross-linkers have two identical reactive groups. Heterobifunctional cross-linkers have two different reactive groups that allow sequential conjugation reaction. Various types of commercially available cross-linkers are reactive with one or more of the following groups: primary amines, secondary amines, sulphhydryles, carboxyls, carbonyls and carbohydrates.

Non-covalent methods of conjugation also may be used to join the targeting moiety and the UCP inhibitor or activator. Non-covalent conjugation may be accomplished by direct or indirect means including hydrophobic interaction, ionic interaction, intercalation, binding to major or minor grooves of a nucleic acid and other affinity interactions.

Covalent linkages may be noncleavable in physiological environments or cleavable in physiological environments, such as linkers containing disulfide bonds. Such molecules may resist degradation and/or may be subject to different intracellular transport mechanisms. One of ordinary skill in the art will be able to ascertain without undue experimentation the preferred bond for linking the targeting moiety and the UCP inhibitor or activator, based on the chemical properties of the molecules being linked and the preferred characteristics of the bond.

For indirect linkage, the plant cell targeting sequence may be part of a particle, such as a liposome, which targets the liposome to the plant cell or organelle. The liposome, in turn, may contain the UCP inhibitor or activator. The manufacture of liposomes containing a protein or nucleic acid such as a UCP inhibitor or activator is fully described in the literature. Many are based upon cholesteric molecules as starting ingredients and/or phospholipids. They may be synthetically derived or isolated from natural membrane components. Virtually any hydrophobic substance can be used, including cholesteric molecules, phospholipids and fatty acids preferably of medium chain length (12C-20C). Preferred are naturally occurring fatty acids of between 14 and 18 carbons in length. These molecules can be attached to the UCP inhibitor or activator of the invention, with the lipophilic anchor inserting into the membrane of a liposome

- 35 -

and the UCP inhibitor or activator tethered on the surface of the liposome for targeting the liposome to the cell.

In some embodiments the UCP activators and inhibitors are targeted to the intracellular organelles or to the cell wall or plasma membrane, including the plasma
5 desmata or pores. These types of targeting molecules are described above and can be linked to the activators and inhibitors as described herein.

The term "heterologous," as used herein in reference to a membrane attachment domain operatively fused to a UCP inhibitor or activator, means a membrane attachment domain derived from a source other than the gene encoding the UCP inhibitor or
10 activator. A heterologous membrane attachment domain can be synthetic or can be encoded by a gene distinct from the gene encoding the UCP inhibitor or activator to which it is fused.

The term "operatively fused," as used herein in reference to a UCP inhibitor or activator and a heterologous membrane attachment domain, means that the UCP
15 inhibitor or activator and membrane attachment domain are fused in the correct reading frame such that, under appropriate conditions, a full-length fusion protein is expressed. One skilled in the art would recognize that such a fusion protein can comprise, for example, an amino-terminal UCP inhibitor or activator operatively fused to a carboxyl-terminal heterologous membrane attachment domain or can comprise an amino-terminal
20 heterologous membrane attachment domain operatively fused to a carboxyl-terminal UCP inhibitor or activator

The term "membrane-bound," as used herein in reference to a fusion protein means stably attached to a cellular membrane. The term "fusion protein," as used herein, means a hybrid protein including a synthetic or heterologous amino acid sequence.

25 As used herein, the term "dissipation of cellular proton motor force" refers to the relative amount of protons in the cell. It can be assessed by measuring cell wall/ plasma, chloroplast, or mitochondrial membrane potential depending on the UCP being studied. As used herein "cell wall/ plasma membrane potential" is the pressure on the inside of the cell wall/ plasma membrane measured relative to the extracellular fluid which is
30 created by the generation and dissipation of charge within the cell. The "chloroplast membrane potential" is the pressure on the inside of the chloroplast membrane measured relative to the cytoplasm which is created by the generation and dissipation of charge

- 36 -

within the chloroplast. The cell wall/ plasma or chloroplast membrane potential is maintained by the energy generating system of the cell wall/ plasma or chloroplast membrane respectively. In most tissues electron transport is coupled to oxidative phosphorylation resulting in the production of ATP from glucose. UCPs can cause the reversible uncoupling of electron transport and oxidative phosphorylation, which leads to a decrease in the mitochondrial membrane potential, or as discovered herein the cell wall/ plasma or chloroplast membrane potential.

The absolute levels of the cell wall/ plasma membrane potential vary depending on the cell or tissue type. As used herein an "increase in cell wall/ plasma or chloroplast membrane potential" is an increase relative to the normal status of the cell being examined and results from the prevention of dissipation of proton motor force with respect to cell wall/ plasma or chloroplast respectively. "Prevention" as used herein refers to a decrease or reduction in the amount of dissipation that would ordinarily occur in the absence of the stimulus applied according to the methods of the invention to cause coupling. If electron transport and oxidative phosphorylation are normally uncoupled within the cell wall/ plasma or chloroplast membrane of the cell then the baseline potential will be relatively low and when the ATP generating systems are coupled an increase in cell wall/ plasma or chloroplast membrane potential from that baseline level is observed. Likewise, a "decrease in cell wall/ plasma or chloroplast membrane potential" is a decrease relative to the normal status of the cell being examined and results from the dissipation of proton motor force. If electron transport and oxidative phosphorylation are normally coupled within the cell then the baseline potential will be relatively high and when the ATP generating systems are uncoupled a decrease in cell wall/ plasma membrane potential from that baseline level is observed. Cell wall/ plasma or chloroplast membrane ATP synthase is likely the source of ATP for the cell wall/ plasma or chloroplast membrane UCP.

Changes in cell wall/ plasma or chloroplast membrane potential can be assessed by any method known in the art for making such measurements. For example the cell wall/ plasma or chloroplast membrane potential may be assessed using the well known comet assay, where whole cells are electrophoresed on an agarose gel and examined for the presence of a tail. Alternatively it may be measured using electrodes placed on opposite sides of the membrane. Cell wall/ plasma or chloroplast membrane potential

may also be measured cytometrically by incubating cells for approximately 20 minutes at room temperature with a cell wall/ plasma or chloroplast membrane specific fluorescent probe. The aggregation state and consequently the fluorescence emission of fluorescent probe changes as the cell wall/ plasma or chloroplast membrane potential is altered.

5 Flow cytometry permits the examination of more than one, for instance eight, fluorescent markers concurrently.

The invention also relates to the discovery that modulation of UCP activity also influences reactive oxygen generation and accumulation. This finding has important implications for the regulation of many physiological processes including infectious
10 disease. Thus the invention relates to the treatment and prevention of disease in plants.

Each of the compositions of the invention may optionally be associated with a delivery system or vector. In its broadest sense, a "vector" is any vehicle capable of facilitating: (1) delivery of a composition to a target cell or (2) uptake of a composition by a target cell, if uptake is important. In general, the vectors useful in the invention are
15 divided into two classes: colloidal dispersion systems and biological vectors.

As used herein, a "colloidal dispersion system" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering to and releasing the active agent to the plant cell. Colloidal dispersion systems include macromolecular complexes, beads, and lipid-based systems including
20 oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vessels. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2 - 4.0 μ can encapsulate large macromolecules within the aqueous interior and these macromolecules can be delivered to cells in a biologically active form (Fraley, et al.,
25 *Trends Biochem. Sci.*, 6:77 (1981)).

Lipid formulations for transfection are commercially available from QIAGEN, for example as EFFECTENE™ (a non-liposomal lipid with a special DNA condensing enhancer) and SUPER-FECT™ (a novel acting dendrimeric technology) as well as Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of
30 cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many

- 38 -

publications. Liposomes were described in a review article by Gregoriadis, G., *Trends in Biotechnology* 3:235-241 (1985), which is hereby incorporated by reference.

It is envisioned that the UCP activator or UCP inhibitor may be delivered to the subject in a biological vector which is a nucleic acid molecule which encodes for the UCP activator or UCP inhibitor such that the UCP activator or UCP inhibitor is expressed. The nucleic acid encoding the UCP activator or UCP inhibitor is operatively linked to a gene expression sequence, such as that described above.

The UCP activator or UCP inhibitor nucleic acid of the invention may be delivered to the cell alone or in association with a vector. In its broadest sense, a "vector" is any vehicle capable of facilitating the transfer of the UCP activator or UCP inhibitor nucleic acid to the appropriate cells so that the UCP activator or UCP inhibitor can be expressed on the cell wall/ plasma membrane or within the cell respectively. Preferably, the vector transports the nucleic acid to the cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. The vector optionally includes the above-described gene expression sequence to enhance expression of the UCP activator or UCP inhibitor nucleic acid. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the UCP activator or UCP inhibitor nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited to nucleic acid sequences from the following viruses: retrovirus, such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rouse sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known to the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. An example of virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication -deficient

- 39 -

and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions.

5 Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al., "Molecular Cloning: A Laboratory Manual," Second Edition, Cold Spring Harbor Laboratory Press, 1989. These plasmids having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid. Some
10 commonly used plasmids include pBR322, pUC18, pUC19, pRC/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

Other exemplary compositions that can be used to facilitate uptake by a target
15 cell of the compositions of the invention include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a composition of the invention into a preselected location within the target cell chromosome).

As used herein the term "transgenic" when used in reference to a plant or fruit
20 (i.e., a "transgenic plant" or "transgenic fruit") refers to a plant or fruit that contains at least one heterologous gene in one or more of its cells.

As used herein, the term "sample" is used in its broadest sense. In one sense it can refer to a plant cell or tissue. In another sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples.
25 Biological samples may be obtained from plants or animals and encompass fluids, solids, tissues, and gases. Environmental samples include environmental material such as surface matter, soil, water, and industrial samples. These examples are not to be construed as limiting the sample types applicable to the present invention.

The words "transformants" or "transformed cells" include the primary
30 transformed cell and cultures derived from that cell without regard to the number of transfers. All progeny may not be precisely identical in DNA content, due to deliberate

or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included in the definition of transformants.

As used herein, the term "selectable marker" refers to the use of a gene that encodes an enzymatic or other detectable activity (e.g., luminescence, fluorescence, or radioactivity) that confers the ability to grow in medium lacking what would otherwise be an essential nutrient. A selectable marker may also confer resistance to an antibiotic or drug upon the cell in which the selectable marker is expressed. Selectable markers may be "dominant"; a dominant selectable marker encodes an enzymatic or other activity (e.g., luminescence, fluorescence, or radioactivity) that can be detected in any cell line.

The term "transfection" as used herein refers to the introduction of foreign DNA into cells. Transfection may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, glass beads, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, viral infection, biolistics (i.e., particle bombardment) and the like.

The following examples are provided to illustrate specific instances of the practice of the present invention and are not to be construed as limiting the present invention to these examples. As will be apparent to one of ordinary skill in the art, the present invention will find application in a variety of compositions and methods.

20

Examples

Example 1:

Wild type (CC124, mt-) and cell wall-less (CC, mt+) *C. reinhardtii* were tested for the presence of UCP by flow cytometry. Non-permeabilized cells were stained with anti-UCP2 antibody (Santa Cruz Technologies). Cells were prepared for staining with goat anti-UCP2 antibody (Santa Cruz Pharmaceuticals) followed by fluorescein conjugated anti-rabbit or goat outer step antibodies, respectively. Data were acquired on a Coulter Elite Epics flow cytometer (Coulter, Hialeah, Florida) and analyzed with CellQuest software, (Becton Dickinson, San Jose, California). Cells were stained for intracellular peroxide using 6-carboxy-2'-7'-dichlorodihydrofluorescein diacetate (DCF-DA, Molecular Probes, Eugene, Oregon). Briefly, cells were incubated with DCF-DA for 20 minutes, washed twice in PBS containing 5% fetal calf serum and analyzed flow

30

cytometrically. Mitochondrial membrane potential was assessed using Mitotracker Red (CM-H2XROS, Molecular Probes, Eugene, Oregon). The cells were resuspended in cold, or room temperature, PBS containing 13% fetal calf serum, 0.5 micromolar Mitotracker Red dye was then added to the suspension. The cells were incubated at 37°C for 20 minutes, pelleted, and resuspended in prewarmed medium for analysis. The Coulter Excel flow cytometer was used with a single excitation wavelength (488 nm) and band filters for PE (575 nm), FITC (525 nm) and Red613 (613 nm) to analyze the stained cells. Each sample population was classified for cell size (forward scatter) and complexity (side scatter), gated on a population of interest and evaluated using 40,000 cells.

Figure 1, Panel A, illustrates that in wild type (cell-walled [CC124-]), but not in cell wall-less strains (cw15+) of *C. reinhardtii*, as shown in Figure 1, Panel B, express cell surface molecules recognized by antibodies to UCP2. This result confirms that UCP can be localized to the cell wall, in addition to mitochondria and chloroplast.

It was also hypothesized that if cell wall expression of UCP2 facilitates uptake of acetate as an alternative carbon source during non-photosynthetic periods, then mutant strains of *C. reinhardtii* that die in the dark should not express cell wall UCP2. Such mutants were tested for the presence of cell wall UCP. Figure 2, Panel A, shows that light-sensitive, cell-walled strains of *C. reinhardtii* (lts) express high levels of UCP. However, as seen in Figure 2, Panel B, dark sensitive strains (CC2654; dark-dier) of *C. reinhardtii* express no cell-wall UCP over control samples. These results demonstrate a role of the cell wall UCP in non-photosynthetic metabolism.

It was discovered that wild type strains of algae can be made light-sensitive in the presence of the herbicide norflurazon. Thus, it was reasoned, in view of the discoveries described above, that norflurazon upregulates cell wall expression of UCP. Algae made light-sensitive by treatment with norflurazon were tested for the presence of cell wall UCP. Figure 3 demonstrates that norflurazon does indeed upregulate cell wall expression of UCP in wild type strains of *C. reinhardtii*. The above experiments, when taken together, demonstrate that UCP functions in *C. reinhardtii* when an alternative energy source to photosynthesis is required.

RNA from *C. reinhardtii* was also examined. Total RNA was isolated from wild type, wild type treated with norflurazon, cell wall less CW15+, and light sensitive cells.

- 42 -

Four concentrations of RNA were attached to the blot, 20ug, 10 ug, 5 ug, and 2,5 ug. A ³²P labeled probe from mouse clone in Bluescript was utilized. The results are shown in Figure 4.

Regulation of UCPs may also be utilized to protect plants, tissues, or cells against free radical damage. Experiments conducted during the development of the present invention have demonstrated that UCP in *C. reinhardtii* cell walls protects against free radical damage. Specifically, *C. reinhardtii* was tested for changes in reactive oxygen levels flow cytometrically using DCF-DA (Molecular Probes, Eugene, Oregon). It was shown that levels of peroxide are different between strains of *C. reinhardtii*. It was reasoned that UCP functions to prevent increased levels of oxygen free radicals, thus, mitochondrial membrane potential was measured using Cm-CS ros (Molecular Probes, Eugene, Oregon). The accuracy of this method for free radical quantification has been validated. The results demonstrate that UCP in *C. reinhardtii* protects against free radical damage.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

We claim:

CLAIMS

1. A plant expressing a cell wall UCP encoded by a heterologous UCP gene.
- 5 2. The plant of claim 1, wherein the heterologous UCP gene comprises a gene encoding UCP2.
3. The plant of claim 1, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding UCP1, UCP3, UCP4, UCP5, and UCP6.
- 10 4. The plant of claim 1, wherein the heterologous UCP gene comprises a gene encoding PUMP.
5. The plant of claim 1, wherein the heterologous UCP gene comprises a gene
15 encoding StUCP.
6. The plant of claim 1, wherein the heterologous UCP gene comprises a gene encoding AtPUMP.
- 20 7. A method for regulating fuel metabolism in a plant, comprising,
regulating UCP expression in a plant cell wall/ plasma membrane or chloroplast to regulate fuel metabolism of the plant.
8. The method of claim 7, wherein the method involves increasing the expression
25 or activity of UCP in the plant cell wall/ plasma membrane or chloroplast.
9. The method of claim 8, wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by introducing into the plant cell an expression vector including a gene encoding a heterologous UCP.
- 30 10. The method of claim 8, wherein the expression of activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by stably transforming the plant cell with an expression vector including a gene encoding a heterologous UCP.

11. The method of claim 9 or 10, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding UCP1, UCP2, UCP3, UCP4, UCP5, and UCP6.

5

12. The method of claim 9 or 10, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding PUMP, StUCP, and AtPUMP.

13. The method of claim 8, wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP activator.

14. The method of claim 13, wherein the cell wall UCP activator is a compound selected from the group consisting of sugars including but not limited to glucose, sucrose, maltose, and dextrose, structural analogs of sugars including but not limited to glucose, sucrose, maltose, and dextrose, inhibitors of nucleotides and nucleotide analogs, omega 3 fatty acids, omega 6 fatty acids, and norflurazon.

15. The method of claim 8, wherein the expression of UCP in the cell wall/plasma membrane is increased by contacting the plant with a cell wall targeted UCP molecule.

16. The method of claim 15, wherein the cell wall targeted UCP molecule is a UCP molecule linked to a targeting molecule selected from the group consisting of glucose transporters, sucrose transporters, maltose transporters, and fatty acid transporters.

17. The method of claim 8, wherein the expression of UCP in the chloroplast is increased by contacting the plant with a chloroplast targeted UCP molecule.

30

18. The method of claim 17, wherein the chloroplast targeted UCP molecule is a UCP molecule linked to a targeting molecule selected from the group consisting of a

- 45 -

chloroplast transit protein and a peptide of N terminus small subunit of ribulose 5-phosphate carboxylase.

19. The method of claim 8, wherein the expression of UCP in the cell
5 wall/plasma membrane, is increased by contacting the plant with a plasma membrane targeted UCP molecule.

20. The method of claim 19, wherein plasma membrane targeted UCP molecule
is a UCP molecule linked to a targeting molecule which is plant specific membrane
10 targeting sequence lacking a VSS or KDEL sequence.

21. The method of claim 8, wherein the expression of UCP in the cell
wall/plasma membrane is increased by contacting the plant with a plasma desmata
targeted UCP molecule.
15

22. The method of claim 21, wherein the plasma desmata targeted UCP molecule
is a UCP molecule linked to a plasma desmata targeting molecule which is a porin-like
targeting sequences.

23. The method of claim 8, wherein the expression of UCP in the cell
20 wall/plasma membrane is increased by contacting the plant with a pore targeted UCP molecule.

24. The method of claim 23, wherein the pore targeted UCP molecule is a UCP
25 molecule linked to a targeting molecule selected from the group consisting of a porin peptide, a VSS tail and a KDEL tail.

25. The method of claim 7, wherein the method involves decreasing the
expression or activity of UCP in the plant cell wall/plasma membrane or chloroplast.
30

- 46 -

26. The method of claim 25 wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is decreased by contacting the plant with a UCP inhibitor.

5 27. The method of claim 26, wherein the cell wall UCP inhibitor is a compound selected from the group consisting of UCP binding peptides such as anti-UCP antibodies, UCP anti-sense nucleic acids, UCP dominant-negative nucleic acids, nucleotides, nucleotide analogs tocopherols, and non-omega-3, -6 fatty acids.

10 28. An expression system, comprising:
a promoter sequence,
a first structural gene encoding a heterologous UCP and a second structural gene encoding a plant cell wall targeting peptide or a chloroplast targeting peptide, the first and second structural genes arranged to form a fusion protein and operably linked to and
15 under the control of the promoter sequence.

29. The expression system of claim 28, wherein the promoter sequence is a plant specific promoter.

20 30. The expression system of claim 28, wherein the UCP encoded by the first structural gene is a mammalian UCP.

31. The expression system of claim 28, wherein the UCP encoded by the first structural gene is a plant UCP.

25 32. A plant stably transformed with the expression system of claim 28.

33. A seed of the plant of claim 32.

30 34. A progeny, clone, cell line or cell of the plant of claim 32.

- 47 -

35 A transgenic plant transformed with a nucleic acid construct comprising a nucleic acid sequence encoding a UCP operably linked to a promoter sequence, wherein the nucleic acid contract also encodes a plant cell wall targeting peptide or a chloroplast targeting peptide.

5

36. A seed of the transgenic plant of claim 35.

37. A progeny, clone, cell line or cell of the transgenic plant of claim 35.

10

38. A method for producing a nutritionally enhanced plant, comprising:
decreasing the expression or activity of UCP in the plant cell wall/ plasma
membrane or chloroplast to produce a nutritionally enhanced plant.

15

39. The method of claim 38, wherein the expression or activity of UCP in the
plant cell wall/ plasma membrane or chloroplast is decreased by contacting the plant with
a UCP inhibitor.

20

40. The method of claim 38 wherein the UCP inhibitor is a chloroplast or cell
wall UCP antisense sequence.

41. A plant produced by the method of claim 38.

42. A method for improving the light and cold sensitivity of a plant, comprising:
increasing the expression or activity of UCP in the plant cell wall/ plasma
25 membrane or chloroplast to improve the light and cold sensitivity of the plant.

30

43. The method of claim 42, wherein the expression or activity of UCP in the
plant cell wall/ plasma membrane or chloroplast is increased by introducing into the
plant cell an expression vector including a gene encoding a heterologous UCP.

- 48 -

44. The method of claim 43, wherein the expression of activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by stably transforming the plant cell with an expression vector including a gene encoding a heterologous UCP.

5 45. The method of claim 43, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding UCP1, UCP2, UCP3, and UCP4.

 46. The method of claim 43, wherein the heterologous UCP gene is a gene selected from the group consisting of a gene encoding PUMP, StUCP, and AtPUMP.
10


 47. The method of claim 42, wherein the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP activator.

15 48. The method of claim 42, wherein the expression of UCP in the plant cell wall/ plasma membrane or chloroplast is increased by contacting the plant with a UCP molecule.

 49. A method for preventing an infection in a plant, comprising:
20 decreasing the expression or activity of UCP in the plant cell wall/ plasma membrane or chloroplast in an amount to prevent an increase in oxygen free radicals and to prevent infection in the plant.


1/6

FIG. 1



2/6

FIG. 2



3/6




FIG. 3A

| |
|---------|
| FIG. 3A |
| FIG. 3B |
| FIG. 3C |




FIG. 3B

5/6






FIG. 3C


6/6



LIGHT
SENSITIVE
CELLS



CELL WALL LESS
CW15+



WILD TYPE
TREATED WITH
NORFLURAZON



WILD TYPE
CC124-

FIG. 4

SEQUENCE LISTING

<110> University Technology Corporation

<120> Compositions and methods for regulating metabolism in plants

<130> C1102/7002WO

<140> Not assigned

<141> 2001-03-30

<150> US 60/193,533

<151> 2000-03-31

<160> 16

<170> PatentIn version 3.0

<210> 1

<211> 924

<212> DNA

<213> Homo sapiens

<400> 1

| | |
|---|-----|
| atggggggcc tgacagcctc ggacgtacac cggaccctgg ggggccagct cttctcagct | 60 |
| ggaatagcgg cgtgcttggc ggacgtgatc accttcccgc tggacacggc caaagtccgg | 120 |
| ctccaggtcc aaggtgaatg cccgacgtcc agtgttatta ggtataaagg tgtcctggga | 180 |
| acaatcaccg ctgtggtaaa aacagaaggc cggatgaaac tctacagcgg gctgcctgcg | 240 |
| gggcttcagc ggcaaatcag ctccgcctct ctcaggatcg gcctctacga cacgggccag | 300 |
| gagttcctca ccgcagggaa agaaacagca cctagtttag gaagcaagat tttagctggt | 360 |
| ctaacgactg gaggagtggc agtattcatt gggcaacca cagaggtcgt gaaagtcaga | 420 |
| cttcaagcac agagccatct ccacggaatc aaacctcgct acacggggac ttataatgcg | 480 |
| tacagaataa tagcaacaac cgaaggcttg acgggtcttt ggaaagggac tactcccaat | 540 |
| ctgatgagaa gtgtcatcat caattgtaca gagctagtaa catatgatct aatgaaggag | 600 |

gcctttgtga aaaacaacat attagcagat gacgtccctt gccacttggg gtcgggtctt 660
 atcgctggat ttgcgcaac agctatgtcc tccccggggtg atgtagtaaa aaccagattt 720
 attaattctc caccaggaca gtacaaaagt gtgcccaact gtgcaatgaa agtggttcaact 780
 aacgaaggac caacggcttt cttcaagggg ttggtacctt cttcttgcg acttggtatcc 840
 tggaacgtca ttatgtttgt gtgctttgaa caactgaaac gagaactgtc aaagtcaagg 900
 cagactatgg actgtgccac ataa 924

<210> 2

<211> 307

<212> PRT

<213> Homo sapiens

<400> 2

Met Gly Gly Leu Thr Ala Ser Asp Val His Pro Thr Leu Gly Val Gln
 1 5 10 15
 Leu Phe Ser Ala Gly Ile Ala Ala Cys Leu Ala Asp Val Ile Thr Phe
 20 25 30
 Pro Leu Asp Thr Ala Lys Val Arg Leu Gln Val Gln Gly Glu Cys Pro
 35 40 45
 Thr Ser Ser Val Ile Arg Tyr Lys Gly Val Leu Gly Thr Ile Thr Ala
 50 55 60
 Val Val Lys Thr Glu Gly Arg Met Lys Leu Tyr Ser Gly Leu Pro Ala
 65 70 75 80
 Gly Leu Gln Arg Gln Ile Ser Ser Ala Ser Leu Arg Ile Gly Leu Tyr
 85 90 95
 Asp Thr Val Gln Glu Phe Leu Thr Ala Gly Lys Glu Thr Ala Pro Ser
 100 105 110
 Leu Gly Ser Lys Ile Leu Ala Gly Leu Thr Thr Gly Gly Val Ala Val
 115 120 125
 Phe Ile Gly Gln Pro Thr Glu Val Val Lys Val Arg Leu Gln Ala Gln
 130 135 140
 Ser His Leu His Gly Ile Lys Pro Arg Tyr Thr Gly Thr Tyr Asn Ala
 145 150 155 160
 Tyr Arg Ile Ile Ala Thr Thr Glu Gly Leu Thr Gly Leu Trp Lys Gly
 165 170 175

Thr Thr Pro Asn Leu Met Arg Ser Val Ile Ile Asn Cys Thr Glu Leu
180 185 190

Val Thr Tyr Asp Leu Met Lys Glu Ala Phe Val Lys Asn Asn Ile Leu
195 200 205

Ala Asp Asp Val Pro Cys His Leu Val Ser Ala Leu Ile Ala Gly Phe
210 215 220

Cys Ala Thr Ala Met Ser Ser Pro Val Asp Val Val Lys Thr Arg Phe
225 230 235 240

Ile Asn Ser Pro Pro Gly Gln Tyr Lys Ser Val Pro Asn Cys Ala Met
245 250 255

Lys Val Phe Thr Asn Glu Gly Pro Thr Ala Phe Phe Lys Gly Leu Val
260 265 270

Pro Ser Phe Leu Arg Leu Gly Ser Trp Asn Val Ile Met Phe Val Cys
275 280 285

Phe Glu Gln Leu Lys Arg Glu Leu Ser Lys Ser Arg Gln Thr Met Asp
290 295 300

Cys Ala Thr
305

<210> 3

<211> 1105

<212> DNA

<213> Homo sapiens

<400> 3

gttcctctat ctcgtcttgt tgctgattaa aggtgccctt gtctccagtt tttctccatc 60
tcctgggacg tagcaggaaa tcagcatcat ggttggttcc aaggccacag atgtgcccc 120
tactgccact gtgaagtttc ttggggctgg cacagctgcc tgcacgcag atctcatcac 180
ctttcctctg gatactgcta aagtccggtt acagatccaa ggagaaagtc agggggccagt 240
gcgcgctaca gccagcgccc agtaccgcgg tgtgatgggc accattctga ccatggtgog 300
tactgagggc ccccgaaagg tctacaatgg gctggttgcc ggctgcagc gccaaatgag 360
ctttgcctct gtccgcacgc gctgtatga ttctgtcaaa cagttctaca ccaagggtc 420
tgagcatgcc agcattggga gccgcctcct agcaggcagc accacaggtg ccttggtgtg 480
ggctgtggcc cagcccacgg atgtggtaaa ggtccgattc caagctcagg cccgggctgg 540
aggtggctcg agataccaaa gcaccgtcaa tgcctacaag accattgccc gagaggaagg 600

```

gttccggggc ctctggaaag ggacctctcc caatgttgct cgtaatgcca ttgtcaactg      660
tgctgagctg gtgacctatg acctcatcaa ggatgccctc ctgaaagcca acctcatgac      720
agatgacctc ccttgccact tcacttctgc ctttggggca ggcttctgca ccactgtcat      780
cgctccccc ctgagacgtgg tcaagacgag atacatgaac tctgccctgg gccagtacag      840
tagcgctggc cactgtgccc ttaccatgct ccagaaggag gggcccccag ccttctacaa      900
agggttcatg cctccttttc tccgcttggg ttcttggaac gtggtgatgt tcgtcaccta      960
tgagcagctg aaacgagccc tcatggctgc ctgcacttcc cgagaggtc ccttctgagc     1020
ctctcctgct gctgacctga tcacctctgg ctttgtctct agccggggcca tgctttcctt     1080
ttcttccttc tttctcttcc ctccg                                           1105

```

<210> 4

<211> 314

<212> PRT

<213> Homo sapiens

<400> 4

```

Gln Glu Ile Ser Ile Met Val Gly Phe Lys Ala Thr Asp Val Pro Pro
1              5              10              15
Thr Ala Thr Val Lys Phe Leu Gly Ala Gly Thr Ala Ala Cys Ile Ala
20              25              30
Asp Leu Ile Thr Phe Pro Leu Asp Thr Ala Lys Val Arg Leu Gln Ile
35              40              45
Gln Gly Glu Ser Gln Gly Pro Val Arg Ala Thr Ala Ser Ala Gln Tyr
50              55              60
Arg Gly Val Met Gly Thr Ile Leu Thr Met Val Arg Thr Glu Gly Pro
65              70              75              80
Arg Ser Leu Tyr Asn Gly Leu Val Ala Gly Leu Gln Arg Gln Met Ser
85              90              95
Phe Ala Ser Val Arg Ile Gly Leu Tyr Asp Ser Val Lys Gln Phe Tyr
100             105             110
Thr Lys Gly Ser Glu His Ala Ser Ile Gly Ser Arg Leu Leu Ala Gly
115             120             125
Ser Thr Thr Gly Ala Leu Ala Val Ala Val Ala Gln Pro Thr Asp Val
130             135             140

```

Val Lys Val Arg Phe Gln Ala Gln Ala Arg Ala Gly Gly Gly Arg Arg
145 150 155 160

Tyr Gln Ser Thr Val Asn Ala Tyr Lys Thr Ile Ala Arg Glu Glu Gly
165 170 175

Phe Arg Gly Leu Trp Lys Gly Thr Ser Pro Asn Val Ala Arg Asn Ala
180 185 190

Ile Val Asn Cys Ala Glu Leu Val Thr Tyr Asp Leu Ile Lys Asp Ala
195 200 205

Leu Leu Lys Ala Asn Leu Met Thr Asp Asp Leu Pro Cys His Phe Thr
210 215 220

Ser Ala Phe Gly Ala Gly Phe Cys Thr Thr Val Ile Ala Ser Pro Val
225 230 235 240

Asp Val Val Lys Thr Arg Tyr Met Asn Ser Ala Leu Gly Gln Tyr Ser
245 250 255

Ser Ala Gly His Cys Ala Leu Thr Met Leu Gln Lys Glu Gly Pro Arg
260 265 270

Ala Phe Tyr Lys Gly Phe Met Pro Ser Phe Leu Arg Leu Gly Ser Trp
275 280 285

Asn Val Val Met Phe Val Thr Tyr Glu Gln Leu Lys Arg Ala Leu Met
290 295 300

Ala Ala Cys Thr Ser Arg Glu Ala Pro Phe
305 310

<210> 5

<211> 1132

<212> DNA

<213> Homo sapiens

<400> 5

| | |
|---|-----|
| tcctgggatg gagccctagg gagccctgt gctgccctg cctgggcagg actcacagcc | 60 |
| ccacogctgc actgaagccc agggctgtgg agcagcctct ctcttggac ctctctcgg | 120 |
| ccctaaaggg actgggcaga gccttccagg actatggttg gactgaagcc ttcagacgtg | 180 |
| cctcccacca tggctgtgaa gttcctgggg gcaggcacag cagcctgttt tgctgacctc | 240 |
| gttacctttc cactggacac agccaaggtc cgcctgcaga tccaggggga gaaccaggcg | 300 |
| gtccagacgg cccggctcgt gcagtaccgt ggcgtgctgg gcaccatcct gaccatggtg | 360 |
| cggactgagg gtcctgcag ccctacaat gggctggtgg ccggcctgca gcgcagatg | 420 |

```

agcttcgcct ccattccgat cggcctctat gactccgtca agcaggtgta ccccccaaa 480
ggcgcggaaca actccagcct cactaccggg attttggccg gctgcaccac aggagccatg 540
gcggtgacct gtgcccagcc cacagatgtg gtgaaggtcc gatttcaggc cagcatacac 600
ctcggggccat ccaggagcga cagaaaatac agcgggacta tggacgccta cagaaccatc 660
gccagggagg aaggagtcag gggcctgtgg aaaggaactt tgcccaacat catgaggaat 720
gctatcgtca actgtgctga ggtggtgacc tacgacatcc tcaaggagaa gctgctggac 780
taccacctgc tcactgacaa cttcccttgc cactttgtct ctgcctttgg agccggcttc 840
tgtgccacag tgggtggctc cccggtggac gtggtgaaga cccggtatat gaactcacct 900
ccaggccagt acttcagccc cctcgactgt atgataaaga tgggtggcca ggagggcccc 960
acagccttct acaaggggtg agcctcctcc tgcctccagc actccctccc agagaacagg 1020
ggcttctttc ttttcgaatg tggctaccgt gggtaacct gggatgtagc ggtgaagagt 1080
acagatgtaa atgccacaaa gaagaagttt aaaaaacat gcaaaaaaaaa aa 1132

```

<210> 6

<211> 284

<212> PRT

<213> Homo sapiens

<400> 6

```

Arg Asp Trp Ala Glu Pro Ser Arg Thr Met Val Gly Leu Lys Pro Ser
1          5          10          15
Asp Val Pro Pro Thr Met Ala Val Lys Phe Leu Gly Ala Gly Thr Ala
20          25          30
Ala Cys Phe Ala Asp Leu Val Thr Phe Pro Leu Asp Thr Ala Lys Val
35          40          45
Arg Leu Gln Ile Gln Gly Glu Asn Gln Ala Val Gln Thr Ala Arg Leu
50          55          60
Val Gln Tyr Arg Gly Val Leu Gly Thr Ile Leu Thr Met Val Arg Thr
65          70          75          80
Glu Gly Pro Cys Ser Pro Tyr Asn Gly Leu Val Ala Gly Leu Gln Arg
85          90          95
Gln Met Ser Phe Ala Ser Ile Arg Ile Gly Leu Tyr Asp Ser Val Lys
100         105         110

```

Gln Val Tyr Thr Pro Lys Gly Ala Asp Asn Ser Ser Leu Thr Thr Arg
 115 120 125

Ile Leu Ala Gly Cys Thr Thr Gly Ala Met Ala Val Thr Cys Ala Gln
 130 135 140

Pro Thr Asp Val Val Lys Val Arg Phe Gln Ala Ser Ile His Leu Gly
 145 150 155 160

Pro Ser Arg Ser Asp Arg Lys Tyr Ser Gly Thr Met Asp Ala Tyr Arg
 165 170 175

Thr Ile Ala Arg Glu Glu Gly Val Arg Gly Leu Trp Lys Gly Thr Leu
 180 185 190

Pro Asn Ile Met Arg Asn Ala Ile Val Asn Cys Ala Glu Val Val Thr
 195 200 205

Tyr Asp Ile Leu Lys Glu Lys Leu Leu Asp Tyr His Leu Leu Thr Asp
 210 215 220

Asn Phe Pro Cys His Phe Val Ser Ala Phe Gly Ala Gly Phe Cys Ala
 225 230 235 240

Thr Val Val Ala Ser Pro Val Asp Val Val Lys Thr Arg Tyr Met Asn
 245 250 255

Ser Pro Pro Gly Gln Tyr Phe Ser Pro Leu Asp Cys Met Ile Lys Met
 260 265 270

Val Ala Gln Glu Gly Pro Thr Ala Phe Tyr Lys Gly
 275 280

<210> 7

<211> 6428

<212> DNA

<213> Solanum tuberosum

<400> 7

| | |
|--|-----|
| gaattcatca catataaata gtgtggtcct ccttgtgttg ggtagaagta gaaacaacaa | 60 |
| gaaatataaa agagaaagag tggaagaaaa gatgagaaat attatattgt gtatattgag | 120 |
| taagtgtagt gaacgagaga gttgagacag agaaaatatt ttaagtcttt aactatatct | 180 |
| actatacaaa ggagaatatt catatgttga aggaaagtgt tcttgtgtgg agttttggac | 240 |
| tcttcaacta attcagagtt gtacaacggt attggactat tgtatcctgg agaggacaag | 300 |
| tcaagagtga tactgctgga tcggtgtaga ttatgccgta gttgacttga atcttcttaa | 360 |
| agagagtgag atattcgtgc ctcaagtctaa aaatttggtt attcattttt gtcattttat | 420 |

| | |
|--|------|
| tttcaactat aatattttgt atttgtggtg tattacactg ccttatcatg ataatcatcg | 480 |
| tgattttctaa ctagatcatg acgtctcaat taaatgtttt cttccaacta aacacatccc | 540 |
| atattttatat tattcgacat tgggttaattt gattattttat cccactttta gcctatgcac | 600 |
| aggggtag ctatgttaaa gtcaggggtgt taaattgaat atccttcgtc aaaaactaat | 660 |
| atcatattta tgtaaaatta tatacgaagt gattaaataa catatttttg acattcttaa | 720 |
| cagaacaagg tgttgttgcc caatcgtttc attattttctg tcacaattaa caaatctacc | 780 |
| atgtgaaata ggtgtacttc accatggccc ttgaatgtat gacaagccgt atattcgata | 840 |
| ggaaagagta acgtttacgc atccttaata aaatgttaga tgatgaatga ggatctaata | 900 |
| agcatatgtg caaagctcca accaatcatg attatctaata aaagtgtgct ttattcatta | 960 |
| ttctaaaatt caacaattaa taaaataatt aggtcaaaag cacatgggtg agtggatgag | 1020 |
| tttgatcaac ttgtaaatat attattgcct ttattcatct ctagcttcat tattattatt | 1080 |
| ttattaggtt ctatttaatt tctcgtattt gatatttgca ttaaaattca attaatgtt | 1140 |
| attcacatga tataaaaccc caatcacact actcgaattt aaaaccttta attaagggga | 1200 |
| gtaacaattg aataacaaaa aaaaatctgt tgggagtgcc acccccgaat agaccctgta | 1260 |
| gagcgcgatt caaatttaat cgaaactcta atgtgggctc cgagaaacaa aaaaaaaaaa | 1320 |
| caattgaata gcaaaggaaa acagagtagt gctgactgag caagcaaaag cccaattgaa | 1380 |
| atattagtag taaatgacag caatggccgt tgcgtaggac aagcacagca gcagccccgt | 1440 |
| tttcgctttt cccaagatct ctctgcaaaa tccttagcct tctttactat ataatagccc | 1500 |
| ctaaaacccc attttttact ataccattt cttactcttg ctctgtgatc atcctttctt | 1560 |
| ctaggagtag ccatctccta gaaccctttt agtttctctt tgtgtttttt tgggtcaattt | 1620 |
| agtcattggga ggaggagatc acggcggaac atcggatata tcattcgccg gaatattcgc | 1680 |
| aagtagtgcc tttgctgctt gtttcgctga ggtaattctt ccatcaatct aatccctttt | 1740 |
| ttgcaatcct gtcttgaaac ttgctttgtt gattcagtct tacatctgtt gctaagattt | 1800 |
| ttgatgattc gaataggata aatgggggtt tttccttttc cttttttttt ttgtttctgg | 1860 |
| attgtcagga attgttgatc cccattgagc tggttaagtgt ttatgagctt ataatccttt | 1920 |
| actggattgc tttgctggtc aatttaagtt ttgtttaatc tcctaatact gtatgtttgt | 1980 |
| attaaggtgc aatctgtttt ggcagataaa tgagtctctt ggttgagtgt ttgagtcag | 2040 |
| cgagagggtg agtaagaata ctattgatcc tccttttggg gggcgggggg atctgtttcg | 2100 |

gcagataagt gaggccttggg tggagggttg agtcacactg gagggtaagt aggaacacta 2160
ttgatecctcc ttttaggggg tggggaatct gtttcagcaa ataagtgagg cttgggttga 2220
gggtgtgactc aactggagg gtatgtagga acagtattga tcctcctttt agggagggtg 2280
ggaatctgtt tcggcagata attgaggctt ggttgagggt tcgagtcaca ctggagggtg 2340
agtaggaaca ttattgatcc tcctagaaga aagtgagggt tgatttggtc tgtatttagt 2400
ttaagagatt aatcacctta ctacagcatc tgttaggaag ggaaaagagg atatcggtg 2460
acctttaaac aagggtgatga tggtaaaaa taaatttgta ctcatgtttc cttaaaaata 2520
attacttgta gaaatttggg ggacttgatt gtgtgaatac ttttatgaaa aaccatgact 2580
tgcttaattt tggaggaatc agttttctat cttttgcttt ttatgaagct aggccttgat 2640
gatgtatgta gttttcaaag aacagtgtat tgcgtatggg tgtatgaaat gaggtttgtt 2700
aagttttgat tgcgtctttt gggtcacccg acatgtatgg tgtctacatg tagtagatcg 2760
ttttgaagtg tgcgtgccgt gctattattc gtgttattga tcctctcgct gcctgttaat 2820
cttgtttgct gcatacaaaa ttctgttctc caggcgtgta ctttaccatt ggatactgct 2880
aaagtttagac ttcagcttca aaagaaggca gttgaagggg atgggctagc tttacctaaa 2940
tataggggat tattaggtac tgttggcacc attgcaaagg aagaaggaat agcttcacta 3000
tggaagggta tcgtacctgg gttacatcgt caatgtatat atggagggtc tcggattggg 3060
atgtatgaac ctgtaagtta acatttctag cttaaacagc tacaagttta ttttggcctt 3120
ttacggactg tttgctgggt gaccagggtta aaaacttata tgttggcaaa gatcatgttg 3180
gggatgtgcc attgtcaaag aaaatacttg ctgcacttac aactgggtgag tgccttttag 3240
atgttttgcg tttattgtca ctttgctcga gagtaaatgg acagcgaagc ttttatatcc 3300
atttagaaaa catctggaca taggctatag aagttcagt ttaagattat caataacata 3360
cttctgtttt tccttgatt attcttttat actgtctggg ctttcaatat attttaagt 3420
aatttgggtg ttctttatca aatagggtcg ttgggcatta caattgcaaa tcctacagat 3480
ctagttaaag tacgtcttca agctgaagga aaattgccag cagggtgtgcc gaggcgttat 3540
tctggagctc taaatgccta ctcaacaata gtgaaacagg ttatatgtct tgtctagctc 3600
agttgtttac taaatcatga taactaacga cagcgggggc tgtgaaattg tgtacaccta 3660
ctttgaatca tgacttgga attagttacc cttgaattg aaattcaata ttacctaaac 3720
aattatatat gtgttgctat tcaaactccc acaatgtcta cctatcaagc ggacatacaa 3780
cctgcaaaaa tatgtgcctt tagtatgtaa catttaacaa ctattatgtc cctagaattg 3840

gatacatgac atttctttaa gattctttcg ttgaactatt ctttgataac tgattctttg 3900
ttcgactttc tcattctcca tctaacttag tgtattcggt tatcattctc agagaaaaag 3960
ggtagtactt ttcttctctg tgtggtttcc attctcctgg aaatgttagg aaattatgaa 4020
aagttctatt tcattttaa taatcaaacc cccaggtctg tcagcttact ggagcatttg 4080
caatataatg taaatagaac aggtttcaca tgtgaaaatt tgaggaaaact cattgttgag 4140
tcatagtttt cccaacaaaa taagactcct atttgaactt gcatgttaac ctctttgcat 4200
tttgtttcta ccatatcttg attttaggaa ggagttcgag ctctgtggac tggctcttga 4260
cccaatattg ggcggaatgc catcatcaat gcagctgaat tagcaagtta tgatcaagtg 4320
aaggaggtag agaaaccata aatttcttat tcccacctca ttttccggac catctaattg 4380
ggtgttttct tgaatttgga tgtttacatt gtcattcttt tcaactgttg ttctttaaaa 4440
atcttctgtc aggtctgtct taggattcct gggttcacag acaatgttgt tactcatttg 4500
attgcggggc ttggagctgg tttttttgca gtttgcatag ggtctcctgt tgatgtggta 4560
tcttctatgt ttcttattat ttgaaattgc tttcttttta gtctttctg acggcagccc 4620
atgattcagt aatatttggt agtattttag atcttcttgc ccaaatagag gatcttcttg 4680
gctatatagg gggaaaagtt atgcatagtc ttacttttca tgaaaaagat tatcaaagtc 4740
aatatctagc ctgttaaaca cacgccttca tcttgtgaat ttgaagtcct ctgctcatga 4800
atcttcttta ttattgtgca gtgcgtgcct aataataaaa ctctagtttg gctggggtaa 4860
atggaggagg gattaaagga ttaaaagtaa cattgggagt gtaaggggat gtcttgtaat 4920
taaaaaagga tcaataaaaa ataaaataaa gagagataat ctgtcctaaa ttgggcggaa 4980
gcatgtctat ttacaaaata ttaaaaccat acaaagaacc ataaacaaat atagataatt 5040
cacttaacaa gttacttttt cttttctcaa ccgcttcctt ccccttctg gaatcaaca 5100
tagtagagct gggatcaaca gtactgatat cttgttactt ggttggtgat gatggcaata 5160
ccgatttttt tcaaatttgc gtacttaaga agttcaccaa acaccaaatt gcttcttata 5220
ttttgggttag gtgattttta ttcaacacta atcttttaga tcaccatttt taatctgtct 5280
tctaatttca tcccttttaa gttgcattat caatagactt tgtaaaaatt tattagatta 5340
atcttggtga ttattcttgt atagccatga agcactgaca tggtaaaactg tggatgcagg 5400
taaagtcgag aatgatggga gattccgcat acaaaaatac tcttgattgt tttgtcaaaa 5460
cattgaagaa tgatgtgagt tcatgatctg tctttctat tggttattga agaattccagc 5520

cgttttgcag acataaattt tcctcttagt ctttttgttt aaataactta tcgtggcttc 5580
 ttattagatg cagaactcta cctaaaacaa cataacctct cttttctctc aagatagttt 5640
 aatttttttt actaaaatca gatccctatt attacaaatt ttccctactg ctattagttt 5700
 tttggttgtg tagttttcag ttccctgcca acagcaactt taatgtgtaa tgactgcaaa 5760
 aatgacactt ctccatggtc ctttatgttt gcagggacct ttggctttct acaaaggctt 5820
 tatcccaaatt tttggacgct tgggatcttg gaatgtcatt atgtttctaa cattggagca 5880
 ggtaaagagt ggaaccatat tcccagcgac acaaattctt ttccatttca caattattta 5940
 taaaacttta tgccagatta ctattccaga ctagcacatg ttttgcttca atgagaggct 6000
 ttctcaattt ccagttgctt cctgtttcaa ctgttgactt ggcaacactt tgttccatta 6060
 ggctttgaca aattcctgat gaatagctga ctggcttacc ctttgtttct tttttttgg 6120
 caggcgaaga agttcgtaa aagtttagaa tcacctgat gtcaaagagg aatgaatcat 6180
 caagcagagg attactaatt tacattaaac atggattggt tcagcaatca ttagaagatg 6240
 gaatcaacaa agatattttt caatattccc ctttttttct gtttttttat caataattcc 6300
 cattggggaa cccatagaaa ctatgagaaa ccaagcttag aagtgttag ttttctcctt 6360
 taaaggggac ccttactctt actattctta gactgcaaaa tgttttctt tccttttggt 6420
 tgccatgg 6428

<210> 8

<211> 1225

<212> DNA

<213> *Arabidopsis thaliana*

<400> 8

gacgatcttt tctataactg aaacactact cgaggccaag ttgcttttagc cgtaatcgtc 60
 gtcgctccctc ttcccgaaat tatctcttct ctgttcttctg atttcgaaac cctaacctcc 120
 tctctttaat tcgcgttttc tggatcgaag atggtggcgg ctggtaaata cgacctttcc 180
 ttgccccaaa ctttcgcctg cagtgccttc gctgcttgcg tcggcgaggt atgcacaatt 240
 ccattggaca ctgctaaagt taggcttcag ctccaaaagt ctgctcttgc tgggtgatgtt 300
 actctgccta aatatcgagg attgttggga actgttggta ccatagcaag ggaagaaggg 360
 ttacgttcac tatggaaagg tgttgtaact ggattgcata gtcaatgcct atttggaggt 420

12

cttaggattg gaatgtatga gccggtgaaa aacttgatg ttggaaaaga ctttgtagg 480
 gatgttccat tgagcaagaa aattcttgct ggtttgacaa caggtgcact gggatatcatg 540
 gtagcaaata cactgatct tgtgaaagt aggcttcagg cggaaggaaa attagctgca 600
 ggtgcgccaa gacggtaactc tggagcgtg aatgcgtatt caacaattgt gagacaggaa 660
 ggagtcgag ctctttggac tgttcttgga cctaacgtag caagaaacgc tattatcaat 720
 gctgctgaat tagcgagtta cgatcaagt aaagagacta tcttgaagat tccagggttc 780
 actgacaacg ttgtcacaca tattctatct ggactggggg caggattctt tgctgtttgc 840
 atcggttctc ctgttgacgt ggttaagtca agaagatgag gagattctgg tgcttacaag 900
 ggcaccattg attgcttcgt caaaactctg aagagcgacg gtcctatggc attttacaag 960
 ggtttcatcc ccaactttgg acgccttggc tcatggaacg taatcatgtt ttgaccctc 1020
 gaacaggcaa agaagtatgt ccgggaactc gatgcgtcca aaagaaactg agacacaaag 1080
 ttttaagcag agggaatgag agcaacattg ttttcttctt cattttcggg gattgagaga 1140
 ggccagaact tgggtgaata ttgttttcgg aatagagatt cagttttcga gtaaaactgt 1200
 gaaataaaat ttctgtggat tgctc 1225

<210> 9

<211> 1088

<212> DNA

<213> *Arabidopsis thaliana*

<400> 9

tcctatagca taacaatggc ggatttcaaa ccaaggatcg agatttcggt ccttgaaacc 60
 ttcatattgca gcgctttcgc tgcttggttt gctgagttat gtactatacc gttggacaca 120
 gccaaagta gacttcagct tcaaagaaag attccactg gagatgggtga gaatttgccc 180
 aagtatagag gatcaattgg tactctagct accatagcta gagaagaagg tatttcaggt 240
 ctttggaag gtgttattgc aggacttcac cgccaatgta tctatggtgg ctttaaggatt 300
 gggttatatg agcctgtgaa gacacttttg gttggaagt actttattgg cgatattcct 360
 ttatatcaaa agattcttgc agctttgtta actggagcta tagctattat ttagctaat 420
 ccaactgatc ttgttaaagt tcggcttcaa tcagaaggaa agttaccggc tggggttcct 480
 aggcgttatg caggagctgt agacgcttat ttcaccattg tgaagctgga aggagttagt 540

```

gcgctatgga ctggacttgg tcccaatatt gcccggaatg ctattgtaaa tgctgcagag      600
ttagctagtt atgatcaaat aaaggagaca attatgaaaa ttccgttctt cagagacagt      660
gtttttaactc atctactagc tggtttagct gcaggcttct tcgctgtctg catcggttct      720
ccaattgatg tggtgaaatc tagaatgatg ggagactcta cttaccgaaa cacagtcgat      780
tgcttcatca aaacgatgaa gaccgagggg attatggcat tctacaaagg atttctcccg      840
aattttacac ggctaggaac ctggaatgcc attatgttcc tcacattaga acaagtgaaa      900
aaagtgtttc taagagaagt cttgtacgat tgattctcag atccctagtc gaaaaccata      960
ccttattaca taatcccttc tataaaactt tgaattgtta gaattaaaac atatatactt     1020
tctatgttat gtgagctttg ttatttagat tagtatagaa acattttatc caaaaaaaaaa     1080
ttcttttgc                                     1088

```

<210> 10

<211> 972

<212> DNA

<213> Homo sapiens

<400> 10

```

atgtccgtcc cggaggagga ggagaggctt ttgccgctga cccagagatg gccccgagcg      60
agcaaattcc tactgtccgg ctgcgcggct accgtggccg agctagcaac ctttcccctg     120
gatctcacia aaactcgact ccaaatgcaa ggagaagcag ctcttgctcg gttgggagac     180
ggtgcaagag aatctgcccc ctatagggga atggtgcgca cagccctagg gatcattgaa     240
gaggaagget ttctaaagct ttggcaagga gtgacacccg ccatttacag acacgtagtg     300
tattctggag gtcgaatggt cacatatgaa catctccgag aggttgtgtt tggcaaaagt     360
gaagatgagc attatcccct ttggaaatca gtcattggag ggatgatggc tgggtgttatt     420
ggccagtttt tagccaatcc aactgacctt gtgaagggtc agatgcaaat ggaaggaaaa     480
aggaaaactgg aaggaaaacc attgcgattt cgtggtgtac atcatgcatt tgcaaaaatc     540
ttagctgaag gaggaatacg agggcttttg gcaggctggg tacccaatat acaaagagca     600
gcactgggtga atatgggaga tttaaccact tatgatacag tgaaacacta cttggtattg     660
aatacaccac ttgaggacaa tatcatgact cacggtttat caagtttatg ttctggactg     720
gtagcttcta ttctgggaac accagccgat gtcatcaaaa gcagaataat gaatcaacca     780

```

14

cgagataaac aaggaagggg acttttgtat aaatcatcga ctgactgctt gattcaggct 840
 gttcaagggtg aaggattcat gagtctatat aaaggctttt taccatcttg gctgagaatg 900
 accccttggt caatgggtgtt ctggcttact tatgaaaaaa tcagagagat gagtggagtc 960
 agtccatttt aa 972

<210> 11

<211> 974

<212> DNA

<213> *Triticum aestivum*

<400> 11

cttctaccct tctttccctc tgctcgccat cgaccgaacc acagccgccg ccgcttcccc 60
 ggggataaaa tggcgacggc ctcttccttc gccgccgtct tcatcagcag cgccatcgcc 120
 tcctgcttcg ctgaggtgtg caccattcct ctggacacag ccaaggtgcg tcttcagctg 180
 caaaagaaaa cagctgctgg gcctgcaggt acagtaggaa tgctgggcac aatgatgtcg 240
 attgcaaggg aggaaggcgt caccgcactt tggaagggca tcatccctgg ctttcatcgc 300
 cagtgcctct atggcggcct ccgtgtcggc ttgtatgagc ctgtcaaage cttatttgtg 360
 tttgtaggtg atgccacttt aatgaacaag attcttgccg ctcttacaac tgggtgtcata 420
 gcgattgctg tcgcaaatcc aactgatctt gtcaaagtga gattgcaage agatggaaaa 480
 tctactgccg tcaagaggca ctattctgga gcccttaatg cgtatgccac catagtcaga 540
 caggaaggta tcggagcttt gtggactggc cttggctcta atatggcacg aaatgctttg 600
 attaatgccg ccgagttggc cagctacgac caatttaaac agatgtttct aggtcttcct 660
 gggtttacag ataatgttta tactcatctt ttagctggac tcggtgccgg tatttttgc 720
 gtttgcatcg gatctccagt ggatgtggtg aaatcaagaa tgatgggcga ttcaacatac 780
 agaagtacat ttgattgttt cgccaagaca ttaaaaaatg atggacttgc tgctttctac 840
 aaggggttta ttgcaaactt ttgtcgagtt gggatcatgga atgtgataat gttcttaact 900
 ttggaacagg ttagaagctt ctttcagtaa ggattatata tgaaatctgc gctgcaagg 960
 ttcattggaac aagc 974

<210> 12

<211> 1592

<212> DNA

<213> Homo sapiens

<400> 12

| | | | | | | |
|-------------|-------------|-------------|------------|------------|-------------|------|
| gcttaacggg | cctctgggtct | ctctctcccc | tcagctgagt | cccttccctg | tctttcactc | 60 |
| ttctggcctc | ggtgggttta | cttcttcgat | tgaaccctgc | ttctctgacc | cccctgggag | 120 |
| gcgccttct | tcaggcgct | cccttctctc | cacgagctcg | ctctgacagc | tgaggaactg | 180 |
| gcaagatcct | gctaccaga | gggtgaatgg | gtatctttcc | cggaataatc | ctaatttttc | 240 |
| taaggggtgaa | gtttgcaacg | gcggccgtga | ttcaccagaa | aagtaccact | gtaagtcattg | 300 |
| agatgtcttg | tctgaattgg | aaaccctttg | tatatggcgg | ccttgccctc | atcgtggctg | 360 |
| agtttgggac | tttccctgtg | gaccttacca | aaacacgact | tcaggttcaa | ggccaaagca | 420 |
| ttgatgcccg | tttcaaagag | ataaaatata | gagggatgtt | ccatgcgctg | tttcgcatct | 480 |
| gtaaagagga | aggtgtattg | gctctctatt | caggaattgc | tcctgcgttg | ctaagacaag | 540 |
| catcatatgg | caccattaaa | attgggattt | accaaagctt | gaagcgctta | ttcgtagaac | 600 |
| gtttagaaga | tgaaactctt | ttaattaata | tgatctgtgg | ggtagtgtca | ggagtgatat | 660 |
| cttccactat | agccaatccc | accgatgttc | taaagattcg | aatgcaggct | caaggaagct | 720 |
| tgttccaagg | gagcatgatt | ggaagcttta | tcgatata | ccaacaagaa | ggcaccaggg | 780 |
| gtctgtggag | gggtgtgggt | ccaactgctc | agcgtgctgc | catcgttgta | ggagtagagc | 840 |
| taccagtcta | tgatattact | aagaagcatt | taatattgtc | aggaatgatg | ggcgatacaa | 900 |
| ttttaactca | cttcgtttcc | agctttacat | gtggtttggc | tggggctctg | gcctccaacc | 960 |
| cggttgatgt | ggttcgaact | cgcattgatga | accagagggc | aatcgtggga | catgtggatc | 1020 |
| tctataaggg | cactgttgat | ggtattttta | agatgtggaa | acatgagggc | ttttttgcac | 1080 |
| tctataaagg | attttgcca | aactggcttc | ggcttggaac | ctggaacatc | atttttttta | 1140 |
| ttacatacga | gcagctaaag | aggcttcaaa | tctaagaact | gaattatatg | tgagcccagc | 1200 |
| cctgccagcc | tttctactcc | tttgcccttt | tcccggtgtc | taatgtattt | tgacaatgtt | 1260 |
| gtaagtgttt | accaagccgt | tggtctccta | agggcctcct | gatggaagaa | cagtgggggtg | 1320 |
| gttcaaagtt | atttctatgt | ttgtgttacc | atgttaactt | ttccccgaga | gaaagtgtta | 1380 |
| acattgagac | tctggcccca | gattgggtatc | ttctatgaag | atggatactg | atgggtgaca | 1440 |
| ttgaaaacgg | cctgctttcc | aaatgtgggt | aaatgtaatt | ggtagcccc | agacttgggc | 1500 |

tagagcagaa ggcataggcc aggggtggta ttgctatatg tgttacagac ctcggttctc 1560

attaaagtat ttattggcag aatcacaaaa aa 1592

<210> 13

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> Artificial Sequence

<222> (1)..(27)

<223> Synthetic oligonucleotide

<400> 13

gtaccgggccc ccatggttgg tttcaag

27

<210> 14

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> Artificial Sequence

<222> (1)..(27)

<223> Synthetic oligonucleotide

<400> 14

ggccatctcg aggaaaggtg cctcccg

27

<210> 15

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<221> Artificial Sequence

<222> (1)..(30)

<223> Synthetic oligonucleotide

<400> 15

gtaccggggcc ccattgggctc ttttgagctg

30

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> Artificial Sequence

<222> (1)..(27)

<400> 16

cttggccatc tcgagcatgc aggcac

27

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/10236

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/82 C12N15/63 A01H1/00 A01H5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, MEDLINE, SCISEARCH, CHEM ABS Data, BIOTECHNOLOGY ABS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|--|
| X Y | WO 90 08831 A (ICI PLC) 9 August 1990 (1990-08-09) claims 1,2,9-11; examples 4,5 --- -/-- | 1,3, 7-11,15 2-6, 11-14, 17,18, 23-37, 42-48 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

24 October 2001

Date of mailing of the international search report

09/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG., A

INTERNATIONAL SEARCH REPORT

Inventor's Application No

PCT/US 01/10236

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-------------------------------------|
| Y | <p>RICQUIER DANIEL ET AL: "The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP." BIOCHEMICAL JOURNAL, vol. 345, no. 2, 15 January 2000 (2000-01-15), pages 161-179, XP002180562 ISSN: 0264-6021 page 173, right-hand column, last paragraph -page 174, left-hand column, paragraph 1 page 167, right-hand column, paragraph 2 - paragraph 3</p> | 2,3,5, 11,12, 25-27, 42-48 |
| Y | <p>--- LALOI M ET AL: "A plant cold-induced uncoupling protein." NATURE, vol. 389, no. 6647, 11 September 1997 (1997-09-11), page 135-136 XP002180563 the whole document</p> | 5,12 |
| Y | <p>--- MAIA IVAN G ET AL: "AtPUMP: An Arabidopsis gene encoding a plant uncoupling mitochondrial protein." FEBS LETTERS, vol. 429, no. 3, 16 June 1998 (1998-06-16), pages 403-406, XP002180564 ISSN: 0014-5793 the whole document</p> | 4,6,12 |
| Y | <p>--- SAVIANI ELZIRA E ET AL: "Fatty acid-mediated uncoupling of potato tuber mitochondria." BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, vol. 44, no. 4, April 1998 (1998-04), pages 833-839, XP001034371 ISSN: 1039-9712 the whole document</p> | 13,14 |
| Y | <p>--- FR 2 767 058 A (CENTRE NAT RECH SCIENT) 12 February 1999 (1999-02-12) page 6, line 21-28 page 3, line 11 -page 5, line 15</p> | 13 |
| Y | <p>--- WO 88 02402 A (CALGENE INC) 7 April 1988 (1988-04-07) see examples and claims</p> | 17,18, 28-37 |
| Y | <p>--- US 5 360 726 A (RAIKHEL NATASHA V) 1 November 1994 (1994-11-01) examples 1,2</p> | 23,24 |
| | <p>--- -/--</p> | |

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/10236

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| T | <p>WINKLER EDITH ET AL: "UCP3 expressed in yeast is primarily localized in extramitochondrial particles." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 282, no. 1, 23 March 2001 (2001-03-23), pages 334-340, XP002180565 ISSN: 0006-291X</p> <p>-----</p> | |

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No

PCT/US 01/10236

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9008831 | A | 09-08-1990 | AU 621201 B2 | 05-03-1992 |
| | | | AU 5022690 A | 24-08-1990 |
| | | | CA 2008697 A1 | 26-07-1990 |
| | | | EP 0455690 A1 | 13-11-1991 |
| | | | WO 9008831 A1 | 09-08-1990 |
| | | | ZA 9000606 A | 31-10-1990 |
| FR 2767058 | A | 12-02-1999 | FR 2767058 A1 | 12-02-1999 |
| | | | AU 8543098 A | 01-03-1999 |
| | | | EP 1018338 A1 | 12-07-2000 |
| | | | WO 9907358 A1 | 18-02-1999 |
| | | | ES 2147519 A1 | 01-09-2000 |
| WO 8802402 | A | 07-04-1988 | AU 620317 B2 | 20-02-1992 |
| | | | AU 8079787 A | 21-04-1988 |
| | | | EP 0285646 A1 | 12-10-1988 |
| | | | JP 1501038 T | 13-04-1989 |
| | | | WO 8802402 A1 | 07-04-1988 |
| US 5360726 | A | 01-11-1994 | US 5525713 A | 11-06-1996 |
| | | | US 6127532 A | 03-10-2000 |
| | | | US 5276269 A | 04-01-1994 |

This Page Blank (uspto)

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**

This Page Blank (uspto)